Supportive Care in Cancer

Supportive Care in Cancer Official Journal of the

Multinational Association of

Supportive Care in Cancer

Editor-in-Chief F. D. Ashbury

Toronto, Canada

Associate Editors-in-Chief J. Epstein Los Angeles, USA • Deputy Associate Editor – R. Logan J. Herrstedt

Adelaide, Australia

Odense, Denmark

Associate Editors R. Arnold Pittsburgh, USA R. Crevenna Vienna, Austria A. Glaus St. Gallen, Switzerland • Deputy Associate Editor – R. J. Bensadoun M. Lacouture New York City, USA • Deputy Associate Editor – M. Anadkat J. Smith Texas, USA E. Maranzano Terni, Italy • Deputy Associate Editor – K. Dennis S. Mercadante Palermo, Italy P. Schofield Victoria, Australia • Deputy Associate Editor – T. Hack

Nice, France

St. Louis, USA

Ottawa, Canada

Winnipeg, Canada

S. Sonis Boston, USA A. Surbone New York City, USA W. J. E. Tissing Groningen, The Netherlands • Deputy Associate Editor – M. A. Grootenhuis Amsterdam, The Netherlands

K. White

Sydney, Australia

13 A2

Editorial Consultants M. S. Aapro Genolier, Switzerland N. Aaronson Amsterdam, The Netherlands S. Aranda Melbourne, Australia J. J. Body Brussels, Belgium E. Bruera Houston, USA M. Davis Cleveland, USA E. Demin St. Petersburg, Russia E. Ernst Exeter, UK S. Eychmueller St. Gallen, Switzerland R. Feld Toronto, Canada M. Fitch Toronto, Canada C. Freytes San Antonio, USA C. J. Fürst Stockholm, Sweden D. Gupta Schaumburg, USA D. Iverson Melbourne, Australia M. Keller Heidelberg, Germany T. Lehrnbecher Frankfurt, Germany A. S. Lübbe Bad Lippspringe, Germany D. B. McGuire Baltimore, USA A. Molassiotis Manchester, UK K. Mystakidou Athens, Greece H. Okamura Hiroshima, Japan D. Oneschuk Edmonton, Canada D. E. Peterson Farmington, USA K. Rolston Houston, USA R. Sanson-Fisher Sydney, Australia P. Sloan Lexington, USA D. Walsh Cleveland, USA Emeritus Editor-in-Chief H. J. Senn St. Gallen, Switzerland

Supportive Care in Cancer Volume 23 · Supplement 1 · June 2015

ABSTRACTS Abstracts of the MASCC/ISOO 2015 Annual Meeting

S1

Indexed in Current Contents, Index Medicus and EMBASE Instructions for Authors for Support Care Cancer are available at www.springer.com/520

ABCD

springer.com

New Challenges in Communication with Cancer Patients A. Surbone, New York University, NY, USA; M. Zwitter, M. Rajer, Institute of Oncology Ljubljana, Slovenia; R. Stiefel, The New York Academy of Sciences, NY, USA (Eds.) The relationship between oncologists and their cancer patients is rapidly evolving. Oncologists and other cancer professionals master new anticancer and supportive treatment options, while working under increasing economic pressure and time constraints, and are often unprepared to deal with all the challenges of their new position in a therapeutic relationship with cancer patients and families. Good communication is as essential as are modern laboratory tests and sophisticated diagnostics to achieve the best clinical results. This book updates the evolution of truth-telling and communication patterns worldwide and offers insights into the recent trends and emerging challenges in communication with cancer patients and families. New Challenges in Communication with Cancer Patients is an invaluable resource to medical professionals, educators and patients in establishing a strong and effective partnership built on trust and mutual understanding. Please visit springer.com for the latest information about this book. 2012. XIII, 540 p. 25 illus., 22 in color. Hardcover ISBN 978-1-4614-3368-2 7 approx. $209.00

Easy Ways to Order for the Americas 7 Write: Springer Order Department, PO Box 2485, Secaucus, NJ 07096-2485, USA 7 Call: (toll free) 1-800-SPRINGER 7 Fax: +1(201)348-4505 7 Email: [email protected] or for outside the Americas 7 Write: Springer Distribution Center GmbH, Haberstrasse 7, 69126 Heidelberg, Germany 7 Call: +49 (0) 6221-345-4301 7 Fax : +49 (0) 6221-345-4229 7 Email: [email protected] 7 Prices are subject to change without notice. All prices are net prices.

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 DOI 10.1007/s00520-015-2712-y

ABSTRACTS

S2

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

Explanation of Abstract Coding System Invited Speaker Presentations appear first followed by abstracts grouped according to Topic. Each abstract Topic is assigned a code (01–27). For each Topic, following the Topic code the abstracts are numbered in sequential order starting with 01. Within each Topic, oral abstracts appear first followed by posters. Oral abstracts are marked “O” and posters are marked “P.”

The abstracts are presented in the following order with the below codes: IS Invited Speaker Presentations

IS-01 to IS-29

01 Bone

01-01-O to 01-31-P

02 Cachexia

02-01-O to 02-14-P

03 Cancer Pain

03-01-O to 03-38-P

04 Education in Supportive Care

04-01-O to 04-41-P

05 End-Stage Disease

05-01-O to 05-09-P

06 Fatigue

06-01-O to 06-23-P

07 Geriatrics

07-01-O to 07-13-P

08 Hematologic Toxicity

08-01-O to 08-11-P

09 Lymphedema

09-01-O to 09-10-P

10 Mucositis

10-01-O to 10-50-P

11 Nausea-Vomiting

11-01-O to 11-61-P

12 Neurological Complications

12-01-O to 12-21-P

13 Neutropenia-Infections

13-01-O to 13-27-P

14 Nutrition

14-01-O to 14-19-P

15 Oral Care

15-01-O to 15-33-P

16 Pediatrics

16-01-O to 16-25-P

17 Palliative Care

17-01-O to 17-95-P

18 Psychooncology

18-01-O to 18-61-P

19 Respiratory

19-01-O to 19-04-P

20 Skin toxicity

20-01-O to 20-19-P

21 Thromboembolic Events

21-01-O to 21-10-P

22 Quality of Life

22-01-O to 22-62-P

23 Rehabilitation

23-01-O to 23-50-P

24 Survivorship

24-01-O to 24-53-P

25 Treatment of Specific Toxicities

25-01-O to 25-19-P

26 Other Supportive Care

26-001-O to 26-103-P

27 Late Breakers

27-01-O to 27-08-P

S3

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Author Index A Aapro, M. Abadi, S. Abe, K. Abe, M. Abe, T. Abernethy, A. Abildgaard, O. Aboshady, H. Abouassi, A. Abouzaid, S. Abrahamsson, J. Abramov, M. Abrams, G. Abreu, A.K.C. Abrosimova, A.A. Abu Qayyas, B. Abu-Shkara, R. Abuidris, D. Acharya, B. Ackerman, I. Adamietz, I.A. Adamsen, L. Adda, A. Addae, M. Adeyemi, J. Aditya, M. Agarwal, G. Agerbæk, M. Aggarwal, S. Aguilar-Ponce, J. Ahmed, M. Ahmedzai, S. Ahmedzai, S.H. Ahn, H.Y. Ahn, J. Ahn, J.B. Ahn, S. Ahrari, S. Aiba, K. Aihara, Y. Aitichou, M. Ajay, D. Ajay, G. Akgun Kostak, M. Akman, T. Akmansu, M. Aktas, B. Akyol, M. Al Ghor, M. Al-Ajarmeh, S. Al-Arja, G. Al-Dasooqi, N. Al-Hadithy, N. Al-Rimawy, D. Alacacioglu, A. Alahari Dhir, A. Alavi Majd, H. Alawneh, A. Albers, A. Albert, U.S. Alberts, S. Albrand, G. Albrand, H.

11-09-P 12-16-P 23-45-P 11-14-P 11-34-P 17-09-P, 02-02-O, 02-01-O O. 23-46-P 26-007-O 26-033-P 11-19-P, 11-18-P 16-02-O 22-43-P 03-12-P, 03-02-O 20-19-P 13-11-P 22-31-P 25-02-O 01-13-P 15-24-P, 10-49-P, 04-31-P 04-13-P 10-43-P IS-25, 23-28-P, 23-01-O, 23-41-P 08-11-P 05-09-P 18-33-P 17-39-P 12-21-P 12-04-P 12-07-P 04-09-P 15-17-P, 24-51-P 03-32-P 19-01-O, 11-54-P, 11-27-P 24-10-P 04-22-P 24-18-P 20-10-P, 26-099-P 10-04-O 11-26-P 17-35-P 07-01-O 24-23-P 17-75-P, 07-09-P 22-53-P, 26-094-P 17-76-P 26-045-P 18-57-P 04-28-P, 18-24-P, 18-25-P 22-02-O 17-40-P 17-40-P 10-17-P 05-05-P 17-40-P 18-24-P, 18-25-P 21-01-O 17-45-P, 17-30-P, 16-14-P 17-40-P, 26-030-P, 22-31-P 10-14-P 18-02-O 23-07-O 07-01-O 13-17-P, 13-07-P, 13-06-P, 13-05-P, 13-01-O

Alcasabas, P. Aldroubi, H. Aleksenko, L. Alevizopoulos, N. Alfaro, E. Alfonso, S. Algun, Z.C. Alhatem, A. Ali, A. Ali, N.N. Ali, Z. Ali, Z.V. Alkalay, Y. Allam, A. Allende-Perez, S. Allenidekania, A. Allers, T. Allum, T. Almeida, A. Almeida, A.M. Alonso Orduña, V. Alós Cïvico, F. Altundağ, O. Alvarez-Avitia, M. Alves, M.T. Amadori, F. Amano, K. Amaral Mendes, Amdur, R. Amidi, A. Amir, E. Amiwero, C. Amlani, B. Ammar, K. An, H.J. Anagnostopoulos, A. Anampa Mesias, J. Andersen, B. Andersen, C. Andersen, D. Andersen, E. Andersen, K. Andersen, O. Anderson, A. Andreasen, A. Andrew Wotherspoon, A. Andrews, R. Andreyev, J. Andrianopoulos, T. Andrijic, M. Andrijono, A. Andrykowski, M. Ann Muls, A. Anstey, S. Antonacci, G. Antoniou, F. Antonuzzo, A. Antunes, M.F.R. Aoki, O. Aoki, S. Aouizerat, B. Aouizerat, B.E. Aoyama, T.

16-13-P 12-12-P 05-09-P 10-48-P 16-17-P 13-03-O 04-32-P 17-42-P 15-25-P 12-10-P 17-88-P 17-88-P 16-08-P 22-28-P, 17-34-P 17-18-P 15-21-P, 04-18-P 18-09-P 10-21-P 26-092-P 24-50-P, 23-30-P 03-16-P 18-49-P 20-14-P 04-09-P 16-24-P, 10-12-P 15-18-P, 15-04-P, 10-09-P, 10-02-O 17-25-P R. 15-33-P 23-08-P 24-33-P, 12-04-P 26-022-P, 11-06-O 26-102-P 11-01-O 22-31-P 05-04-P 10-30-P 02-13-P, 02-04-O 26-055-P IS-25, 22-17-P, 23-41-P 26-055-P, 26-031-P 24-09-P 08-09-P 10-33-P 11-16-P 26-055-P, 26-031-P 11-60-P 26-090-P 25-07-P 26-052-P, 18-39-P, 18-37-P, 13-23-P, 13-22-P, 11-50-P, 06-04-P, 03-17-P 26-069-P, 18-56-P 24-52-P 06-06-P 14-08-P 03-33-P 10-44-P 01-20-P 26-088-P 22-47-P 23-15-P 17-25-P 03-12-P, 03-02-O 06-02-P 23-09-P, 02-07-P, 02-06-P

S4

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

Appaji, L. Appel Esbensen, B. Aprile, G. Arai, H. Arana-Chavez, V.E.

18-16-P IS-09 05-01-O 23-21-P 26-064-P, 1512-P, 25-14-P Aranda, S. 18-05-O Araujo, D. 11-15-P Arber, A. 03-15-P Arce-Salinas, C. 17-18-P, 04-09-P Ardavanis, A. 01-01-O, 10-30-P Argiris, A. 10-15-P Ariana, S. 04-10-P Arias de la Vega, F. 10-01-O Armero, N. 17-10-P Armes, J. 06-11-P, 06-08-P Armstrong, A. 24-51-P Arogunmati, Q. 18-33-P Arora, S. 11-20-P, 11-03-O, 1111-P, 11-38-P, 11-39-P Arthur, J. 17-07-P Arzate-Mireles, C. 17-18-P Asakura, M. 09-02-P Asdahl, P.H. 13-13-P, 16-11-P Ashbury, F. IS-24 Ashkenazi, S. 25-02-O Ashkvari, P. 04-37-P Ashmore, T. 24-24-P Ashraf M, S. 08-03-P Aslan Erdem, S. 10-25-P Aslan, Ö. 17-86-P, 04-28-P Asmah, R. 05-09-P Assi, T. 22-02-O Ates, Y. 26-027-P Atfy, M. 08-03-P Athanasiadis, I. 10-30-P Atherton, P. 12-06-P, 12-02-O, 18-01-O Atik, A. 09-07-P, 09-06-P Attali, P. 10-08-P, 10-01-O Aubaret, C. 26-014-P Auber, M. 11-13-P Augustine, D. 22-57-P Aulino, J. 09-03-P Avatar, C. 13-19-P Avelino, S.R. 20-19-P Aviles-Robles, M.J. 13-13-P Awan, S. 15-25-P Awni, M. 17-40-P Axelsen, L. 08-09-P Ayakdas, S. 18-24-P Aydemir, A. 18-48-P Azizian, M. 15-29-P Azuero, A. 24-21-P B Babacan, T. Babu, A.S. Baca, E. Baccher, G.K. Badru, A.I. Badyal, D. Bae, H.S. Bae, S.B. Bafaloukos, D. Baggi, F. Baharvand, M.

18-57-P 23-03-O 23-32-P 23-49-P 17-78-P, 17-73-P, 04-34-P 11-04-O 09-05-P 26-096-P 01-20-P, 01-01-O 23-18-P 15-29-P, 16-19-P

Baheti, G. 11-20-P Bahrami, F. 22-23-P Baile, W. 17-07-P Baillie, L. 24-45-P Bain, E. 12-18-P Bairati, I. 25-16-P Bakhshi, S. 01-02-O Bakhshi, S.A. 01-17-P Bakic, N. 19-04-P, 26-069-P, 18-56-P Balabagno, A. 17-36-P Balachandar, V. 03-35-P, 03-36-P Balachandran, D. 06-20-P, 17-06-O Balcı Yangın, H. 26-091-P Balding, L. 12-13-P Ball, D. 18-05-O Ballard, T. 23-12-P Ballatori, E. 06-21-P Ballesteros Bargues, J. 03-16-P Balneaves, L. 04-02-O Bang Christensen, K. IS-25, 23-01-O Banipal, R. 18-40-P Banno, T. 26-013-P Bansal, S. 17-04-O Barak, F. 14-16-P Barbera, L. 04-13-P Barbo, A. 13-18-P Barbosa, C.A.M. 15-09-P Barbour, S. 11-07-P Barcellos Dalri, M.C. 15-06-P Bardellini, E. 15-18-P, 15-04-P, 10-09-P, 10-02-O Barnes, T. 04-13-P Barron, R. 13-10-P Barros Ferreira, E. 20-19-P Barrueco, J. 26-007-O Barsevick, A. 24-13-P Barsky, A.J. 18-02-O Bartels, F. 23-34-P Bartels, F.R. 26-054-P Barua, C. 26-073-P Basaran, B. 23-32-P Basford, J. 23-33-P, 23-07-O, 01-27-P Basharova, E. 16-04-P Bashoura, L. 17-06-O Baskent, A. 09-07-P Bastian, S.E.P. 10-39-P, 10-29-P Basu, A. 22-34-P Batehup, J. 24-02-O Batehup, L. 06-11-P Bateman, E. 27-06-P, 10-27-P, 1017-P, 10-20-P, 10-41-P Bates, U. 17-21-P Bauer, A. 22-52-P Baumann, W. 04-11-P Bayoglu, V. 18-24-P, 18-25-P Baytekin, M. 22-53-P Bazin, I. 20-04-P Beale, P. 26-010-P Beard, C.J. 24-14-P Beauchamp, M. 16-06-P Beck-Mannagetta, J. 01-21-P Becker, G. 26-068-P Beckford-Brathwaite, E. 27-02-O Beckman, V. 01-04-P Bedard, G. 22-58-P, 22-10-P, 1125-P, 09-10-P, 11-35-P

Bedi, A. 23-16-P Beeckman, D. 18-22-P Beernaert, K. 17-13-P, 17-38-P Begam, S. 11-55-P, 10-46-P Behrentzs, A. 11-51-P Beijers, A. 12-01-O Beith, I. 24-36-P Bektas-Kayhan, K. 27-08-P, 23-32-P Bektas, H. 04-01-O Belling, R. 26-056-P Belonogov, A. 20-04-P Belsante, M. 25-06-P, 24-23-P Belton, L. 26-046-P Bender, M. 01-21-P Bendix, M.T. 26-034-P Bendixen, M.H. 26-034-P Bengtson, M. 27-01-O Beniwal, S. 26-025-P, 06-09-P Benjamin, R. 11-15-P Bennaoum, N. 08-11-P Bennett, M. 03-33-P Benney, M. 24-42-P Bensadoun, R. 10-01-O Bensadoun, R.J. IS-19 Benser, J. 04-11-P Benter, M. 22-42-P Benthien, K.S. 03-08-P Benz, R. 24-21-P berardi, D. 13-21-P, 06-13-P berardi, G. 13-21-P, 06-13-P Berardi, R. 08-02-O Bergenmar, M. 15-05-P Berger, K. 13-08-P, 10-31-P Berget, O.S. 24-46-P Bergmann, K. 16-11-P Bergnolo, P. 11-42-P Berkvens, N. 22-37-P, 20-12-P Bernard, R. 13-08-P Bernardo, M. 18-20-P Bernareggi, A. 11-28-P, 11-09-P, 11-30-P Bertelsen, A. 10-22-P Berthou, C. 13-17-P, 13-07-P, 1306-P, 13-05-P, 13-01-O Beuzeboc, P. 24-17-P Beylich, A. 04-11-P Bezbarua, B. 26-073-P Bhadriraju, S. 25-01-O Bhargava, M. 12-14-P Bhargava, R. 23-25-P, 11-45-P Bhargava, S. 12-21-P, 12-14-P Bhargava, V. 12-21-P, 12-14-P Bhatia, A. 22-58-P Biason, E. 22-11-P Bickerstaff, M. 17-02-O Biester, I. 23-11-P Bilodeau, K. 26-076-P, 26-048-P, 24-49-P Bird, R. 08-10-P Birenbaum-Carmeli, D. 24-27-P Birgegård, G. 26-002-O Birgens, H. 23-01-O Bittner, E.C. 13-13-P Bjarnason, G. 18-04-O Bjordal, K. 15-05-P Bjørner, J.B. 22-26-P Black, P.C. 24-05-O Blackwell, S. 17-21-P

S5

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Blagden, S. 24-37-P Blanchard, P. 10-01-O Blank, A. 22-09-P Blecher, C.S. 04-05-P, 04-03-O Bleda, M. 22-20-P Blijlevens, N. 15-14-P Blijlevens, N.M.A. IS-27 Blinman, P. 26-010-P Bloomquist, K. IS-25, 23-41-P Blum, D. 17-46-P, 02-03-O Boccia, R. 26-046-P Bodduluru, L. 26-073-P Bødtcher, H. 11-47-P Boers-Doets, C.B. 04-21-P Boese, S. 23-10-P, 22-52-P Boglione, A. 11-42-P Bohac, C. 21-02-P, 26-046-P Boisen, M.K. 26-018-P Boller, E. 11-33-P Bollig, A. 10-31-P Boltong, A.G. IS-12 Bonacossa, E. 23-18-P Bondarenko, I. 26-007-O Bontempo, P.S.M. 20-19-P Boos, J. 16-05-P, 16-03-P Booth, C. 17-31-P Boquiren, V. 23-02-O Borges, U. 04-11-P Borimnejhad, L. 16-14-P Borisov, P. 20-04-P Bosani, R. 25-02-O Boscagli, G. 26-066-P Bose, N. 18-52-P Bosnjak, S. 19-04-P, 26-069-P, 18-56-P Bossi, P. 25-01-O, 10-44-P, 26-060-P Botana Rodríguez, C. 16-17-P, 16-16-P, 16-09-P, 16-07-P Botti, S. 15-14-P Boughey, J. 18-09-P Bowen, J. 10-06-P, 10-03-O, 2706-P, 10-27-P, 10-20-P Bowen, J.M. 12-11-P, 10-16-P, 10-18-P Bowman, C.A. 14-09-P Boyle, F. 22-37-P, 20-12-P Bozkaya, T. 09-06-P Bozkurt, M. 19-03-P Braccia, D. 11-10-P Bracelli, S. 17-82-P Brady, A. 17-61-P Brahimi, M. 08-11-P Brames, M. 11-44-P Brames, M.J. 22-04-P Brao, I. 17-68-P Brasnu, D. 26-014-P Breckons, M. 06-11-P, 06-08-P Breen, L.J. 04-23-P Breen, T. 11-44-P Breitenstein, U. IS-25 Brems-Eskildsen, A.S. 26-017-P Brennan, M.T. 10-10-P, 10-05-O, 15-08-P Brennan, R. 23-35-P Brinch, L. 15-02-O Brink, C. IS-05, 07-02-O, 10-22-P Brinkman, T. 22-03-O Brito-Dellan, N. 25-01-O, 06-07-P Broch, B. 08-09-P

Brochmann, N. 22-17-P Brock Johansen, J. 26-009-P Brock, P. 26-065-P Brodie, H. 24-42-P Brooks Young, P. 17-79-P Brown, C. 11-10-P Brown, L. 22-29-P Brown, S. 24-37-P Bruera, E. 04-26-P, 17-26-P, 17-07-P, 03-04-P, 03-11-P, 23-16-P, 03-03-P, 03-07-P, 26-016-P, 17-09-P, 17-08-P, 17-04-O, 17-01-O, 03-21-P, 17-05-O, 17-47-P Bruera, S. 17-47-P Bruns, C.J. 17-71-P Bruun, B. 07-03-P Buchanan, A. 03-15-P Buchanan, H. 18-47-P Buck, U.M. 11-58-P Buelens, O. 17-42-P Buhren, B.A. 25-12-P Bukreeva, E. 23-20-P, 01-22-P Bulens, P. 20-01-O Bulog, A. 03-34-P Burdaeva, O.N. 13-11-P Burdon, J. 11-54-P Burhenn, P. 04-05-P, 04-03-O Burke, L. 17-21-P Burns, A.M. 23-25-P Busch, S. 11-46-P Buthion, V. 26-070-P Butow, P. 22-15-P Buttignol, S. 17-82-P Buzzi, J. 21-04-P Byham-Gray, L. 14-12-P Byrne, J. 27-04-P Byun, M. 12-17-P C Cabezón Gutiérrez, L. 03-16-P Cabral Castellá, C. 16-16-P Caissie, A. 26-051-P Cajucom, L. 17-36-P Calderillo-Ruiz, G. 04-09-P Caldwell, B. 25-08-P Caliskan Yilmaz, M. 26-087-P, 17-59-P Calman, L. 24-02-O, 06-11-P, 06-08-P Calman, L.Y.N.N. 06-19-P Camacho, E.S. 27-02-O Cameron, M. 03-06-P Campbell, F. 10-50-P Campbell, K. 17-79-P, 16-06-P Campbell, K.L. 23-12-P Campos Pereira Silveira, R.C. 15-06-P Campos, L. 26-064-P, 15-12-P, 25-14-P Canada, T. 14-07-P Cannavale, K. 08-05-P, 08-01-O Cantoreggi, S. 10-20-P Cantu, H. 17-07-P Carabellese, B. 13-21-P Caraceni, A. 17-09-P Carafizi, N. 17-91-P Caramanti, M. 08-02-O Caran, E. 16-24-P, 10-12-P Cardenal, F. 17-68-P

Carle, M.E. 26-076-P Carlos, D. 01-23-P Carlson, L.E. 18-59-P, 04-02-O Carmona-Bayonas, A. 13-03-O Carnaby-Mann, G. 23-08-P Carnaby, G. 18-29-P Carnaby, G.D. 23-23-P Carnelli, L. 18-21-P Carr, S. 17-61-P Carrara, M. 26-060-P Carroll, J.D. 20-16-P Caruso, D. 08-07-P Carvalho, R.A.O. 24-50-P Casalta-Lopes, J. 22-35-P Cascinu, S. 08-02-O Case-Eads, S. 22-04-P, 11-44-P Case-Eads, S.L. 24-14-P Cassel, B. 03-13-P Castro-Arantes, J. 26-081-P, 17-92-P Castro, D.G. 22-01-O Castro, J. 15-12-P, 21-08-P Castro, J.R. 26-064-P Cattaruzza, M. 05-01-O Cauwenbergh, G. 22-61-P Cavallo, A. 26-060-P Cavatorta, C. 26-060-P Cavus, S. 27-08-P, 23-32-P Çay Şenler, F. 24-38-P Cay-Senler, F. 18-57-P, 17-76-P Cazzaniga, M.E. 18-53-P Ceciliano, A. 16-07-P Cehreli, R. 17-76-P Censabella, S. 20-01-O Ceruse, P. 10-01-O Cetinkaya, Y. 15-23-P Cevas Chopitea, F. 03-16-P Çevik, B. 20-14-P Chacón, R. 26-035-P Chaen, M. 24-44-P Chagnon-Pennel, H. 25-13-P Chahine, G. 22-02-O Chambers, S. 18-05-O Champion, V.L. 22-04-P Chan, A. 26-038-P, 14-02-O, 24-40-P, IS-10, 22-41-P, 18-03-O Chan, C.H. 17-19-P Chan, C.W.H. 18-23-P Chan, R. 14-02-O Chang, C.S. 03-25-P Chang, K.P. 07-08-P Chang, M.I.A.E. 04-22-P Chang, Y. 17-32-P Chang, Y.C. 25-01-O Chantada, G. 16-07-P Chao, C. 08-05-P, 08-01-O Chapman, O. 21-07-P Charalambous, A. IS-23, IS-13 Chari, U. 18-16-P Chasen, M. 11-03-O, 17-83-P Chasen, M.R. 23-25-P, 11-45-P, 11-38-P Chatterjee, P. 17-43-P, 14-05-P Chatzichalepli, C. 02-10-P Chaudhry, Z.S. 22-48-P, 18-44-P Chaumard-Billotey, N. 07-01-O Chauvin, F. 24-41-P Chavez Mac Gregor, M. 11-02-O

S6 Cheah, K.Y. Chebib, R. Chebolu, S. Check, D. Chen, C. Chen, D. Chen, E. Chen, J.M.T. Chen, J.S. Chen, L. Chen, L.M. Chen, S. Chen, Y.J. Cheng, A. Cheng, C. Cheng, M. Cheng, S. Cheng, W. Cheng, Y. Cheon, J.H. Cheon, P.

10-40-P 22-02-O 11-22-P 26-003-O 26-020-P 03-20-P 01-30-P 18-23-P 18-38-P, 03-25-P 03-12-P 03-02-O 15-26-P 18-38-P, 03-24-P, 24-08-P 01-25-P 23-17-P 17-27-P 26-097-P 17-27-P 26-006-O 24-18-P 22-30-P, 11-37-P, 26-097-P, 11-25-P, 06-14-P, 01-26-P, 17-94-P, 04-27-P, 17-84-P, 12-18-P Cheon, P.M. 03-38-P Cheon, S. 17-84-P Cheraghi, M.I.N.A. 04-37-P Cherny, N. 17-09-P Cheung, H.Y.S. 18-28-P Cheung, Y. 18-03-O Chevalier, E. 20-15-P Cheville, A. 23-33-P, 23-07-O, 01-27-P Chew, C. 20-11-P Chhabria, K. 18-29-P Chi Kin Cheng, A.M.B.B.S. 18-28-P Chiadò Cutin, S. 11-42-P Chiao, E. 13-18-P Chidiac, J. 21-04-P Chin, L. 01-24-P Chinen, E. 26-064-P Chiou, T.J. 03-25-P Chisholm, G. 17-07-P, 03-04-P, 17-01-O Chisholm, G.B. 23-16-P Chiu, L. 04-27-P, 01-23-P Chiu, N. 17-85-P, 04-27-P, 01-23-P Chivers Seymour, K. 24-02-O Cho, I. 11-31-P Choi, C.W. 11-56-P Choi, D. 20-10-P Choi, H.J. 26-096-P, 24-18-P Choksey, G. 22-54-P Chou, F. 26-074-P, 22-24-P Chourasia, P.K. 05-03-P Chow, E. 11-40-P, 03-28-P, 01-30-P, 01-05-P, 01-31-P, 01-24-P, 22-30-P, 11-37-P, 26-097-P, 11-61-P, 01-28-P, 22-58-P, 22-10-P, 11-25-P, 09-10-P, 06-14-P, 01-26-P, 01-09-P, 11-35-P, 22-27-P, 22-16-P, 03-38-P, 01-29-P, 01-12-P, 17-94-P, 17-85-P, 04-27-P, 01-23-P, 17-84-P, 12-18-P Chow, R. 11-37-P, 26-097-P, 22-10-P, 01-09-P Chow, S. 01-09-P

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Christakis, M. 01-30-P Christensen, C. 01-03-O Christensen, I.J. 22-07-P Christensen, J. 11-07-P Christiansen, A.B.. 26-018-P Christodoulou, C. 01-01-O, 10-30-P Christoffersen, C. 11-58-P Chu, D. 17-85-P Chu, S.T. 18-38-P Chudakov, K. 22-49-P Chung, H. 11-35-P Chung, S.H. 09-09-P, 09-05-P Chung, W. 20-10-P Ciccolini, K. 20-18-P Citterio, G. 10-35-P Çıracı, Y. 17-81-P, 17-15-P Claes, S. 20-01-O Clark, F. 23-37-P Clark, M. 18-01-O, 23-07-O Cleeland, C.S. 12-10-P Clemmensen, O. 20-07-P Cloud, M. 18-52-P Coche, B. 26-100-P Cockle-Hearne, J. 24-42-P Codorniu, N. 17-68-P, 22-20-P Coffey, L. 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P Cohen, J. 17-38-P Coller, J.K. 10-18-P Colleran, M. 17-93-P, 17-37-P Collett, A. 25-09-P Colloud, V. 07-01-O Comandone, A. 11-42-P Combemale, P. 20-09-P Combrez, P. IS-08 Commatteo, A. 13-21-P Concha, A. 03-23-P Cong, Z. 26-032-P, 12-07-P Coniconde-Arca, D. 16-13-P Conley, A. 11-15-P Constenla Figueiras, M. 03-16-P Conti, F. 01-14-P Contreras-Martinez, J. 10-01-O Conway, E. 17-21-P Cooke, D. 23-30-P, 24-42-P Cooksley, T. 13-12-P Cooper, B. 03-12-P, 03-02-O, 06-02-P Coppes, R.P. 15-11-P Copson, E. 24-51-P Cormie, P. 24-11-P Corner, J. 24-02-O, 06-11-P, 06-08-P Corradini, A. 08-09-P Correa-Bautista, J.E. 04-12-P Cortes, J. 17-04-O Cortinovis, D. 11-01-O Cote, M. 25-16-P Cotterell, P. 06-11-P Cougnenc, O. 26-100-P Coupé, V.M. 18-32-P Cox, S. 18-52-P, 26-057-P, 17-17-P Coyne, E. 26-024-P Coyne, K. 03-32-P Cranston, C. 23-25-P Crary, M. 23-23-P, 23-08-P Creedy, D.K. 26-024-P Cremen, I. 17-21-P

Cristino, J. 01-11-P Crocker, M. 12-12-P Croghan, I. 06-01-O Croghan, K. 06-01-O Cronin Fenton, D. 01-03-O Cross, S. 23-35-P Crumpei, G. 18-30-P Crumpei, I. 18-55-P Cruz, F.O.A.M. 20-19-P Cruz, J. 13-03-O Cruz, P. 21-08-P Crvenkova, S. 08-06-P Cuijpers, P. 18-32-P Cullen, V. 10-11-P Currie, M. 24-24-P Currow, D. 17-09-P, 02-02-O, 02-01-O Cutress, R. 24-51-P, 24-29-P Cysdorf, A. 13-15-P D D’Alimonte, L. 04-13-P D’amico, F. 13-21-P Dadda, P. 23-18-P Daddi, A. 21-01-O Daem, M. 18-22-P Dagan, E. 24-27-P Dakhil, S. 12-06-P Dal Canton, O. 11-42-P Dalakou, E. 03-31-P Dalal, S. 26-016-P, 17-47-P Dalenc, F. 20-09-P Daliani, D. 10-30-P Dalle, E. 26-100-P Dalton, S. 24-06-O, 26-028-P Dalton, S.O. 24-09-P, 23-36-P Daniel-Macdougall, C. 02-08-P Daniel, M. 11-15-P Daniela, F. 04-10-P Danieli-Zigelman, N. 14-16-P Danielson, B. 22-30-P Danjoux, C. 11-25-P, 06-14-P Danklou, J. 26-011-P Dardoufas, K. 10-15-P Darmani, N. 11-22-P DasGupta, T. 17-58-P Datta, S. 26-079-P Daugaard, G. 22-07-P Daugaard, R. 23-14-P Dauvissat, C. 21-05-P David, E. 01-28-P, 01-09-P Davidson, P.M. 17-56-P Davies, A. 17-17-P, 03-15-P Davies, J. 17-57-P Davies, P. 10-21-P Davis, J. 26-033-P Davis, M. 17-09-P Day, L. 04-05-P, 04-03-O, 04-13-P Day, R. 26-033-P Dayan, M. 24-05-O De Abreu, M. 26-035-P De Angelis, C. 10-04-O De Boel, K. 10-37-P De Cicco, L. 17-82-P De La Cruz, G. 03-10-P De la Cruz, M. 03-11-P, 17-05-O, 03-07-P De la Garza-Salazar, J. 04-09-P

S7

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 De Laat, M. 17-38-P De Lemos, M. 26-037-P De lujan, L. 21-08-P De Ryck, T. 10-24-P De Souza, J.C.L. 07-10-P De Vleminck, A. 17-13-P DeAngelis, C. 11-40-P, 03-28-P, 13-16-P, 11-37-P, 26-097-P, 11-61-P, 22-58-P, 22-10-P, 11-25-P, 06-14-P, 01-09-P, 11-35-P, 22-27-P, 17-85-P Dearnaley, D. 24-36-P Decoene, E. 18-22-P Deeke Sasse, A. 23-18-P Deepika rikhi, D. 13-19-P Defachelles, A.S. 25-05-P Degardin, M. 26-100-P Dégi, C. 18-17-P DeGore, L. 09-04-P Deguzman, C. 18-04-O Dehnel, A. 05-05-P Del Barco, E. 13-03-O Del Fabbro, E. 03-13-P Delbey, S. 26-011-P Delgado-Guay, M. 17-05-O Deliens, L. 17-13-P, 17-38-P Della-Fiorentina, S. 26-010-P Delmar, C. 26-101-P, 26-067-P Delord, J.P. 20-03-P, 20-09-P Demin, E. 24-53-P Demir, B. 26-071-P Demir, F. 26-087-P Demir, L. 18-24-P, 18-25-P Demiri, M. 10-30-P Demizu, A. 17-25-P Deng, J. 09-03-P, 26-015-P, 14-01-O Deng, Q. 17-77-P Denisov, M. 22-49-P Deniz, O. 24-38-P Denlinger, C. 24-13-P Dennis, K. 01-26-P, 11-35-P, 26-029-P, 04-39-P Denollet, J. 24-06-O Dent, R. 18-03-O Deo, S.V.S. 07-09-P Deray, G. 26-004-O, 24-17-P Derevyanko, T.I. 22-32-P Dericquebourg, A. 26-011-P DeRyck, T. 10-37-P Deschepper, R. 17-13-P Desmond, D. 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P Desses, N. 01-20-P Desti, C. 26-066-P Detlefsen, M. 26-055-P, 26-031-P Dev, R. 03-21-P Devriendt, D. 20-15-P, 12-03-P Dholam, K. 23-49-P, 22-54-P Dhuibhir, P. 17-67-P Di Cristo, C. 26-066-P Di lullo, L. 13-21-P, 06-13-P Di marzio, L. 13-21-P, 06-13-P Di Mattei, V.E. 18-21-P Di Prospero, L. 04-13-P Dickman, A. 17-28-P, 17-02-O Diefenbach, M. 24-33-P

Diel, I. Diep, P.P. Dieperink, K.B. Dietric, M. Dietrich, M.S. DiGiacomo, M. DiGiovanni, J. Dijkers, M. Dimitriadou, A. Dimitrijevic, J. Dimitrovska, A. Ding, J. Dirican, A. Dispenzieri, A. Diwan, S. Djordjevic, F. Do, J. Dobbins, T. Dobrian, A. Dodo, M. Doherty, J. Doi, A. Doi, T. Doiron, E. Doki, Y. Dokou, A. Domen, K. Dongsgaard, T. Donovan, G. Dörfel, S. Dos Santos, A.F.J. Dos Santos, R. Dose, A. Douillard, J.Y. Dow, R. Downey, P. Dowsett, R. Doyle, N. Dr Kar, S. Drakakou, E. Dreyers, J. Drummond, F.J. Dubinina, V. Dubois, S. Ducrocq, J.L. Dudov, A. Dugad, J. Duke, S. Dulcineia, P. Dumitrescu, C. Dunan, C. Dunn, J. Dunne, S. Durand, M.J. Durante, V. Durcinoska, I. Dusetzina, S.

11-46-P, 01-11-P 15-02-O 23-38-P, 26-024-P, 23-24-P 26-015-P, 14-01-O 09-03-P 17-56-P 01-30-P 24-33-P 10-48-P 19-04-P, 26-069-P, 18-56-P 08-06-P 18-54-P 18-24-P, 18-25-P 22-05-P 15-17-P 19-04-P, 26-069-P, 18-56-P 18-07-P 22-15-P 15-16-P 15-28-P 25-10-P 11-23-P 25-17-P 26-051-P 11-32-P 18-18-P 23-15-P 11-57-P, 26-017-P 10-21-P 11-33-P 14-17-P 17-01-O 23-33-P 26-007-O 24-16-P 23-12-P 06-16-P 24-45-P 26-079-P 18-18-P 25-02-O 24-01-O 11-59-P 26-048-P 21-05-P 27-01-O 22-54-P 03-33-P 13-20-P 12-03-P 10-34-P 21-07-P 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P 24-49-P 01-14-P 26-021-P, 26-001-O, 22-15-P 26-003-O

E Easton, L. Eccles, C. Eccles, D. Ecclestone, C. Eckes, J. Eckhoff, L.

04-13-P 24-51-P 24-51-P, 24-29-P 22-58-P, 22-10-P, 09-10-P 20-05-P IS-17

Edgren, G. Edwards, B. Edwards, S. Eeltink, C. Eftimova, B. Egenvall, M. Eifel, P. Eilers, J. Einarsdottir, A. Einhorn, L. Einhorn, L.H. Ejlertsen, B. Ekholm, O. El Bedoui, S. El Gemayel, M. El Karak, F. El osta, B. El osta, L.

24-03-O 27-03-O 17-62-P 12-01-O 05-08-P 24-03-O 27-03-O 10-47-P 05-06-P IS-01 24-14-P, 22-04-P, 11-44-P IS-25 17-29-P 26-100-P 01-19-P, 01-15-P 22-02-O, 17-49-P 03-09-P, 01-19-P, 01-15-P 15-03-P, 03-09-P, 01-19-P, 01-15-P El osta, N. 15-03-P, 03-09-P, 01-19-P, 01-15-P El Rassy, E. 22-02-O, 17-49-P Elad, S. 15-16-P Elalamy, I. 21-04-P Elangovan, A. 04-07-P Elbeg, S. 26-045-P Ellershaw, J. 17-02-O Elliott, S. 24-05-O Ellis, J. 22-58-P, 22-10-P Elting, L. 11-02-O Elting, L.S. 25-01-O Emami, H. 22-23-P Emami, Z. 18-46-P Emi, N. 26-013-P Emmenegger, U. 26-097-P Enami, A. 25-11-P Engelholm, S.A. 22-26-P, 25-04-O Erdemir, U.G.U.R. 27-08-P Erdogan, B. 03-26-P Eriksen, J. 15-15-P Eriksen, J.G. 15-01-O, 10-22-P, 20-07-P Eriksen, V. 22-08-P Erinfolami, A. 18-33-P Ermacora, P. 05-01-O Erol, O. 26-071-P, 03-26-P Erturan, Z. 13-25-P Escalante, C. 04-33-P, 25-01-O, 06-07-P, 17-06-O Esquivel, N. 16-16-P Esquivel, Y. 16-07-P Estfan, B. 22-45-P Etzelsdorfer, M. 01-21-P Eurlings, M. 12-01-O Eusébio, S. 18-20-P Eva Grace, E. 14-08-P Evangelista, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Evans, G. 24-51-P Evans, M. 26-059-P, 26-058-P Ewer, M.S. 26-005-O Ewertz, M. 26-009-P, IS-17, 01-03-O Ewings, S.M. 06-08-P Exner, A. 23-11-P F Fach, E.M.

22-52-P

S8 Fader, M. 17-80-P Fadiloglu, C. 15-23-P Fagertun, H. 17-70-P Faithfull, S. 03-15-P Faiz, S.A. 17-06-O Fajardo, P. 16-13-P Falkmer, U. 26-101-P, 26-067-P Fallai, C. 26-060-P Fallone, S. 02-11-P Family, L. 08-05-P Fang, Y.Y. 03-24-P, 24-08-P Farajzadegan, Z. 22-50-P, 22-23-P Faria, C. 11-19-P, 11-18-P Farid, M. 26-038-P Farman, H. 25-02-O Farrell, C. 10-21-P, 07-06-P Farrington, N. 17-80-P Farroni, J. 26-008-P Farsi, F. 26-075-P Fasola, G. 05-01-O Fatemeh Keshavarzi, B. 26-089-P Fatigoni, S. 06-21-P Fatiregun, O. 18-33-P, 18-33-P Fatma VARAL, F.V. 22-60-P Fattahy rad, A. 26-089-P Fausel, C. 11-44-P Fearon, K. 02-02-O, 02-01-O Feitosa, E.F. 15-09-P Feldman, D.R. 24-14-P Feldstain, A. 17-83-P Felice, M. 16-17-P Feliu, J. 21-08-P Fellman, B. 17-06-O Fenlon, D. 24-02-O, 06-11-P, 06-08-P Fernandes, D.J. 23-03-O, 06-17-P Fernández-Ortega, P. 11-01-O Ferrari, M. 26-098-P, 26-063-P, 18-14-P Ferreira, A.D. 15-09-P Ferreira, D.M. 26-081-P Ferreira, M.V.M. 15-09-P Ferreira, S. 26-092-P Ferri, A. 15-18-P, 15-04-P Ferruccio, L.F. 11-06-O Feyer, P. 15-14-P, 11-08-P Fidarova, E. 22-01-O Filon, O.V. 13-11-P Fink, O. 25-02-O Finkelstein, J. 01-09-P, 19-02-P Fiordoliva, I. 08-02-O Fisch, M. 13-18-P Fischer, I. 06-15-P Fisher, S. 15-05-P Fitch, M. 22-40-P, 22-39-P, 17-58-P Fizazi, K. 01-10-P Flachs, E. 22-17-P Flohr, A. 22-40-P Florence, W.M. 04-40-P Floyd, P. 12-12-P Fogelman, D. 02-08-P Fonfria Esparcia, M. 03-18-P Fonseca, E. 13-03-O Font-Gonzalez, A. 16-01-O, 27-04-P Font, C. 13-03-O Fontanella, C. 05-01-O Ford, B. 17-58-P Ford, M. 01-09-P

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Forde, C. Forgione, A. Fornaro, J. Foro, P. Fortin, A. Fossa, S.D. Fossella, F. Foster, C.

13-04-O 03-28-P 02-03-O 22-30-P 25-16-P 24-14-P, 24-19-P 17-04-O 24-51-P, 24-29-P, 24-29-P, 24-02-O, 06-19-P, 06-11-P, 06-08-P, 24-42-P Foster, N. 26-026-P Foster, R. 24-42-P Fox, P. 26-023-P Fragakis, G. 13-27-P, 13-26-P, 13-24-P, 12-20-P, 03-29-P Frambati, L. 22-11-P Franchi, G. 23-29-P Frandsen, K.B. 22-07-P Frank, M. 26-039-P Frankland, J. 24-42-P Fraquelli, L. 16-17-P, 16-16-P, 16-09-P, 16-07-P Frederiksen, K. 24-09-P Fredslund, S.V. 23-36-P Freedman, O. 07-12-P Freitas, A. 15-09-P Fricain, J.C. 20-03-P, 10-36-P Friend, J. 02-02-O, 02-01-O Frisbee-Hume, S. 17-07-P Fritz, G. 10-27-P, 10-14-P Froelund, J.C. 11-58-P Frøslev, T. 01-03-O Frost, M. 18-09-P Früh, M. 17-46-P Fryer, C. 16-06-P Fu, C. 11-16-P Fuady, A. 24-52-P Fujii, M. 09-08-P Fujimori, M. 18-06-P Fukui, K. 18-19-P Fukunaga, M. 11-32-P Fukushima, T. 09-02-P Fukuzaki, T. 11-32-P Fulman, L. 10-50-P Fumi, G. 06-21-P Fundakowski, C. 18-11-P Fung, C. 24-14-P Furfari, A. 17-94-P Furukawa, N. 11-43-P Futagami, M. 18-12-P G Gabra, H. Gaggl, A. Gakii, G.K. Galeas, J.N. Galiti, D. Gall, T. Gallagher, P. Galli, L. Gallina, F. Galvao, D.A. Gamnagati, S. Gamnagatti, S.A. Gan, Y.

24-37-P 01-21-P 07-13-P 02-13-P, 02-04-O 01-20-P, 10-30-P, 10-15-P 18-50-P 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P 26-088-P 18-53-P 24-11-P 01-02-O 01-17-P 18-03-O

Gandhi, J. 27-01-O Gandini, S. 23-18-P Ganzer, H. 14-12-P Gao, Y. 17-77-P Garbin, L.M. 15-06-P Garcia Gonzalez, A.G. 12-10-P García Mata, J. 03-16-P Garcia peña, T. 21-08-P Garcia-Torres, F. 18-49-P Garcia, J. 13-10-P Garetto, F. 11-42-P Gasent, J.M. 03-18-P Gastinger, I. 17-71-P Gatengo-Modiano, S. 24-27-P Gatta, F. 01-11-P Geboes, K. 17-38-P Genka, T. 17-35-P Genot, M. 20-15-P Genot, M.T. 01-18-P George, A. 05-05-P Georgopoulos, I. 26-052-P, 18-39-P, 18-37-P, 13-23-P, 13-22-P, 11-50-P, 06-04-P, 03-17-P Georgopoulos, N. 25-09-P Geraghty, M. 18-52-P, 26-057-P Gerber, P. IS-14 Gerber, P.A. 25-12-P Gernhardt, D. 25-10-P Gerty, S. 24-29-P Gervais, C. 26-014-P Ghaemmaghami, F. 03-37-P Gharaei, D. 23-11-P Ghazal, H.H. 26-046-P Ghosh Dastidar, A. 17-43-P, 14-05-P Ghosh, S. 22-01-O Ghoshal, S. 08-08-P, 04-07-P GhoshDastidar, A. 22-34-P Ghosn, M. 22-02-O, 17-49-P Giandini, T. 26-060-P Giannarelli, D. 08-07-P Giassas, S. 10-30-P Gibo, T. 15-31-P Gibson, F. 26-056-P, 24-45-P Gibson, R. 10-06-P, 10-03-O, 10-17-P Gibson, R.J. 12-11-P, 10-16-P, 10-18-P Gigli, R. 13-21-P, 06-13-P Gill, J. 13-19-P Gill, S. 12-16-P Giordani, E. 08-07-P Giordano, G. 13-21-P, 06-13-P Giordano, S.H. 11-02-O Giordano, T. 13-18-P Giorgadze, M. 26-103-P Giotis, A. 13-16-P, 11-37-P, 26-097-P, 10-04-O Giralt, J. 10-01-O Giri, N. 25-10-P Gishen, F. 04-04-O Giuliano, C. 11-05-O Giusti, R. 01-14-P Glackin, M. 26-044-P Gleave, M.E. 24-05-O Glimelius, B. 27-01-O Gloria, G.K. 04-40-P Głowacka, I. 24-48-P, 23-48-P, 23-47-P, 23-19-P

S9

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Godtfredsen, N. Goedendorp, M. Goerloev, J.S. Gogalis, T. Gogoi, R. Goh, Y.T. Goldenberg, S.L. Goldman, L. Goldman, S. Goldman, Y. Goldwasser, B. Goleta-Dy, A. Golla, A. Golluscio, M.

22-14-P 06-06-P 26-054-P 03-31-P 26-073-P 22-41-P 24-05-O 23-16-P 22-36-P 15-16-P 02-13-P, 02-04-O 16-13-P 23-10-P 16-17-P, 16-16-P, 16-09-P, 16-07-P Golubovic, S. 03-34-P Golubovic, V. 03-34-P Gomes, A.M. 16-15-P Gómez, S. 16-09-P Gonçalves, G. 18-20-P Gonzalez merino, T. 21-08-P Gonzalez-Barboteo, J. 01-16-P González-Jiménez, E. 23-05-O, 23-04-O Gonzalez, C.E. 26-065-P Goodwin, P. IS-04 Gordon, D. 02-13-P, 02-04-O Gordon, N. 18-08-P Gorla, F. 10-09-P, 10-02-O Gørløv, J. 23-34-P Gornitzka, J. 26-080-P Goshima, M. 17-25-P Goto, K. 17-25-P Götte, M. 16-05-P, 16-03-P Gottfried, M. 26-007-O Gottlieb, M. 22-14-P Gough, K. 18-05-O Gough, P. 14-13-P Gozzo, T. 26-092-P Gozzo, T.O. 24-50-P, 23-30-P Grace, E. 25-07-P Graffigna, G. 06-10-P Gralla, R.J. 11-21-P, 05-03-P, 02-13-P, 02-04-O Granot, T. 25-02-O, 18-08-P Granwehr, B. 26-065-P, 13-18-P Gray Brunton, C. 17-79-P Grechi, E. 23-29-P Greenwood, K.M. 18-13-P Gregoraci, G. 05-01-O Gridelli, C. 11-38-P Griffin, J. 23-33-P Grimison, P. 26-023-P Grimmett, C. 24-51-P, 24-02-O, 06-19-P, 06-11-P, 06-08-P Grivas, T. 10-30-P Groen, A.K. 10-07-P Groenkjaer, M. 26-101-P, 26-067-P Grønkjær, M. 11-51-P Grønlie Guren, M. 26-095-P Grothey, A. 12-06-P Grufstedt, H. 23-34-P Grufstedt, H.K. 26-054-P Grumett, J. 21-07-P Grypdonck, M. 18-22-P Grzyb, K. 24-46-P Gu, X. 17-27-P

Guernsey, B. 11-16-P Guillen, C. 13-03-O Guillou, A.N.N.E. 26-014-P Guiton, M. 25-16-P Gulacsi-Bárdos, P. 25-18-P Gullo, G. 12-15-P Gülsüm Nihal Güleser, G.N.G. 22-60-P Gultas, C. 17-59-P Gumus, Z. 18-24-P, 18-25-P Gunnarsson, U. 24-03-O Guo, D. 10-34-P Guo, F.J. 01-08-P, 01-07-P Guo, W. 01-25-P Gupta, S. 25-06-P, 24-23-P Guth, D. 11-46-P Güveli, M. 27-08-P Gyoda, Y. 17-25-P H Ha, S.Y. 16-02-O Haas, N. 06-07-P Habib Lindkær-jensen, N. 17-70-P Hack, T. 23-02-O Hadji, P. 18-02-O Hafız, G. 13-25-P Haghighat, S. 22-51-P Hagner, W. 23-48-P Haider, A. 03-11-P Haines, T. 14-04-O Haitz, K. 18-04-O Haji-Michael, P. 13-12-P Halbert, R.J. 26-085-P Halkett, G. 18-15-P Halm, J. 26-008-P, 25-01-O Halyard, M. 26-019-P Hamad, F. 01-13-P Hameed, S. 17-65-P Hamer, J. 22-58-P, 22-10-P, 17-85-P Hamilton, R.J. 24-14-P Hammadi, M. 08-11-P Han, H.S. 11-12-P Han, X. 01-08-P, 01-07-P Hanai, A. 23-21-P Hancocks, H. 21-07-P Hand, A.R. 15-12-P, 25-14-P Handrup, M.M. 16-11-P Hanli, L. 18-52-P Hanna, N. 11-44-P Hanna, N.H. 22-04-P Hannon, B. 17-48-P, 17-11-P, 17-03-O, 17-50-P, 17-22-P Hans, S. 26-014-P Hansen, C.R. 15-01-O, 10-22-P Hansen, L. 22-08-P Hansen, M.K. 24-09-P Hansen, N.C.G. 07-02-O Hansen, O. 07-02-O, 24-04-O Hansen, T. 11-47-P Haq, S. 12-10-P Harada, M. 12-19-P Harber, G. 17-92-P Harder, E. 25-04-O Hariharan, S. 03-20-P Harle, I. 17-31-P Harmer, V. 10-21-P Harner, J. 01-23-P

Harsh, K.K.

25-03-O, 17-23-P, 26-025-P Harth, T. 04-13-P Harti, S. 22-61-P Hasaba, M. 18-61-P Hasegawa, Y. 25-17-P Hasenburg, A. 20-05-P Hashemi, L. 17-60-P Hashimoto, K. 17-25-P Haslam, I. 25-09-P Hasle, H. 16-02-O, 16-11-P Hassan, A. 22-28-P, 17-34-P Hasselbalch, H. 22-17-P Hasséus B. 10-05-O Hastürk, S. 19-03-P Hata, T. 11-32-P Hatamipour, K. 17-45-P, 17-30-P Hatano, Y. 18-19-P Hatoum, H.T. 11-19-P, 11-18-P Häusermann, S. 04-30-P Havinga, R. 10-07-P Havliand, J. 24-02-O Hawson, G. 26-023-P He, W. 11-02-O Heaven, C. 07-06-P Hebard-Massey, K. 13-10-P Hechmati, G. 01-11-P Heckler, C. 24-20-P, 19-02-P, 06-22-P Hedenus, M. 21-02-P Hedley, M.L. 11-20-P, 11-07-P Hegarty, J. 06-12-P, 24-47-P Hegedüs, L. IS-05 Hehli, D. 17-46-P Heike, Y. 22-33-P Helfer, H. 21-04-P Hendershot, E. 25-06-P Henderson, J.D. 26-065-P Henke, M. 10-01-O Hennequin, M. 15-03-P, 01-15-P Hennessy Anderson, N. 18-05-O Henninger, C. 10-14-P Henry, D. 01-10-P, 26-002-O, 26-085-P, 21-02-P Henry, D.H. 26-046-P Hentati, D. 22-01-O Heras, P. 26-052-P, 18-39-P, 18-37-P, 13-23-P, 13-22-P, 11-50-P, 06-04-P, 03-17-P Herlofson, B. 15-05-P Herlofson, B.B. 24-19-P, 15-02-O Hermann, P. 01-03-O Herrstedt, J. 07-03-P Hervé, C. 26-014-P Hervik, J.A. 26-086-P, 26-062-P Herz, S. 26-012-P, 13-09-P Hesketh, P. 11-39-P, IS-24 Hesketh, P.J. 11-08-P Hess, K. 17-01-O Hettler, D. 21-05-P Hewitt, C. 22-29-P Higa, G. 11-13-P Higano, C.S. 24-05-O Higgins, S. 12-13-P Higuera, O. 21-08-P Hildenbrandt, R. 26-012-P

S10 Hilling, T. Hindenburg, H.J. Hira, N. Hirakawa, T. Hirashima, Y. Hirayama, M. Hirayama, Y. Hiremath, A. Hirisave, U. Hjermstad, M. Hjermstad, M.J. Ho, H. Hobbs, G. Hocke, J. Hoffman, K. Hofmeister, D. Høgdal, N. Holden, L. Holder, J. Hollen, P. Hollen, P.J. Holm, A. Holmer, C. Holmes, H. Holzhauer, P. Honda, T. Hong, C. Hong, D. Hong, D.S. Hong, J. Hong, J.F. Hong, S.P. Honorio, H.M. Hopkinson, J. Hopman, W. Horaiya, K. Hori, H. Horn, O. Horne, J. Horneber, M. Hoskin, T. Hosokawa, R. Hostrup, S. Hou, W. Houghton, D. Houts, A.C. Hovan, A.J. Hovde, O. Hovgaard, D. Howarth, G.S.

Hoy, S. Hsieh, P.Y. Hsieh, R.K. Huang, D. Huang, I. Huang, T. Hubbard, J. Hudson, M. Huggins, C. Hughes, C. Hughes, J. Hughes, L. Hughes, S.

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 26-017-P 11-46-P 22-62-P 11-14-P 11-14-P 11-23-P 14-06-P 26-008-P 18-16-P 15-05-P 24-19-P 18-03-O 11-13-P 26-007-O 26-033-P 15-05-P 26-054-P, 23-34-P 03-28-P, 06-14-P 23-28-P 22-25-P, 02-13-P 05-03-P, 02-04-O 26-055-P, 26-031-P 26-055-P 07-07-P 10-45-P 15-10-P 15-08-P 25-19-P 26-096-P 18-54-P, 18-27-P, 18-26-P, 22-38-P, 18-43-P 22-46-P 24-18-P 04-17-P 03-33-P 17-31-P 23-45-P 09-02-P 26-012-P 10-50-P 06-15-P 18-09-P 15-28-P, 15-27-P 13-14-P 18-28-P 10-50-P 12-07-P 10-05-O 24-46-P 23-28-P 10-38-P, 10-39-P, 10-29-P, 14-18-P, 10-40-P 10-50-P 24-08-P 03-25-P 18-27-P, 18-26-P 22-03-O 22-06-P 26-019-P 22-03-O 14-04-O 26-044-P 03-33-P, 03-33-P 11-20-P 06-11-P

Hui, D.

Hulme, C. Hung, S. Huntley, A. Hunyh, L. Huo, S. Hur, H. Hussain, M. Hussain, O. Hussain, R. Hussaini, N. Hussian, R. Husson, O. Huszno, J. Hwang, J. Hwang, S.W. Hwang, W.L. Hyun, M.K. Hyung, W.J.

03-04-P, 17-40-P, 03-03-P, 26-016-P, 17-09-P, 17-08-P, 17-04-O, 17-01-O, 03-21-P, 17-47-P 06-08-P 16-06-P 26-059-P, 26-058-P 11-61-P 05-04-P 24-18-P 24-22-P, 26-018-P 25-09-P 17-66-P, 17-20-P, 14-14-P 16-23-P 17-64-P 06-05-P 25-15-P, 11-53-P 11-35-P, 13-18-P 24-10-P 03-25-P 03-14-P 24-18-P

I Iacovelli, N.A. 26-060-P Ibrahim, E. 08-03-P Ichikawa, Y. 11-14-P İçli, F. 24-38-P Ide, Y. 11-32-P Ihbe-Heffinger, A. 13-08-P Ihenacho, I. 17-47-P Iijima, W. 15-28-P Ikegame, K. 23-15-P Ikenberg, R. 01-11-P Ikoma, A. 17-14-P Ilmek, M. 03-26-P Imai, H. 25-17-P Inaguma, Y. 26-013-P Inano, T. 02-07-P Inder, W.J. 14-02-O Ingholt, L. 23-26-P Innabi, A. 26-030-P Innominato, P. 18-10-P, 18-04-O Iobashvili, N. 26-103-P Ionova, T. 20-04-P Irfan, M. 17-64-P Irwin, M. 04-05-P, 04-03-O Isenring, E. 11-24-P, 08-10-P, 04-19-P Isenring, E.A. 14-02-O, 02-14-P Ishida, T. 11-34-P Ishida, Y. 18-61-P Ishiguro, H. 23-21-P Ishii, T. 09-08-P, 23-09-P, 02-06-P Ishikawa, A. 23-27-P Ishitani, K. 14-06-P Isola, M. 05-01-O Ito, E. 15-28-P, 15-27-P Ito, F. 11-43-P Ito, K. 26-013-P, 11-14-P Itonaga, Y. 11-14-P Ivanov, R.A. 13-11-P Ivanova, N. 23-20-P, 01-22-P Iwasaki, A. 11-29-P Iwashima, A. 11-34-P Iwata, H. 23-09-P, 02-06-P Iyer, R. 27-03-O

Izgu, N. Izuegbuna, O. J Jackowich, R. Jackson, R. Jacobs, V.R. Jacobsen, P. Jadoon, N.A. Jaehde, U. Jafari, N. Jahana, S. Jahn, F. Jahn, P. Jain, A. Jain, R. Jain, S. Jakhar, S.L.

10-25-P 26-102-P

24-05-O 17-02-O 13-08-P 06-06-P 24-22-P, 22-48-P, 18-44-P 26-068-P 22-23-P, 22-23-P, 22-50-P 17-35-P, 17-63-P 11-08-P 11-08-P, 23-10-P, 11-01-O 18-03-O 12-21-P 18-60-P 25-03-O, 17-23-P, 26-025-P, 06-09-P Jakobsen, J. 23-13-P Jaladhar, P. 21-01-O James, P. 24-42-P Jamshed, A. 17-66-P, 17-64-P, 17-20-P, 14-14-P Janelsins, M. 24-20-P, 19-02-P, 06-22-P, 06-23-P Jänich, S. 11-33-P Jankovic, M. 18-53-P Jansen, C. 26-068-P Jansen, F. 22-18-P, 18-32-P Janus, N. 26-004-O, 24-17-P jarban, M. 22-51-P Jarden, M. 23-13-P, 23-06-O, 26-084-P, 23-28-P, 23-01-O Jatoi, A. 26-026-P, 25-10-P Javier, F.O. 03-10-P Jbouri, O. 17-40-P Jean-Pierre, A. 26-006-O, 18-11-P Jean-Pierre, P. 26-006-O, 18-52-P, 18-11-P, 26-057-P Jegina, K. 18-35-P Jelvakova, I.A. 13-11-P Jenik, H. 10-45-P Jenkins, S. 06-01-O Jensen, B.B. 26-017-P Jensen, C.B. 26-017-P Jensen, K. 10-33-P Jensen, M.B. 26-009-P Jeon, S.H. 18-45-P Jeong, J. 11-12-P Jeong, Y. 11-12-P Jeppesen, S. 07-02-O Jeremic, B. 22-01-O Jervoise Andreyev, J. 14-08-P, 11-60-P Jeter, K. 17-21-P Jeyaraj, P. 11-04-O Jhajj, C. 18-40-P Jhingran, A. 27-03-O Jiang, R. 01-07-P Jiménez Rubiano, B. 03-16-P Jimenez, C. 27-03-O Jimenez, P. 13-03-O Jin, M. 18-54-P, 18-43-P Joannette, S. 07-05-P Joerger, M. 02-03-O Johansen, C. 24-09-P, 23-36-P

S11

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Johansen, J. Johansen, J.S. Johansson, P. John, V. John, W. Johnson, C.D. Johnson, E.M. Johnson, L.A. Johnson, R. Jolliffe, R. Jones, K. Jones, R. Jónsson, O. Jontell, M. Joo, J. Joo, Y. Joos, S. Jordan, K. Jorgensen, M. Jorgensen, T.L. Jose, M. Joseph, A. Joseph, D. Joseph, J. Jovenin, N. Juhler, M. Julieron, M. Jun, H. Jung, M. Jung, Y.J. Jungberg, P. Jurincic, L. Just, L.

IS-05, 26-028-P, 10-22-P 26-018-P 22-07-P 02-12-P 17-72-P 07-04-P 24-14-P 04-05-P, 04-03-O 09-04-P 26-036-P 23-35-P 22-25-P, 06-11-P 16-02-O 10-23-P 24-34-P, 24-30-P, 09-09-P 12-08-P 22-42-P, 22-42-P 07-04-P, 11-21-P, 11-08-P 26-021-P 07-03-P 13-20-P, 04-10-P 27-05-P 24-11-P 06-11-P 21-05-P, 13-07-P, 13-06-P, 13-05-P 23-13-P 26-100-P 27-07-P 24-18-P 03-14-P 11-46-P 04-13-P 11-41-P

K Kaae, J. 15-01-O, 15-15-P Kaalund, I. 20-07-P Kaasa, S. 17-29-P, 17-09-P Kabickova, E. 16-04-P Kadiev, R. 22-55-P Kadiev, R.M. 22-32-P Kado, N. 11-14-P Kagamu, H. 11-34-P Kagawa, M. 25-11-P Kahn, S. 15-07-P Kähnert, H. 23-11-P Kahwaji, M.C. 17-49-P Kaida, K. 23-15-P Kaiser, R. 26-007-O Kakumae, Y. 26-013-P Kaleta, B. 25-15-P Kalkat, K. 14-09-P Kállay, E. 18-17-P Kallen, M. 06-07-P Kam Man Lau, B.A. 18-28-P Kamata, T. 15-10-P, 15-31-P Kamath, J. 26-090-P, 06-16-P Kamen, C. 24-20-P, 06-22-P, 06-23-P Kamigaki, S. 25-11-P Kamioner, D. 13-17-P, 13-07-P, 13-06-P, 13-05-P, 13-01-O Kamisako, M. 09-02-P Kamizato, M. 24-31-P, 17-35-P, 17-63-P Kanda, T. 23-45-P, 09-08-P Kandwal, A. 15-17-P

Kanellopoulos, A. Kang, E. Kang, H. Kang, J.H. Kang, M. Kang, S. Kang, Y. Kanioura, L. Kanmodi, K.K. Kansra, V. Kao, H.K. Kapoor, A.

24-19-P 04-22-P 20-10-P 17-08-P 20-10-P 24-07-P, 09-09-P, 09-05-P 05-04-P 15-22-P 17-78-P, 17-73-P, 04-34-P 11-20-P, 11-07-P 07-08-P 25-03-O, 17-23-P, 26-025-P, 06-09-P Kapoor, R.K. 08-08-P Karaaslan Eser, A. 20-14-P Karabatić, S. 02-12-P Karahacioglu, E. 26-045-P Kargo, A. 07-03-P Karlberg, M. 27-01-O Karlsen, R. 24-09-P Kartal, M. 10-25-P Karydis, A. 15-13-P Kasala, E. 26-073-P Kasamatsu, Y. 11-14-P Kasi, P. 26-026-P Kaste, S. 15-13-P Kasuga, R. 15-10-P Kataoka, T. 15-20-P Kato, R. 09-08-P Kato, T. 15-28-P Katsumata, N. 11-29-P, 02-07-P Kattan, J. 22-02-O, 17-49-P Kav, S. 04-20-P, 20-14-P Kawabe, S. 11-34-P Kawahara, M. 17-25-P Kawamorita, K. 14-19-P Kayani, M. 15-07-P Keam, B. 03-14-P Kebudi, R. 13-25-P Keefe, D. 27-06-P, 10-27-P, 10-17-P, 10-20-P, 25-10-P, 10-41-P Keefe, D.M. 10-16-P Kehlet, H. 26-054-P, 23-34-P Kelaart, A. 14-10-P, 14-03-O Kelly, K.M. 03-01-O Kenholm, J. 24-04-O Kenmotsu, H. 23-09-P, 02-06-P Kennedy, C. 17-79-P Kenny, P. 18-05-O Keogh, I. 24-39-P, 24-28-P, 24-43-P, 24-32-P Kepka, L. 22-01-O Kerba, M. 22-30-P Kerob, D. 17-14-P Kerr, J. 12-07-P Kersten, C. 03-06-P Kesting, S. 16-05-P Kesting, S.V. 16-03-P Kevill, L. 27-02-O Kevin, F. 26-006-O Kfoury, M. 26-014-P Khadwal, A. 13-19-P Khaleeq, U. 17-66-P, 17-65-P, 17-64-P, 17-20-P, 14-14-P Khalighi, H. 15-29-P Khalili, N. 22-50-P

Khamash, O. Khan, S. Khan, S.A. Khanani, S.A. Khanra, L. Khatib, M. Khazaeipour, Z. Khazzaka, A. Khimani, F. Khirfan, G. Khodaeifar, F. Khoo, V. Khraisat, M. Kiagia, M. Kiechle, M. Kiely, B.E. Kikuchi, M. Kikuchi, Y. Kilgour, R.D. Kilic, D. Kim, B.S. Kim, C. Kim, C.K. Kim, D. Kim, D.J. kim, H. Kim, H.J. Kim, J. Kim, J.Y. Kim, K.H. Kim, M. Kim, N.K. Kim, S. Kim, S.H. Kim, S.I. Kim, S.T. Kim, T.I. Kim, W. Kim, Y. Kim, Y.J. Kim, Y.W. Kimberg, C. Kimura, M. Kimura, Y. King, A. King, F. Kiprian, D. Kirkham, A. Kirodimos, E. Kirshbaum, M. Kiseleva, M. Kisiel, R. Kiss, N. Kitabatake, T. Kitagawa, K. Kitayama, H. Kitrungrote, L. Kittel, K. Kiymaz, D. Kjaer, T. Kjeldsen, L. Kjerholt, M. Klafke, N. Klastersky, J.

17-40-P 02-11-P, 01-02-O 01-17-P 27-02-O 17-39-P 26-030-P 26-077-P 22-02-O 11-13-P 22-31-P 18-46-P 24-36-P 17-40-P 18-18-P, 03-31-P 13-08-P 26-010-P, 26-023-P 15-28-P 22-33-P, 12-19-P 02-11-P 18-57-P 17-41-P 25-19-P 26-096-P 22-59-P 17-69-P 06-03-P, 25-19-P, 22-59-P, 05-04-P 26-096-P, 26-096-P, 11-56-P 25-19-P, 26-033-P 03-27-P, 24-07-P 26-096-P 04-22-P 24-18-P 25-19-P, 17-12-P, 04-22-P 26-096-P, 18-45-P 24-34-P, 24-30-P, 09-09-P 11-12-P 24-18-P 26-006-O 12-08-P 24-07-P, 05-04-P, 03-21-P 05-04-P 22-03-O 23-09-P, 02-06-P 22-01-O 26-059-P, 26-058-P 03-32-P 15-14-P 23-12-P 10-15-P 06-10-P 22-49-P 05-05-P 04-19-P, 14-10-P, 14-03-O 11-29-P 15-20-P 11-23-P 22-12-P 11-46-P 06-18-P 24-09-P 26-054-P, IS-07, 23-01-O, 23-34-P 23-50-P, 26-072-P, 22-17-P 22-42-P 01-18-P

S12 Klein, A. 04-11-P Klein, G. 10-41-P Klepper, M. 11-16-P Klepstad, P. 17-29-P, 03-08-P Kletas, V. 26-037-P Klika, R. 23-12-P Klimova, K. 25-07-P, 14-08-P, 11-60-P Klopp, A. 27-03-O Klotz, A. 26-099-P Kn, S. 10-49-P, 15-24-P Knopf, K.B. 12-07-P Knoth, R. 11-19-P, 11-18-P Ko, J.Y. 24-08-P Ko, Y. 13-16-P Kobayashi, T. 23-45-P Kober, K.M. 06-02-P Koç, Z. 26-027-P, 18-48-P, 06-18-P Kocaaslan, E. 26-094-P Koch, L. 26-068-P Kodama, N. 23-15-P Koh, P. 04-15-P Koh, S. 03-30-P Koh, S.J. 03-14-P Koitabashi, K. 18-12-P Kokkolaki, M. 03-31-P Kolesnikov, G. 20-04-P Kolidas, E. 22-09-P Kollberg, G. 26-042-P, 13-09-P Komarova, E. 22-49-P Komatsu, H. 22-22-P Komen, M. 25-09-P Komurcu, S. 18-57-P, 17-76-P Kondo, K. 23-45-P Kondo, R. 22-61-P Kondo, T. 11-23-P Koneru, R. 07-12-P Konias, M. 11-46-P Koo, B. 04-22-P Koo, S. 18-03-O Koopman, C. 18-10-P Kopetz, S. 02-08-P Kopp, M.V. 13-11-P Kortmann, R.D. 10-01-O Koseki, T. 15-28-P, 15-27-P Koshy, C. 26-040-P, 17-44-P Koskenvuo, M. 16-02-O Kostadinova, L. 08-06-P Kotecki, N. 26-100-P Kouloulias, V. 15-22-P Kouri, M. 15-22-P Kouvaris, J. 15-22-P Kovacs, G. 16-04-P Kovalenko, N.V. 13-11-P Koyama, T. 23-45-P Kozuma, S. 25-11-P Kraff, S. 02-03-O Krebber, A.M. 18-32-P Kreit, P. 21-05-P Kreitler, S. 16-08-P, 14-16-P Kremer, L.C.M. 16-01-O, 27-04-P Krishnasamy, M. 18-05-O Kristensen, C.A. 10-33-P Kristensen, P.L. 25-04-O Krivorotko, P.V. 13-11-P Kroman, N. 23-44-P Krull, K. 22-03-O

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Kryzanowska, M. Krzakowski, M. Kuang, L. Kucuktulu, E. Kucuktulu, U. Kucukzeybek, Y. Kudo, T. Kuhn, W. Kuiken, N.S.S. Kuji, S. Külahcı, C. Kumar, A. Kumar, D. Kumar, H.S.

17-11-P 26-007-O 26-074-P, 22-24-P 20-17-P 20-17-P 18-24-P, 18-25-P 11-32-P 26-068-P 10-28-P, 10-07-P 11-14-P 19-03-P 23-40-P 08-04-P, 04-24-P 25-03-O, 17-23-P, 26-025-P, 06-09-P Kumar, N. 08-08-P, 22-01-O Kumar, R. 26-025-P Kumari, P. 25-03-O, 17-23-P, 26-025-P Kumari, S. 17-23-P, 26-025-P Kung, S. 18-01-O Kurata, M. 11-29-P Kurbacher, A.T. 26-042-P, 26-012-P, 13-09-P Kurbacher, C. 18-51-P Kurbacher, C.M. 26-042-P, 26-012-P, 13-09-P Kurbacher, J.A. 26-042-P, 26-012-P, 13-09-P Kurbatova, K. 20-04-P Kurihara, M. 23-45-P Kurihara, Y. 18-61-P Kurita, G.P. 17-29-P, 03-08-P Kurita, H. 15-10-P, 15-31-P Kurt, S. 22-44-P, 03-26-P Kurtoglu, E. 04-01-O Kurtoğlu, N. 20-14-P Kusakabe, T. 14-06-P Kust, D. 26-083-P Kutomi, G. 11-29-P Kuznecova, G. 20-02-O, 18-35-P, 18-31-P Kuznecovs, I. 20-02-O, 18-35-P kuznecovs, S. 18-35-P, 20-02-O, 18-31-P Kuznetsova, O. 11-59-P Kwak, K. 17-32-P Kwatra, G. 11-04-O Kwon, J. 03-03-P, 11-12-P Kwon, J.H. 03-04-P, 17-08-P Kwon, M. 04-22-P Kwon, M.S. 11-56-P Kwong, L. 03-10-P L Lacaze, J.L. Lacerda, C. Lacouture, M. Lacouture, M.E. Laenen, D. Lafky, J. Lai, J. Lai, L. Lai, P.Y. Lai, Y.H. Lakiss, S. Lalla, R.V. Lam, H.

20-09-P IS-26 25-10-P 20-09-P, 10-36-P 20-15-P 12-06-P, 12-02-O 22-36-P, 22-06-P 26-043-P 03-25-P 18-38-P, 03-24-P, 24-08-P 01-19-P 10-01-O 03-28-P, 09-10-P, 22-16-P, 01-23-P

Lam, T. 06-07-P, 17-06-O Lamant, L. 20-03-P, 20-09-P Lamb, S. 24-11-P Lamblin, A.N.N.E. 21-03-P Lamuraglia, M. 21-04-P Lanaban, A. 03-23-P Lanceni, A. 17-82-P Landenbeger, M. 22-52-P Landherr, L. 25-18-P Langberg, H. 23-31-P, 23-44-P Langit, M. 24-40-P Langkjer, S.T. 26-017-P, 26-034-P Lanni, G. 23-18-P Lao, N. 03-28-P, 01-31-P, 22-58-P, 11-25-P, 09-10-P, 06-14-P, 01-26-P, 11-35-P, 03-38-P, 01-29-P, 01-12-P, 17-94-P, 17-85-P, 04-27-P, 01-23-P, 17-84-P, 12-18-P Lapid, M. 18-01-O, 23-07-O Larkin, D. 24-24-P Larsen, H.M. 23-38-P, 23-24-P Larsen, K.R. 23-31-P Larsen, L. 11-47-P Larsen, S. 17-70-P Laskarakis, A. 10-48-P Lassauzay, C. 15-03-P Lassen, U. IS-11 Latifyan, S. 01-18-P Latter, S. 03-33-P Lau, A. 23-10-P Launay-Vacher, V. 26-004-O, 24-17-P Lauro, S. 01-14-P Lausen, B. 16-02-O Lauzon, N. 01-30-P Lavezzari, L. 18-21-P Law, K. 22-21-P Lawler, M.L. 10-10-P Lawlor, P. 03-19-P Lawrance, I.C. 14-18-P Lazarova, B. 05-08-P Lazreg, H. 08-11-P Le, L. 17-16-P, 17-11-P Le, N. 24-23-P Le, P. 01-24-P Leahey, A. 22-58-P, 22-10-P, 09-10-P Lebel, S. 17-83-P Lechner, B. 11-25-P Lee-Lin, F. 22-24-P Lee, C. 24-40-P, 11-49-P, 11-36-P, 11-31-P Lee, D.O. 24-34-P, 24-30-P Lee, E. 12-08-P Lee, E.S. 24-07-P Lee, H. 12-08-P Lee, H.D. 11-12-P Lee, J. 04-15-P, 11-37-P, 09-09-P, 11-49-P, 11-36-P, 11-31-P Lee, J.S. 09-05-P Lee, K. 03-30-P, 03-30-P Lee, K.D. 03-25-P Lee, K.H. 11-12-P Lee, K.T. 26-096-P Lee, M.Y. 03-25-P Lee, N.S. 26-096-P Lee, Q. 18-03-O

S13

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Lee, R. Lee, S. Lee, S.C. Lee, S.H. Lee, V. Lee, Y. Lee, Y.J. Lee, Y.U.M.I. Leemans, C.R. Lefebvre, G. Leibbrand, B. Leigha, R. Leighl, N. Lemanska, A. Lemoine, L. Lemonde, M. Lennon, E. Leonidou, C. Lepretre, S. Leroux, S. Leroy, P. Lervat, C. Lester, L. Leung, A. Leung, C.M.S. Leung, D.Y.P. Leung, K.W. Levi, F. Levin, G. Levin, G.T. Levine, J.D. Levy-Milne, R. Lew, K. Lewis, A.J. Lewis, J. Leynes, C. Li, C. Li, H. Li, X. Liang, J. Liang, L.W. Liang, X. Liao, M. Liao, Y.M. licianci, A. Licitra, L. Lifirenko, I.D. Lightwala, Z.L. Lillelund, C. Lim, J.W. Lim, M.C. Lim, S.T. Lima, R. Limaverde, S.M. Lin, B. Lin, C. Lin, H. Lin, J. Lin, K.C. Lin, S.J. Lin, T. Lin, Y.

26-022-P 24-26-P 26-096-P 24-10-P 22-21-P 24-34-P, 09-09-P, 09-05-P, 26-043-P 24-10-P 09-09-P 22-18-P, 18-32-P 26-011-P, 26-100-P 23-11-P 04-27-P 17-11-P 03-15-P 17-87-P IS-18, 07-12-P 06-11-P, 06-08-P 06-11-P 13-07-P, 13-06-P, 13-05-P, 13-01-O, 13-17-P 18-22-P 26-014-P 25-05-P 17-53-P, 17-24-P, 14-15-P, 17-67-P 03-38-P 18-42-P 18-42-P, 18-23-P 23-22-P 18-04-O 18-13-P 18-59-P, 04-02-O 03-12-P, 03-02-O 14-09-P 20-11-P 15-30-P 17-56-P 16-13-P 16-20-P 16-25-P 13-10-P 24-25-P 27-02-O 17-77-P 26-007-O 03-25-P 13-21-P, 06-13-P 26-060-P 13-11-P 10-18-P IS-25, 23-41-P 24-07-P 24-34-P, 24-30-P, 24-07-P, 09-09-P, 09-05-P 26-038-P 16-15-P 22-47-P 24-25-P 22-13-P 13-18-P 03-25-P 23-22-P 11-19-P, 11-18-P 21-09-P 22-13-P

Linardou, H. 01-01-O Linden, K. 26-029-P, 04-39-P Lindkær-Jensen, S. 17-70-P Link, H. 26-039-P Linnet, S. 26-017-P Lippert, H. 17-71-P Lipson-Smith, R. 18-05-O Lipton, A. 01-10-P Lisi, G. 26-041-P List, A.B.. 21-10-P Liu, C. 01-08-P Liu, C.J. 01-07-P Liu, D. 04-26-P, 03-04-P, 03-11-P, 26-016-P, 03-21-P, 17-05-O Liu, D.D. 03-07-P Liu, J. 18-27-P, 18-26-P, 22-61-P Liu, M. 23-27-P, 17-27-P, 09-02-P Liu, T.C. 03-25-P Liu, W. 14-07-P Liu, Y. 17-77-P Llombart Cussac, A. 03-18-P Lo Bianco, A.C. 26-081-P, 17-92-P Lo, A. 20-08-P Lo, S.H. 17-19-P Lobb, E. 18-15-P Lodge, P. 04-04-O Lodygina, K. 22-43-P Loeffen, E.A.H. 16-01-O, 10-28-P, 27-04-P Loeliger, J. 14-10-P, 14-03-O Logan, R. 10-06-P, 10-03-O, 10-32-P Logan, R.M. 12-11-P Loghmani, A. 22-23-P Loh, K. 24-40-P Loh, W. 18-03-O Løhmann, D. 16-02-O Lole, P.V. 11-27-P Lomidze, D. 22-01-O London, W. 10-34-P Long, A. 18-15-P Longo, C. 22-39-P Looker, S. 26-026-P Lopes, N. 16-24-P, 10-12-P Lopez-Flores, O. 04-09-P Loprinzi, C. 12-06-P, 12-02-O Lorton, C. 12-15-P Lossignol, D. IS-03, 17-54-P, 12-03-P Lou, V.W.Q. 18-23-P Loughnan, A. 04-25-P Louie, J. 03-01-O Lovati, E. 11-05-O Lowe, J. 26-097-P Lowson, E. 03-33-P Lozana, R. 13-03-O Lu, Z. 11-05-O Luan, B. 22-38-P Lucchesi, C. 10-32-P, 10-20-P Lucchesi, M. 26-088-P Lucchiari, C. 18-41-P Luczak, A. 26-017-P Ludwig, L. 26-004-O Lui, M. 10-04-O Luijendijk, P. 24-06-O Luini, A. 23-18-P Lukács, G. 18-17-P Lunt, C. 05-05-P Luther, A. 22-19-P

Lutz, S. Lydia, W.W. Lymn, K.A. Lyng, G. Lynggaard Uth, M. Lyracos, D.

01-26-P, 04-27-P 17-95-P 10-38-P, 10-40-P 10-11-P 20-13-P 18-18-P

M Ma, S. 17-77-P Macchi, F. 18-41-P MacDonald, N. 23-25-P Machado, L.E. 15-06-P Maciorowski, G. 18-52-P Mackay, H. 26-022-P MacKintosh, D. 17-61-P Madalo, M. 09-03-P Maddalo, M. 26-015-P, 14-01-O Madhavan, A. 23-23-P Mady, N. 02-11-P Maeda, I. 17-25-P Maeda, N. 11-29-P Maessen, D. 11-48-P Magalhães, R.J.P. 15-09-P Magaya-Kalbermatten, N. 17-46-P Magri, M. 13-21-P, 06-13-P Mahalingam, D. 27-01-O Maharia, S. 25-03-O, 26-025-P Mahé, I. 21-04-P, 21-03-P Mahjabeen, I. 15-07-P Mahler, C. 22-42-P Mahmoudi, J. 03-22-P Mahovlich, S. 24-05-O Mahshid, M. 18-46-P Maillard, S. 26-100-P Mailliez, A. 26-100-P Maimets, M. 15-11-P Mainali, A. 15-24-P, 10-49-P, 04-31-P Maiolino, A. 15-09-P Maiya, A.G. 23-03-O, 06-17-P Major, B. 22-05-P Majorana, A. 15-18-P, 15-04-P, 10-09-P, 10-02-O Makarem, M. 17-50-P Makino, M. 11-34-P Malamos, N. 01-20-P Malhotra, K. 24-36-P Malhotra, P. 13-19-P Malik, F. 15-07-P Malinova, I. 22-49-P Maloisel, F. 13-17-P, 13-06-P, 13-05-P, 13-01-O Maloisel, S. 13-07-P Malsch, M. 10-34-P Malyala, A. 07-12-P Manahan, L. 17-36-P Manaktala, N. 15-30-P Manalo, M. 17-55-P Mancini, M. 10-08-P Mandrelle, K. 22-19-P Mangili, G. 18-21-P Mannion, E. 17-37-P Manojlovic, N. 27-01-O Manzano, J. 26-008-P Manzi, V. 23-29-P Manzullo, E. 04-33-P, 06-20-P, 06-07-P, 17-06-O

S14 Marchetti, P. 01-14-P Marcos, R. 13-03-O Marcotte Le Maire, J. 26-076-P Mareschal, J. 22-11-P Marete, J.G. 07-13-P Margier, J. 26-070-P Margolis, M. 03-32-P Margossian, S. 10-34-P Margulies, A. 15-14-P Maria, D.A. 23-25-P Marioli, A. 18-18-P, 03-31-P Marioli, N. 01-01-O, 02-10-P Mark, E. 26-101-P Marliot, G. 26-011-P, 26-100-P, 25-05-P Marquardsen, J. 23-44-P Marques, A. 22-35-P Marsaa, K. 22-14-P Marschner, N. 26-039-P, 11-33-P Marsh, C. 24-42-P Marshall, A. 21-07-P Marshall, K. 14-10-P, 14-03-O Martell, R. 11-20-P, 11-07-P Martin, G. 13-03-O Martin, L.A. 13-02-O Martinez Marin, V. 21-08-P Martling, A. 24-03-O Marton, C. 04-08-P Martopullo, C. 18-59-P Maruelli, A. 23-29-P Marx, W. 11-24-P, 08-10-P, 04-19-P Mashtoub, S. 10-29-P, 14-18-P, 10-40-P Masino, C. 17-07-P Mason, S. 24-51-P Masoni, C. 17-47-P Masood, A. 17-66-P, 14-14-P Masood, U. 17-65-P Massey, R.L. 26-065-P Mastick, J. 03-12-P, 03-02-O, 06-02-P Masuda, H. 18-12-P Masuda, N. 25-11-P Masuda, Y. 09-08-P, 23-09-P, 02-06-P Masuoka, K. 23-45-P MATÉ, J. 22-20-P Matiello, J. 22-01-O Matos, I. 13-03-O Matrosova, M.P. 13-11-P Matsuda, S. 14-19-P Matsuda, T. 10-13-P Matsunami, N. 25-11-P Matsuoka, J. 11-17-P, 11-29-P Matthews, M. 26-044-P Mau, W. 23-10-P Mauti, E. 06-14-P May, C. 03-33-P, 24-02-O, 06-19-P, 06-19-P, 06-08-P May, C.M. 06-08-P Maynard, V. 11-54-P Mayo, B. 10-27-P, 10-32-P, 10-20-P, 10-41-P Mazza, U. 18-53-P Mazzer, M. 05-01-O Mazzocato, C. IS-20 Mc Carthy, G. 06-12-P Mc Donnell, D. 17-24-P Mc Partlan, P. 26-036-P McAndrew, A. 04-13-P

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 McCarthy, A. McCarthy, A.L. McCormack, J. McCullough, R. McDonald, J. McDonald, R.

11-24-P, 08-10-P, 04-19-P 14-02-O 24-37-P 10-26-P 17-42-P, 17-11-P, 17-03-O 26-097-P, 11-61-P, 01-28-P, 11-25-P, 09-10-P, 01-09-P, 22-27-P, 22-16-P, 03-38-P, 01-29-P, 17-94-P, 17-85-P, 04-27-P, 01-23-P, 17-84-P, 12-18-P McEwan, L. 24-37-P McGregor, M. 19-01-O, 11-54-P McInnes, H. 10-32-P McKavanagh, D. 11-24-P, 08-10-P McKelvey, D. 13-04-O McKiernan, S. 24-11-P McLean, A. 25-08-P McMahon, D. 04-05-P, 04-03-O McNeely, M. 09-01-O McNees, P. 24-21-P McVicars, H. 25-09-P McWilliams, R. 26-026-P Mebis, J. 20-01-O Medina, S. 13-03-O Medina, Y. 16-13-P Mehmood, T. 18-34-P, 17-66-P, 17-65-P, 17-64-P, 17-20-P, 14-14-P Mei, H. 01-25-P Melendres, E. 16-13-P Melisko, M. 03-12-P, 03-02-O Mellemgaard, A. 26-007-O, 13-14-P, 22-14-P, 26-018-P Mello, A. 22-61-P Members of the Study Advisory Committee, . 24-02-O Memon, A. 21-06-P Mendenhall, W. 23-23-P Mendoza-Galindo, L. 17-18-P, 04-09-P Mendoza, T.R. 12-10-P Menekse, E. 09-04-P Meneses Echávez, J. 04-16-P, 04-12-P Meneses Echávez, J.F. 23-05-O Meneses-Echávez, J.F. 23-04-O Meneses, K. 24-21-P Menon, M. 03-05-P, 10-19-P Menon, S. 26-026-P Menotti, P. 05-01-O Merca, E. 10-24-P Mercadante, F. 11-22-P Mercadante, S. 03-08-P Merlotti, A. 17-82-P Merluzzi, T. 26-006-O Merriman, K. 26-065-P Mesidor, K. 26-006-O Messow, C.M. 25-08-P Meyer, C. 26-022-P Meyer, F. 25-16-P, 17-71-P Miaskowski, C. 03-12-P, 03-02-O, 06-02-P Miccinesi, G. 26-098-P, 26-063-P, 18-14-P, 23-29-P Michael, M. 18-05-O Michaud, C. 07-05-P Micovic, V. 03-34-P

Migliorati, C. 15-13-P Mikkelsen, T.B. 23-38-P, 23-24-P Milakovic, M. 01-12-P Milano, M. 19-02-P Miles, P. 17-42-P Milic, J. 22-50-P Milito, G. 26-041-P Miller, T.J. 22-04-P Min, B.S. 24-18-P Minnema, M. 12-01-O Minowa, C. 18-12-P Minowa, T. 18-12-P Minozzi, M. 08-07-P Miralbell, R. 22-11-P Miriyala, R. 04-07-P Mirmohamadi, A. 04-06-P Mitani, A. 23-21-P Mitchell, S. 13-10-P Mitsuda, M. 09-08-P, 23-09-P, 02-06-P Mitsuki, S. 18-19-P Miura, K. 11-29-P Miura, S. 11-34-P Miyagi, K. 11-14-P Miyahara, K. 18-12-P Miyai, E. 17-14-P Miyake, Y. 11-32-P Miyao, H. 11-34-P Miyashita, M. 17-33-P, 15-10-P Miyata, C. 23-27-P, 09-02-P Mizushima, T. 11-32-P Mizuta, S. 26-013-P Mizutani, M. 25-11-P Mjaland, O. 26-086-P, 26-062-P Mjåland, S. 03-06-P Moadel-Robblee, A. 22-09-P Moaed, B. 16-21-P Modiano, M. 11-11-P, 11-39-P Moeller, T. 23-41-P Mogensen, S. 10-33-P Mogensen, T. 10-33-P Mohammed, S. 17-48-P, 17-50-P Mohan Ponnamma, M.I.N.U. 27-05-P, 15-32-P Mohana Devi, S. 03-36-P Mohd Adzlan, F. 14-15-P Mohsen, H. 22-28-P Moiz, B. 21-06-P Mokarian, F. 22-50-P Molani, P. 26-066-P Molfino, A. 02-05-P Molina, A. 16-17-P, 16-16-P, 16-09-P, 16-07-P Møller, P. 26-028-P Møller, T. IS-25, 23-01-O Mols, F. 06-05-P, 12-05-P, 12-01-O Monahan, P.O. 22-04-P Monreal, K. 13-09-P Montel, S. 15-05-P Moon, J.H. 26-096-P Moon, S. 18-45-P Mooney, O. 24-15-P Moore, T. 26-059-P, 26-058-P Morag, A. 25-02-O Moran, C. 23-25-P, 17-21-P Morgese, F. 08-02-O Mori, K. 23-09-P, 02-07-P, 02-06-P

S15

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Mori, M. 02-07-P, 24-10-P, 11-32-P Morimoto, T. 25-11-P Morin, S. 26-014-P Morishita, S. 23-15-P Morita, E. 23-09-P, 02-06-P Morita, T. 17-09-P Mørk, L. 11-57-P Morner, M. 24-03-O Moroso, S. 05-01-O Morris, C. 06-11-P, 06-08-P Morrison, D. 11-16-P Morrow, G. 24-20-P, 19-02-P, 06-23-P Morsi, H. 17-34-P Mortazavi, H. 15-29-P, 16-19-P Mortensen, L. 23-43-P Mortensen, O.S. 22-26-P Morton, D.S. 10-05-O Mosidze, B. 27-01-O Moth, E.B. 26-010-P Mougeot, F.B. 10-05-O Mougeot, F.K.B. 10-10-P Mougeot, J.C. 10-10-P Mougeot, J.L. 10-05-O Moumjid, N. 26-070-P Mountzios, G. 01-20-P Movahhedian, A.M.I.R. 15-29-P Mrakovcic-Sutic, I. 03-34-P Mridha, A. 01-02-O Mridha, R. 01-17-P Msaouel, P. 05-03-P Muckaden, M.A. 17-08-P Mukeshimana, O. 17-52-P Mukhametshina, G.Z. 13-11-P Mukhopadhyay, S. 11-55-P, 11-04-O, 10-46-P Mulay, S. 06-16-P Mulder, R.L. 16-01-O, 27-04-P Muljadi, N. 26-023-P Müller-Tidow, C. 11-08-P Muls, A. 25-07-P Munir, W. 22-48-P, 18-44-P Muñoz, A.J. 21-08-P Munsell, M. 27-03-O Muraca, M. 23-29-P Murakami, H. 23-09-P, 02-06-P Murakami, J. 11-14-P Murphy, B. 26-015-P, 14-01-O Murphy, B.A. 09-03-P, 14-12-P Murthy, N. 01-27-P Muscaritoli, M. 02-05-P Musch, R. 11-48-P Mustafa Çetin, M.C. 22-60-P Mustian, K. 24-20-P, 06-22-P, 06-23-P Mutluay, E. 10-25-P Myall, M. 06-08-P Myhailenko, A. 11-59-P N N.Nair, B. Naamani, L. Nabais, I. Nadal, E. Nagano, K. Nagappa, A. Nagy, A. Nagykálnai, T.

26-050-P 22-02-O 18-20-P 17-68-P 17-35-P 22-57-P 25-18-P 25-18-P

Nair, S. Naito, T.

27-05-P 09-08-P, 23-09-P, 02-07-P, 02-06-P, 18-61-P Nakaho, T. 15-27-P Nakamura, S. 17-14-P Nakashima, T. 10-13-P Nakata, K. 11-32-P Nakayama, T. 25-11-P Nakimbugwe, S. 04-41-P, 04-36-P Nam, B.H. 09-05-P Nam, S. 03-30-P Namvaran Abbas Abad, A. 03-22-P Nandaula, S. 16-12-P Narayan, S. 25-03-O, 17-23-P, 26-025-P Narita, I. 11-34-P Nascimento, L.C. 16-15-P Nascimento, T.G. 24-50-P Nasr, F. 22-02-O Näsström, J. 27-01-O Nasu, K. 11-14-P Naundrup, D. 23-43-P Navari, R. 11-03-O, 11-38-P Navarro-Hernandez, M. 04-09-P Navarro-Perez, V. 17-68-P Navarro, M. 13-03-O Nebolsin, V. 13-15-P Nechaeva, M.N. 13-11-P Nees, C. 23-44-P Neill, C.C. 15-13-P Neimann, J. 26-017-P Neisi, K. 04-37-P Nekolaichuk, C. 17-09-P Nelli, E. 04-17-P Neri, E. 18-10-P Nestoriuc, Y. 18-02-O Neville-Webbe, H.L. 26-099-P Nevola Teixeira, L. 23-18-P Newton, R.U. 18-13-P, 24-11-P Nexø, C. 23-34-P Nexoe, C. 26-054-P Neylon, A. 06-11-P Nezu, R. 11-32-P Ng, A. 23-16-P Ng, P. 26-022-P, 11-06-O Ng, R. 18-03-O Ng, T. 21-09-P, 24-40-P, 18-03-O Ng, V. 24-37-P Ngan, M.P. 11-05-O Ngizwenayo, S. 17-52-P Nguyen, M. 11-06-O Nguyen, P. 21-05-P Ngwang, J. 26-082-P Niazi, S. 18-01-O Nicol, J. 17-79-P Nicolas, E. 15-03-P Nicolas, P. 16-04-P Nicolatou-Galitis, O. 15-22-P, 01-20-P, 01-01-O, IS-28, 10-30-P, 15-05-P, 10-15-P, 02-10-P Nicolau, J. 15-12-P, 25-14-P Niehues, C. 23-11-P Nielsen, A.L. 24-09-P Nielsen, D. 23-43-P Nielsen, H.A. 26-017-P Nielsen, T. 26-072-P

Niihara, M. Nikfarid, L. Nikitina, T. Nikolatou, O.U. Nikolopoulos, G. Nikzad, B. Nilmanat, K. Nirban, R.K. Niro, G. Nishi, T. Nishimura, H. Nishimura, J. Nishimura, K. Nishioka, K. Nitta, Y. Niwa, T. Noergaard Petersen, L. Noga, S.J. Noguchi, K. Noguerido, A.L.B.A. Noh, S.H. Nolte, L. Nomura, T. Nordhausen, T. Nordly, M. Norgaard, A. Nørskov, K. Novello, S. Nowacka, K.

14-19-P 17-60-P, 16-14-P 20-04-P 10-48-P 10-15-P 26-049-P 22-12-P 25-03-O, 26-025-P 13-21-P, 06-13-P 25-11-P 15-20-P 11-32-P 22-62-P 12-19-P 11-29-P 12-19-P IS-25 27-02-O 18-61-P 13-03-O 24-18-P 14-10-P, 14-03-O 25-11-P 07-04-P 03-08-P 22-07-P 23-43-P, 23-06-O 26-007-O 24-48-P, 23-48-P, 23-47-P, 23-19-P Nowacki, M. 24-48-P Nowak, A. 18-15-P Nowara, E. 11-53-P, 25-15-P Nowikiewicz, T. 23-47-P, 23-19-P Nozawa, K. 25-17-P Ntalakou, E. 01-01-O, 02-10-P Ntizimira, C. 17-52-P Nurachmah, E. 04-18-P Nural, N. 17-81-P, 17-15-P Nurhan Altıparmak, N.A. 22-60-P Nurhidayatun, N. 15-21-P Nutt, M. 24-24-P Nygaard, A.B.. 26-017-P O O’ Regan, P. O’Brien, L. O’Cathail, M. O’Connor, B.

O’Connor, M. O’Leary, N. O’Neill, C. O’Neill, K. O’Reilly, A. O’Sullivan, E. O’Connell, J. O’Reilly, A. Obasi, E. Oberkampf, F. Obuya, S.A. Oerlemans, S. Oestergaard, B. Ofir, R.

06-12-P 04-25-P 18-07-P 17-53-P, 17-24-P, 14-15-P, 12-15-P, 12-13-P, 17-21-P 04-23-P 12-13-P 17-24-P 14-15-P 22-37-P 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P 25-10-P 20-12-P 17-47-P 26-014-P 16-22-P 12-01-O 26-024-P 16-21-P

S16 Ogata, H. Ogawa, H. Ogurkowski, K. Oh, J. Oh, J.W. Oh, S. Ohashi, Y. Ohno, Y. Ohoshiro, M. Öhrling, K. Ojha, R.P. Okabayashi, K. Okada, H. Okajima, M. Okayama, T.

11-29-P 23-15-P 24-48-P, 23-48-P 26-033-P 24-07-P 27-07-P, 03-14-P 25-17-P, 11-29-P 11-32-P 17-35-P 01-04-P 13-13-P 24-44-P 25-17-P 11-34-P 09-08-P, 23-09-P, 02-07-P, 02-06-P Okayama, T.A.R.O. 14-19-P Okitsu, T. 09-02-P Olagunju, A. 18-33-P Oliva, C. 11-42-P Oliveira, H. 11-52-P, 07-10-P Oliveira, H.F. 14-17-P Olmo Ortega, P. 03-18-P Olowosulu, R. 26-102-P Olsen, M.H. 26-028-P Olson, K. IS-21, 06-10-P Olver, I. IS-24 Omagari, C. 18-61-P On behalf of PanCareLIFE Consortium 27-04-P On Behalf of the Epidemiology Section of the Mucositis Study Group 2013, M. 25-01-O on behaslf of NICSO, . 26-088-P Ongole, R. 10-49-P Ono, A. 23-09-P, 02-06-P Ono, S. 17-25-P Onoratelli, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Orlandi, E. 26-060-P Orlando, A. 05-01-O Orlando, L. 15-14-P Orlov, S. 26-007-O Ortner, P. 11-41-P Osaka, I. 18-61-P Ostermann, H. 10-31-P Ostrovsky, A. 14-16-P Otomo, S. 17-25-P Ottaviani, D. 11-42-P Otto, R. 17-71-P Ou, D. 22-56-P Ou, M.C. 22-56-P Ouakinin, S. 18-20-P Oudard, S. 26-014-P Oudoux, A. 26-100-P Overgaard, J. IS-05, 26-028-P Owen, L. 18-58-P Öz, B. 19-03-P Oza, A. 26-022-P, 17-11-P Ozcelik, H. 15-23-P Ozdemir, L. 10-25-P Ozdemir, O. 09-07-P, 09-06-P Özençakır, H. 20-14-P Ozkan, A. 18-57-P Ozkaraman, A. 26-053-P Ozsahin, M. 10-01-O Ozyilkan, O. 17-76-P Özyılkan, O. 20-14-P

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 P Pachman, D. 12-06-P, 12-02-O Paessens, B.J. 13-08-P Pagani Bagliacca, E. 18-21-P Page, J. 08-05-P, 08-01-O Paiva, C. 17-08-P Pajkos, G. 10-01-O Palesh, O. 18-10-P, 18-04-O Palle, J. 16-02-O Palmas, M. 11-28-P, 11-09-P Palmero, R. 17-68-P Palsdottir, T. 05-02-P Panchenko, S.V. 13-11-P Pandhya, B. 12-12-P Pang, C.C. 22-56-P Panina, M. 20-04-P Pant, M.C. 08-04-P Papa, A. 08-07-P Papadopoulou, E. 01-20-P, 01-01-O Papoutsakis, D. 13-27-P, 13-26-P, 13-24-P, 12-20-P, 03-29-P Paramanadhan, M. 26-025-P Pardon, K. 17-13-P, 17-38-P Paredes, L. 13-03-O Parent, D. 21-05-P, 07-11-P Parisi, S. 11-28-P Park, G. 25-08-P Park, J.C. 17-26-P, 03-04-P Park, J.N. 24-10-P Park, J.S. 24-18-P Park, K. 03-14-P Park, K.U. 17-69-P, 03-27-P Park, L. 12-08-P Park, M. 26-016-P, 17-08-P, 17-04-O, 03-21-P Park, S. 25-19-P Park, S.C. 18-45-P Park, S.E. 11-56-P Park, S.K. 26-096-P Park, S.Y. 24-34-P, 24-07-P, 09-09-P, 09-05-P Park, Y. 11-49-P, 11-36-P, 11-31-P Parker, G. 10-11-P Parker, I.R. 07-07-P Parnpadung, S. 22-12-P Parris, W. 15-13-P Parry, J. 26-010-P Parsa, P. 04-06-P Parsayekta, Z. 22-51-P Pascoletti, G. 05-01-O Pasetka, M. 11-40-P, 03-28-P, 13-16-P, 11-37-P, 26-097-P, 11-61-P, 10-04-O Pasini, G. 10-35-P Patane, A. 26-035-P Patel, S. 11-15-P Paterson, C. 25-08-P, 26-058-P Patil, J. 22-19-P Patlan, J. 04-33-P Paul, S. 03-12-P Paul, S.M. 03-02-O Paus, R. 25-09-P Pavisic, V. 03-34-P Payne, Y. 11-16-P Pearce, A.M. 24-01-O Pedersen-Bjergaard, U. 25-04-O

Pedersen, B. Pedersen, J.H. Pedersen, L. Pedersen, S. Pedramrazi, S. Pedrini, C. Pedrini, N. Peel, T. Pellegrini, P. Pelletier, G. Pelouchova, J. Pempelfort, K. Penel, N. Peoples, A. Pepin, J. Peppone, L.

26-101-P, 26-067-P 23-31-P 23-44-P 24-06-O 22-51-P 16-16-P 10-09-P, 10-02-O 17-17-P 01-14-P 18-59-P IS-06 10-45-P 25-13-P, 25-05-P 24-20-P, 19-02-P 26-048-P 24-20-P, 19-02-P, 06-22-P, 06-23-P Peralta, L. 16-17-P, 16-16-P, 16-09-P, 16-07-P Perdon, M. 04-33-P Pereira, D.R. 26-081-P Perez-Cruz, P. 17-07-P, 17-08-P Peria, F. 14-17-P Peria, F.M. 11-52-P, 07-10-P Perin, S. 07-11-P Peris Godoy, M. 03-18-P Perkins, J.O.N. 17-34-P Pernod, G. 21-03-P Perrin, S. 07-01-O Perrone-Congedi, F. 08-07-P Perroziello, A. 21-04-P Perry, E. 06-16-P Perry, S. 18-08-P Persad, R. 26-059-P, 26-058-P Peschel, C. 13-08-P Pesevska, M. 08-06-P Pessi, M.A. 26-098-P, 26-066-P, 26-063-P, 18-14-P Petazzi, E. 17-82-P Petersen, J. 10-33-P Petersen, P.M. 22-26-P Peterson, A. 25-06-P, 24-23-P Peterson, D.R. 24-14-P Petkovic, M. 03-34-P petranovic, D. 18-36-P Petrichenko, A. 23-20-P, 01-22-P Petroni, G. 22-25-P Peugniez, C. 25-05-P Pfeiffer, P. 27-01-O, 20-07-P Philipp-Paradisi, S. 22-11-P Phillips, J. 21-07-P Pichard, C. 22-11-P Pietkun, K. 24-48-P, 23-48-P Pietra, C. 11-05-O, 10-20-P Pignoli, E. 26-060-P Piil, K. 23-13-P, 26-084-P Pina, P. 03-19-P Pinheiro, D.D. 22-47-P Pinto, M. 15-05-P Pirnak, J. 14-09-P Pisu, M. 24-21-P Pınar Tekinsoy Kartın, P.T.K. 22-60-P Plath, M. 26-039-P Pleimes, D. 13-15-P Plesner, T. 08-09-P Plestina, S. 02-12-P

S17

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Plews, E. Pochettino, P. Pollock, P. Polsoni, S. Polushkina, I. Poma, A.

10-41-P 11-42-P 24-05-O 15-18-P 22-43-P 11-20-P, 11-07-P, 11-03-O, 11-11-P, 11-38-P, 11-39-P Pon, D. 20-08-P Pongthavornkamol, K. 06-10-P Poon, M. 01-30-P, 11-35-P Pope, A. 17-16-P, 17-48-P, 17-11-P, 17-03-O, 17-50-P, 17-22-P Popovic, G. 17-16-P Popovic, M. 11-40-P, 01-31-P, 09-10-P, 11-35-P, 01-29-P, 01-12-P, 17-85-P Poquet Jornet, J. 03-18-P Poquet, D. 24-41-P Porta, F. 15-04-P, 10-09-P, 10-02-O Porteous, S. 25-08-P Posadas Martínez, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Postovsky, S. 16-21-P Potting, C. 15-14-P Poudel, R. 01-17-P, 01-02-O Pouwer, F. 24-12-P, 12-05-P Powers, C. 06-08-P Pradipta, B. 24-52-P Prakash, G. 13-19-P Pravettoni, G. 18-41-P Preetha, M. 18-03-O Preston, F. 10-38-P Price, L. 10-21-P Pringle, S.A. 15-11-P Pritchard, S. 16-06-P Prityko, A. 23-20-P, 01-22-P Probyn, L. 01-29-P, 17-94-P Protonotarios, D. 10-48-P Pruthi, S. 06-01-O PS, S. 27-05-P, 15-32-P Psyrri, A. 10-15-P Ptok, H. 17-71-P Puget, H. 21-04-P Pugliano, L. 22-37-P, 20-12-P Puglisi, F. 05-01-O Pui, C. 22-03-O Pulenzas, N. 11-40-P, 03-28-P, 01-31-P, 22-58-P, 22-10-P, 11-25-P, 09-10-P, 06-14-P, 01-26-P, 01-09-P, 11-35-P, 03-38-P, 01-29-P, 17-94-P, 17-85-P, 04-27-P, 01-23-P, 17-84-P, 12-18-P Punjwani, S. 16-10-P Purohit, R. 26-025-P Pütz, G. 20-05-P Q Qasem, W. Qian, Y. Qidwai, A. Qin, R. Qiu, E. Quaye, I. Quek, R. Querin, S.

17-40-P 01-11-P 16-10-P 12-06-P 01-05-P 05-09-P 26-038-P 26-100-P

Querre, M. Quinlan, E. Quinn, B. R R, H. Rabelo, P. Raber-Durlacher, J. Radke, L. Rafn, B.S. RAI, B. Raina, V. Rainey, C. Rainone, F. Rainone, M. Raju, S. Rakovitch, E. Raman, S. Ramirez-Morales, R. Ramírez-Vélez, R.

24-41-P 23-02-O 15-14-P, 10-50-P

26-050-P 26-092-P 15-05-P 09-01-O 23-12-P 04-07-P 17-75-P, 07-09-P 11-27-P 22-09-P 12-15-P 03-20-P 22-58-P, 22-10-P 11-61-P, 01-12-P 17-18-P, 04-09-P 23-05-O, 23-04-O, 04-16-P, 04-12-P Rancati, T. 26-060-P Rankin, A. 16-06-P Ransing, V. 17-05-O Rapatoni, L. 14-17-P, 11-52-P, 07-10-P Raphael Kourie, H. 17-49-P Raphael, J. 10-04-O Rapoport, B. 27-02-O, 11-03-O, 11-38-P Rashid, A. 21-06-P Raskin, W. 17-31-P Rasmussen, C.B. 26-034-P Rasmussen, K.M. 21-10-P Rassouli, M. 17-45-P, 17-30-P, 16-14-P Rastog, S. 01-02-O Rastogi, S.A. 01-17-P Rau, K. 22-13-P Rau, K.M. 03-25-P Rauenzahn, S. 03-13-P Rautenberg, B. 20-05-P Ravagnani, F. 26-066-P Ravi, V. 11-15-P Ray-Coquard, I. 24-17-P Ray, T. 26-079-P Raymond, C. 26-022-P Raz, H. 16-08-P Razis, E. 10-30-P Ream, E. 06-11-P, 06-08-P Rebollo, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Reches, H. 25-02-O Recio-Boiles, A. 02-13-P, 02-04-O Recio-Saucedo, A. 24-51-P, 24-29-P Reck, M. 26-007-O Reddy, A. 04-26-P, 03-11-P, 03-07-P, 26-016-P, 17-04-O, 03-21-P, 17-05-O Reddy, S. 03-11-P Regnier-Denois, V. 24-41-P Rehammar, C. 26-009-P Reichelt, R. 18-51-P Reis, P.E.D. 20-19-P Renaud, J. 04-39-P Renfrew, H. 11-20-P Repousis, P. 01-01-O Retroz-Marques, C. 22-35-P Rey, J. 21-03-P

Rey, J.B. 21-05-P, 07-11-P Reyes-Quezada, O. 04-09-P Reynoso-Noveron, N. 04-09-P Rezo, A. 24-24-P Rha, S. 11-49-P, 11-36-P, 11-31-P Rha, S.Y. 24-18-P Rhondali, W. 17-07-P Rhudy, L. 23-33-P Ricci, F. 08-07-P Rice, T. 26-065-P Rice, T.W. 26-099-P Richards, E. 18-52-P Richardson, A. 03-33-P, 24-02-O, 06-19-P, 06-11-P, 06-08-P, 17-80-P, 24-42-P Richardson, C. 23-25-P Richardson, K. 17-83-P Ridner, S. 26-015-P, 14-01-O Ridner, S.H. 09-03-P Ridwelski, K. 17-71-P Ried, K. 11-24-P, 08-10-P Rieder, E. 04-30-P Rief, W. 18-02-O Rieger, C. 10-31-P Riese, C. 04-11-P Rigoli, P. 22-11-P Rimawi, D. 22-31-P Rinaldi, S. 08-02-O Rings, E.H.H.M. 10-07-P Ripamonti, C. 26-098-P, 26-066-P, 26-063-P, 18-14-P Risenbeck, D. 15-14-P Rittenberg, C. 04-05-P, 04-03-O Rittig, A. 11-51-P Rizzi, G. 11-28-P, 11-21-P Rizzuto, I. 24-37-P Roa, W. 22-01-O Robb, K. 23-35-P Roberts, E. 17-02-O Robijns, J. 20-01-O Rocchi, C. 15-11-P Rocha, M. 22-35-P Rock, H. 11-41-P Rodin, G. 17-11-P Rodrigues, I. 26-011-P Rodriguez Salas, N. 21-08-P Rodriguez, C. 13-03-O Rodriguez, R. 08-05-P, 08-01-O Roganovic, J. 16-18-P Rogers, K. 26-044-P Rogers, M. 18-15-P Röhrl, K. 26-095-P Roila, F. 06-21-P Rolland, V. 25-16-P Romagnoli, N. 26-035-P Romane, L. 20-02-O, 18-35-P Rønjom, M.F. IS-05 Rosberg, N. 23-43-P Roscoe, J. 24-20-P, 19-02-P Rose, B. 07-06-P Rose, P. 01-27-P Rosenbaum, D. 16-05-P, 16-03-P Rosenstein, D. 26-003-O Rosenthall, L. 02-11-P Roshangar, L. 26-049-P Rossi Fanelli, F. 02-05-P

S18

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

Rossi, G. 10-35-P Rossi, L. 08-07-P Rosthøj, S. 16-11-P Rothpletz-Puglia, P. 14-12-P Rottmann, N. 24-06-O Rottorf, M. 06-15-P Rouleau, T. 25-01-O Rovlias, A. 13-27-P, 13-26-P, 13-24-P, 12-20-P, 03-29-P Rowbottom, L. 26-097-P, 11-61-P, 01-28-P, 22-27-P, 22-16-P, 03-38-P, 01-29-P, 17-94-P, 17-84-P, 12-18-P Rowland, C. 15-13-P Rua, O. 13-03-O Rubira, C.M.F. 04-17-P Rudd, J. 11-05-O Ruddy, K. 12-02-O Rudnitzki, T. 04-05-P, 04-03-O Rummans, T. 18-01-O, 23-07-O Rustøen, T. 26-095-P Rutkowski, N. 17-83-P Ruud, E. 24-19-P, 15-02-O Ryan, F. 24-01-O Ryan, J. 19-02-P Rybin, A. 11-59-P Ryckewaert, T. 25-05-P Ryoo, H. 17-69-P, 03-30-P Ryoo, H.M. 03-27-P S S. Sommer, M. S.Y., P.A.R.K. Sa, O. Saad, F. Saad, R. Saadallah, N. Sabbatini, A. Sabour, S. Sacco, C.S. Sacramento, C.J. Sadigh-Eteghad, S. Saeki, T. Saevarsson, C.W. Sagar, P. Saglam, Z. Saha, S. Sahai, S. Sahara, E. Saibene, G. Saini, S. Saino, O. Saito, M. Sakai, D. Sakane, R. Sakji, I. Sako, N. Sakuma, Y. Sakuraba, N. Sakurai, K. Sali, A. Salim, O. Salman, T. Salomon, S.M. Samaržija, M.

23-31-P 24-30-P 16-24-P, 10-12-P 01-10-P 15-03-P 03-09-P 15-14-P 15-29-P 05-01-O 20-19-P 03-22-P 11-26-P 26-080-P 04-24-P 26-027-P, 18-48-P, 06-18-P 17-43-P, 14-05-P 25-01-O 11-29-P 10-44-P 15-17-P 23-15-P 25-17-P, 11-17-P, 11-29-P 11-32-P 26-061-P 26-011-P, 25-05-P 10-13-P 15-28-P 26-078-P, 22-62-P 10-13-P 11-24-P, 08-10-P 04-01-O 18-24-P, 18-25-P 18-08-P 02-12-P

Samuel, C. Samuel, M. Samuel, S. Samuel, S.R. Sanada, K. Sancaklı, E. Sanchez La Rosa, C. Sanchez, K. Sandrin, F. Sanga, P. Sangai, T. Sano, Y. Sansoucie, H. Santiago, A. Santoni, M. Santos, D. Santos, M.A. Santos, P.S.S. Saphic, H. Şar Sancaklı, H. Sarfo, V. Sargi, Z. Sarkar, S. Sartain, S. Sarudate, C. Sasikala, K. Satele, D. Sathian, B. Sato, K. Sato, M. Satoh, T. Sattayapiwat, O. Saugat, R. Sauvajot, C. Savina, S. Savini, A. Savva, J. Sawant, S. Sayar, K. Scharll, M.F. Scheuir, C. Schilling, J. Schjoedt, I. Schlitt, A. Schmah, O. Schmalfuss, I. Schmeler, K. Schmidt Río-Valle, J. Schmidt-Wolf, I. Schmidt, H. Schnadig, I. Schneider, B. Schnell, R. Schofield, P. Schøidt, K. Schoormans, D. Schopohl, D. Schrauwen, W. Schrøder, H. Schröder, J. Schrumpf, H. Schultz, H. Schultz, M. Schulze, I.

26-003-O 13-10-P 06-17-P 23-03-O 09-08-P 23-32-P 16-17-P, 16-16-P, 16-09-P 02-13-P, 02-04-O 23-18-P 03-01-O 25-17-P 09-02-P 04-05-P, 04-03-O 21-08-P 08-02-O 26-035-P 20-19-P 04-17-P 26-006-O 27-08-P 24-35-P 18-11-P 17-39-P 17-80-P 15-27-P 03-35-P, 03-36-P 23-07-O 17-51-P 15-27-P 20-06-P 11-32-P 08-05-P, 08-01-O 17-23-P 26-014-P 12-09-P 08-02-O 14-04-O 21-01-O 26-027-P 20-15-P 10-08-P 11-46-P 23-06-O 23-10-P 20-05-P 23-08-P 27-03-O 23-05-O, 23-04-O 26-068-P 07-04-P 11-03-O, 11-11-P, 11-38-P, 11-39-P 10-45-P 18-51-P 18-05-O 23-43-P 24-06-O 10-31-P 18-22-P 16-11-P 26-039-P, 11-33-P 25-12-P 25-04-O 24-46-P 26-068-P

Schumacher, R.F.

15-18-P, 15-04-P, 10-09-P, 10-02-O Schuren, N. 17-47-P Schuricht, F. 18-02-O Schuurhuis, J.M. 15-19-P Schwartzberg, L. 11-28-P, 11-03-O, 11-11-P, 11-38-P, 11-39-P Schweitzer, C. 26-042-P, 26-012-P, 13-09-P Schytte, T. 07-02-O, 24-04-O, 22-08-P Sciotto Marotta, M. 23-18-P Scott, J. 17-28-P Scotte, F. 11-01-O, 26-014-P, 21-04-P, 21-03-P, 26-004-O Scullin, P. 13-04-O Sebatunzi, O. 17-52-P Secombe, K. 10-06-P Secombe, K.R. 12-11-P, 10-18-P Seers, H. 26-036-P Seetsen, T. 22-37-P, 20-12-P Seidenspinner, I. 10-43-P Seisler, D. 12-06-P, 12-02-O Sekhon, S. 14-09-P Sekimoto, M. 11-32-P, 17-25-P Selby, D. 22-40-P Selph, J. 25-06-P, 24-23-P Semanza Mbitse, V. 17-52-P Senuma, K. 11-29-P Senuzun Aykar, F. 15-23-P Seo, J.J. 03-14-P Seo, L. 03-04-P Seo, S.S. 24-07-P, 09-09-P, 09-05-P Seonghoon, S. 12-08-P seref ozdogan, P. 04-20-P Sergio, C. 13-20-P Serra Martins Filho, C. 10-42-P Sesso, H.D. 24-14-P Seto, Y. 12-19-P Sgouros, J. 01-01-O Sha, A. 12-16-P Shahzad, M.A. 22-48-P, 18-44-P Shaikh, M. 14-11-P Shair, N.A. 24-22-P Shamieh, O. 17-40-P, 17-08-P Shankar, A. 22-19-P Shao, Y.Y. 03-25-P Shapiro, P. 24-13-P Shapovalova, J.S. 13-11-P Sharan, K. 17-51-P Sharma, A. 25-03-O, 17-23-P, 26-025-P, 06-09-P Sharma, D.N. 07-09-P Sharma, N. 25-03-O, 17-23-P, 26-025-P, 06-09-P Sharma, S. 18-60-P Sharoev, T. 23-20-P, 01-22-P Sharp, D. 26-059-P, 26-058-P Sharp, L. 24-01-O, 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P Shaw, C. 24-36-P Shaw, T. 18-15-P Shelal, Z. 26-065-P Sheveleva, L.P. 13-11-P Shi, Q. 12-10-P Shiba, E. 25-11-P Shibata, D. 26-013-P

S19

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Shih, J.C. Shiiba, T. Shim, H. Shimane, T. Shimizu, M. Shimo, A. Shimokawa, M. Shimoyama, S. Shimozuma, K. Shin, S. Shinde, S. Shindo, E. Shinjo, T. Shiozaki, H. Shirali, E. Shirayama, H. Shishido, H. Shlaen, M. Shore, N. Shragg, P. Shrotriya, S. Shukla, N.K. Shum, M.B.B.S. Shun, S. Shun, S.C. Shvedova, T. Shwe, M. Sibaud, V. Sicard, J. Sidlow, R. Siedlecki, Z. Sig Emesis, S.I.G. Sigaard, L.

05-03-P 22-61-P 17-32-P 15-10-P, 15-31-P 17-25-P 17-14-P 11-26-P 17-25-P 25-17-P 12-08-P, 24-18-P, 27-07-P 12-02-O 24-44-P 17-25-P 23-09-P, 02-07-P, 02-06-P 26-077-P 17-25-P 17-25-P 13-08-P 01-10-P 07-07-P 22-45-P 07-09-P 18-28-P 24-25-P 24-08-P 22-49-P 18-03-O 20-03-P, 20-09-P, 10-36-P 21-05-P 05-03-P 23-19-P 11-57-P 26-080-P, 23-46-P, 23-38-P, 21-10-P, 23-43-P, 23-24-P Siggins, L. 17-53-P Sigurdardottir, V. 05-06-P Sikora, K. 26-036-P Silva Correa, S. 10-42-P Silva, B.A.B.. 22-47-P Silva, B.M.B. 16-15-P Silva, C. 22-47-P Silva, K.R.M. 20-19-P Silva, L.F.O. 20-19-P Silver, J. IS-02 Silvers, M. 14-04-O Silvestre, J. 03-07-P Sima, A. 03-13-P Sima, L. 01-06-P Siminska, J. 23-48-P, 24-48-P Simões, A. 26-064-P, 15-12-P Simões, A.R. 25-14-P Simoncini, M.C. 23-18-P Simonsen, R. 23-44-P Simron, S. 11-37-P Sims, T. 22-25-P Sin Man Ng, B.S. 18-28-P Sinaika, V. 22-01-O Singer, S. 15-05-P Singh Rana, S.P. 03-05-P Singh, G. 25-03-O Singh, H. 18-40-P Singh, S. 08-04-P Singhal, M. 25-03-O Singhal, M.K. 17-23-P, 26-025-P, 06-09-P Singier, S. 26-100-P Sisson, A. 17-26-P, 17-07-P

Sjoegren, P. Sjøgren, P. Skopin, P.I. Skorpen, F. Skripnik, A. Slama, M. Slatkin, N. Slaven, M. Sleight, A. Sloan, J.

26-054-P 17-29-P, 03-08-P, 23-34-P 13-11-P 17-29-P 20-18-P 11-16-P 03-01-O 03-28-P 23-37-P 26-019-P, 22-05-P, 18-01-O, 23-07-O Smith, M.R. 01-10-P Smith, N. 23-34-P Smith, N.S. 26-054-P Smith, P. 03-33-P Smith, P.W. 24-02-O, 06-08-P Smudde, J. 04-05-P, 04-03-O Snyder, C.F. 22-18-P So, A.I. 24-05-O So, W.K.W. 18-23-P Soanes, L. 26-056-P Soares, G. 16-24-P Sobti, N. 17-26-P Soga, Y. IS-15 Soh, T. 04-15-P Sohmer, J. 23-25-P Soleimani rad, J. 26-049-P Soliman, H. 22-27-P, 22-16-P Solomon, M. 26-021-P, 26-001-O, 22-15-P Somaiah, N. 11-15-P Somani, N. 18-60-P Song, D. 22-25-P Song, J. 14-07-P, 27-03-O Song, S. 11-49-P, 11-36-P, 11-31-P Song, X. 26-032-P Song, Y. 18-27-P, 18-26-P Sonia, G. 13-20-P Sonis, S. 10-08-P, 25-10-P, 10-11-P Sood, A. 27-03-O Soori, G. 12-02-O Soran, A. 09-04-P Sørbye, L.W. 17-74-P Sørensen, G. 11-51-P Sorensen, M. 22-07-P Sørensen, O. 23-50-P Sørensen, O.T. 26-072-P Sørensen, P. 26-031-P Sorgatz, K. 26-026-P Sorrosa, R. 03-23-P Sougat, S.K. 25-03-O Soyanwo, O.A. 17-78-P, 17-73-P Sozu, T. 23-21-P Span, L.F.R. 15-19-P Spasojevic, I. 11-15-P Spencer, A. 01-10-P Sperling, S. 26-042-P, 26-012-P, 13-09-P Spiegel, D. 18-10-P Spijkervet, F.K.L. 15-19-P Spilotti, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Spinelli, G. 08-07-P Spinelli, T. 11-09-P, 16-04-P, 11-30-P Spoelstra, S. 04-05-P, 04-03-O Spruyt, O. 17-42-P Spry, N. 24-11-P Sreedharan, J. 17-51-P

Staehr, N. 23-50-P Stær, M. 23-43-P Stallings-Smith, S. 13-13-P Stan, D. 06-01-O Stanczyk, M.M. 26-093-P Stanic, N. 19-04-P Stansborough, R. 10-17-P Starace, A. 17-82-P Stathopoulos, C.H. 10-48-P Stati, V. 08-07-P Stavraka, C. 24-37-P Steer, C.B. 07-07-P Stefanou, D. 01-01-O, 10-30-P Stefansdottir, B. 05-07-P Steindal, S.A. 17-74-P Steinert, R. 17-71-P Steinmetz, T. 26-039-P Stella, R. 17-95-P, 07-13-P, 04-40-P Stella, W. 17-95-P Stenfeldt, L. 15-01-O, 15-15-P Stern, N. 25-05-P Stern, Y. 25-02-O Stevens, C.B. 10-10-P, 10-05-O Stewart, G. 22-29-P Stinson, J. 13-16-P, 11-37-P, 26-097-P Stocco, L.M. 11-52-P Stocka, J. 23-48-P Stockler, M.R. 26-010-P, 26-023-P Stokman, M.A. 15-19-P, 15-11-P Stone, C. 05-05-P Stopeck, A. 01-10-P Strasser, F. 17-46-P, 02-03-O, 17-09-P Strik, H. 11-41-P Stringer, A. 10-24-P, 10-42-P, 10-27-P, 10-32-P, 10-20-P Strite, S. 01-04-P Strobbe, G. 26-011-P Strohm, G.L. 10-43-P Stroyakovskiy, D.L. 13-11-P Strukov, A. 21-04-P Stuart, M. 01-04-P Stubbin, I. 18-05-O Stump, T.E. 22-04-P Su, C. 17-90-P, 17-89-P Su, J.H. 23-22-P Suarez-Almazor, M. 13-18-P Subramaniam, M. 03-35-P Suda, K. 11-29-P Suenaga, H. 15-28-P Sugazaki, M. 15-28-P Sugimori, N. 23-45-P Sugiyama, J. 11-23-P Sugizaki, K. 11-29-P Suh, S.Y. 24-10-P Sulehri, F.U. 24-22-P Sultan TAŞCI, S.T. 22-60-P Sun, L.L. 11-06-O Sun, M. 27-03-O Sundar, M. 24-05-O Sundar, S. 18-47-P, 18-07-P Sung, Y.C. 03-25-P Surmont, V. 17-38-P Susnjar, S. 19-04-P, 26-069-P, 18-56-P Sut Kahyaoglu, H. 22-44-P, 26-094-P Sutic, I. 03-34-P Svanberg, A. 10-23-P

S20

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

Sveindottir, K. 10-33-P Sveistrup, J. 22-26-P Svendsen, M.D.K. 23-14-P Svetec, B. 26-083-P Swami, N. 17-16-P, 17-48-P, 17-11-P, 17-03-O, 17-50-P, 17-22-P Swati, B. 17-09-P Swift, S. 10-37-P Syahreni, E. 15-21-P Syiem, T. 26-025-P Syrigos, K. 01-01-O, 18-18-P, 03-31-P, 02-10-P Syrjala, K. 23-06-O Sze, W.K. 17-19-P Szeto, A. 22-30-P T Taaffe, D.R. Taarnborg, M. Tabak, N. Tabchi, S. Tada, K. Tae, J.H. Tagliabue, L. Tai, V. Taira, T. Tajer, C. Tajiri, H. Tajiri, K. Takahashi, N. Takahashi, T. Takakura, Y. Takashima, T. Takayama, T. Takebayashi, K. Takekuma, M. Takemasa, I. Takemoto, H. Takemura, K. Tamahara, T. Tamai, N. Tamaki, S. Tamura, K. Tamura, N. Tan, C.M. Tan, K.S. Tan, P.L. Tan, W. Tan, Y. Tana, S. Tanaka, A. Tanaka, H. Tanaka, J. Tanaka, K. Tanasă, M. Tanase, Y. Tanay, M. Tanco, K. Tanda, N. Tanem, K.E. Tanenbaum, M. Tang, G. Tang, K.S. Tang, T. Tannenabaum, S.

24-11-P 11-57-P 16-08-P 22-02-O, 17-49-P 12-19-P 11-56-P 18-53-P 17-61-P 23-09-P, 02-06-P 26-035-P 09-08-P, 23-09-P, 02-06-P 09-08-P 11-14-P 23-09-P, 02-07-P, 02-06-P 23-45-P 25-11-P 25-17-P 14-19-P 11-14-P 11-32-P 11-32-P 17-14-P 15-28-P 25-17-P, 24-31-P, 17-35-P 20-06-P 11-26-P 15-27-P 01-24-P 15-08-P 15-08-P 18-01-O 18-03-O 26-060-P 11-14-P 11-34-P 11-34-P 18-12-P 18-30-P 11-43-P 15-14-P 17-26-P, 17-07-P, 03-04-P, 03-21-P 15-28-P 15-02-O 24-33-P 22-21-P 15-08-P 26-038-P 26-090-P

Tannenbaum, S. Tannock, I. Tannous, R. Tanriverdi, O. Tanuma, A.

06-16-P 17-11-P 01-19-P 18-57-P, 17-76-P 14-19-P, 09-08-P, 23-09-P, 02-07-P, 02-06-P, 23-27-P Tanzi, S. 17-07-P Tao, M. 26-038-P Tarhan, M.O. 18-24-P, 18-25-P Tarozzi, M. 06-10-P Tashvighi, M. 15-29-P Tater, P. 26-045-P Tattersall, M.H.N. 26-023-P Tavakoli-Ardakani, M. 18-46-P Tayjasanant, S. 03-11-P Taylor, S. 26-033-P Tegos, T.H. 10-48-P Teleni, L. 14-02-O, 02-14-P Temel, J. 02-02-O, 02-01-O Teng, H.Y. 03-24-P Tenge, C.N. 16-22-P Terret, C. 07-01-O Terui, T. 14-06-P Teshirogi, F. 15-28-P Teskereci, G. 04-35-P Tezel, H. 15-23-P Thakerar, A. 17-42-P Thariat, J. 24-17-P Thavarajah, N. 01-30-P, 26-097-P, 11-25-P, 09-10-P, 06-14-P, 01-26-P, 17-94-P, 12-18-P Theobald, R. 04-14-P, 03-32-P, 19-01-O, 11-27-P Theodoridou, K. 10-15-P Theodoropoulos, S. 13-27-P, 13-26-P, 13-24-P, 12-20-P, 03-29-P Therkildsen, D.N. 23-46-P Thipphawong, J. 03-01-O Thisted, L. 23-39-P Thomas, A.A. 24-01-O Thomas, G. 04-13-P Thomas, K. 24-36-P Thomas, R. 26-036-P, 14-11-P, 23-02-O Thomas, S. 27-05-P Thomason, S.E. 18-47-P Thomsen, L.A., M.(. 26-002-O Thomson, D. 11-24-P Thomson, M. 22-29-P, 15-14-P, 10-50-P, 25-08-P Thong, M. 24-12-P, 06-05-P Thong, M.S.Y. 12-05-P Thorborg, K. 23-14-P Thorne, S. 22-59-P Tiberg, F. 10-43-P Tiernan, E. 12-15-P Tillard, B. 25-13-P Timmons, A. 24-01-O, 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P Timon, C. 24-39-P, 24-28-P, 24-43-P, 24-32-P, 24-15-P Tipton, J. 04-05-P, 04-03-O Tissing, W.J.E. 16-01-O, 10-28-P, 10-07-P, 27-04-P Titareli Merizio Martins Braga, F. 15-06-P Tjørnhøj-Thomsen, T. 23-26-P

Tjulandin, S.A. Todd, K.H. Togliardi, E. Tohme, A. Tokuda, Y. Tolstrup, J. Tomao, F. Tomao, S. Tomaszewska, I. Tomaszewski, K. Tomita, D. Ton Van, J. Tong, H.J. Topbas, M. Topkan, E. Topp, K. Torniai, M. Torp, J. Torres, H. Torres, S.R. Tothy, P. Touger-Decker, R. Towers, A. Toyama, H. Traficante, D. Trager, S. Trapp, M. Travis, L.B. Treister, N. Treldal, C. Treleaven, J. Tremblay, D.

13-11-P 03-07-P 10-44-P 17-49-P 17-14-P 26-028-P 08-07-P 08-07-P 15-05-P 15-05-P 21-02-P 26-100-P 15-08-P 20-17-P 02-09-P 03-12-P, 03-02-O 08-02-O 11-51-P 13-18-P 15-09-P 18-52-P 14-12-P 23-02-O 26-013-P 13-21-P 26-075-P 23-11-P 24-14-P 10-34-P 10-33-P 10-50-P 26-076-P, 26-047-P, 07-05-P, 24-49-P Tresch, E. 26-100-P Trichas, M. 10-15-P Trier, K. 23-26-P, 23-31-P, 23-14-P Triguboff Ginsberg, E. 03-16-P Trinder, D. 14-18-P Tripault, L. 26-014-P Trochon Joseph, V. 10-08-P Trojan, T. 15-13-P Truby, H. 14-04-O Truong Tan Trung, H. 26-075-P Truong, M.T. 11-06-O Tryfonopoulos, D. 10-30-P Tsakris, A. 15-22-P, 10-15-P Tsao, M. 11-25-P, 06-14-P, 01-12-P Tsimpidakis, A. 10-30-P Tsiverdis, I. 26-052-P, 18-39-P, 18-37-P, 13-23-P, 13-22-P, 11-50-P, 06-04-P, 03-17-P Tsubosa, Y. 14-19-P Tsuboyama, T. 23-21-P Tsuda, M. 23-21-P Tsuji, T. 23-45-P, 23-27-P, 09-02-P Tsuji, Y. 11-23-P Tsukada, H. 11-34-P Tsuneizumi, M. 11-29-P Tsuruta, M. 24-44-P Tubert-Jeannin, S. 15-03-P Tuca, A. 17-68-P, 17-10-P, 22-20-P Tung, Y. 17-19-P Tuqan, W. 26-030-P Turhal, S. 18-57-P, 17-76-P Turner, L. 24-51-P, 06-11-P, 06-08-P

S21

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 U Uchitomi, Y. Udupa, N. Uehara, S. Uematsu, N. Uemura, M. Ugalde, A. Ui Dhuibhir, P.

18-06-P 22-57-P 15-31-P 10-13-P 11-32-P 18-05-O 14-13-P, 17-53-P, 17-24-P, 14-15-P, 12-15-P, 12-13-P, 17-21-P Ulger, E. 18-24-P, 18-25-P Ulger, S. 18-57-P Ülkü Özdemir, U.O. 22-60-P Ullerud, M. 24-46-P Ulusakarya, A. 18-04-O Umay, C. 20-17-P Umutesi, V. 17-52-P Unrau, K. 23-25-P Unsar, S. 22-53-P, 22-44-P, 03-26-P, 26-094-P Ünür, M. 27-08-P, 23-32-P Unutkan, A. 26-091-P Uomori, T. 11-17-P, 11-29-P Urban, L. 11-38-P Uslu, R. 15-23-P Uysal-Sonmez, O. 18-57-P Uyterlinde, W. 26-020-P Uzel, F. 19-03-P Uzunoglu, S. 18-57-P V Vadhan-Raj, S. Vadhiraja, B.M. Vakhabova, J. Valdeón, M. Valentine, L. Vallejos, W. Van Audenhove, C. Van de Poll-Franse, L.

11-15-P 22-57-P 22-43-P 13-03-O 24-11-P 27-02-O 17-13-P 24-12-P, 06-05-P, 24-06-O, 12-01-O Van de Poll-Franse, L.V. 12-05-P Van de Wetering, M.D. 16-01-O, 27-04-P Van de Wiele, T. 10-24-P, 10-37-P Van den Block, L. 17-38-P Van den Hurk, C. 25-09-P, 22-37-P, 20-12-P Van der Laan, S. 17-53-P Van der Speeten, K. 17-87-P Van der Waal, I. IS-16 Van Hecke, A. 18-22-P Van Muilekom, E. IS-22 Van Os, R.P. 15-11-P Van Overeem Hansen, M. 11-47-P Van Patten, C. 24-05-O Van Sebille, Y. 10-06-P Van Sebille, Y.Z.A. 12-11-P, 10-16-P, 10-18-P Vandamme, K. 17-93-P Vandenhoucke, M. 20-15-P Vander Stichele, R. 17-13-P Vanhoecke, B. 10-24-P, 10-42-P, 10-37-P, 10-27-P, 10-32-P Vanlancker, E. 10-24-P Vardas, E. 01-20-P, 01-01-O Vargas-Bermudez, A. 17-68-P, 01-16-P VARGAS, A. 22-20-P Varma, A. 23-40-P

Varma, S. Varol, U. Vasconcelos, A. Vasconcelos, J. Vasile, E. Vaslamatzis, M. Vasseur, B. Vassilakopoulos, T. Vatandoust, M. Vaughn, D.J. Vázquez Estévez, S. Vela, I. Venook, A. Verastegui-Aviles, E. Verbrugghe, M. Verdonck-de Leeuw, I. Verdonck-de Leeuw, I.M. Verhaeghe, S. Verma, S.

13-19-P 18-24-P, 18-25-P 15-14-P 16-24-P 26-088-P 10-48-P, 01-01-O 10-01-O 01-20-P 03-22-P 24-14-P 03-16-P 14-02-O 03-12-P, 03-02-O 17-18-P 18-22-P 15-05-P 22-18-P, 18-32-P 18-22-P 22-58-P, 22-10-P, 09-10-P, 10-04-O Veronesi, P. 23-18-P Verrico, M. 08-07-P Vestergård Svendsen, L. 20-13-P Vestlev, P.M. 11-47-P, 26-017-P Vettori, J.C. 14-17-P Vibe-Petersen, J. 23-26-P, 23-31-P, 23-44-P, 23-14-P Vidal, M. 03-11-P Vidal, R. 13-03-O Vidall, C. 11-01-O Videbæk, L. 26-009-P Vieira, N.N.P. 20-19-P Vietti, M. 11-42-P Vigano, A.L. 02-11-P Vigarios, E. 20-03-P, 20-09-P, 10-36-P Villanueva Palicio, N. 03-16-P Villar, M. 16-17-P, 16-16-P, 16-09-P, 16-07-P Vinnicombe, S. 23-35-P Virji-Babul, N. 16-06-P Vissers, P. 24-12-P, 24-06-O Vissers, P.A.J. 12-05-P Vissink, A. 15-19-P Vitetta, L. 11-24-P, 08-10-P Vladimirov, V.I. 13-11-P Vogel, K. 26-036-P Vogt, M. 26-039-P Vokurka, S. 15-14-P Von Blanckenburg, P. 18-02-O Von Bultzingslowen, I. 15-08-P, 10-05-O Von Hagens, C. 22-42-P Von Pawel, J. 26-007-O Von Schilling, C. 13-08-P Vora, V. 17-57-P, 04-14-P Vordermark, D. 07-04-P Vourli, A. 15-22-P, 01-20-P Vreugdenhil, G. 12-05-P, 12-01-O Vrioni, G. 15-22-P, 10-15-P Vu, K. 14-07-P Vuong, S. 01-31-P, 01-29-P, 17-85-P W Wachtel, A. Wadhwa, D. Waghorn, M. Wagner-Johnston, N.

16-04-P 17-16-P 03-15-P 12-06-P

Waissmann, A. Wakasugi, T. Wakeda, T. Wakuda, K. Waldron, W. Walker, D. Walker, M. Walker, S. Walladbegi, J. Walsh, D.

26-081-P, 17-92-P 23-15-P 22-33-P, 12-19-P 23-09-P, 02-06-P 17-37-P 18-58-P 12-07-P 04-04-O 10-23-P 22-45-P, 17-53-P, 17-24-P, 14-15-P, 12-15-P, 12-13-P, 17-67-P, 17-21-P, 17-37-P Walshe, D. 14-13-P Wan Mohamad Zain, W.N.I. 27-06-P Wang, A.W. 26-085-P Wang, H. 10-39-P, 10-29-P Wang, H.M. 23-22-P Wang, S. 03-01-O, 03-01-O Wang, T. 22-46-P, 18-54-P, 22-38-P, 25-10-P Wang, T.J. 23-22-P Wang, W. 18-54-P, 18-27-P, 18-26-P, 22-38-P, 18-43-P Wang, W.L. 22-46-P Wang, X. 11-20-P, 11-07-P Wang, X.J. 26-038-P, 22-41-P Wang, Y. 16-20-P Wardill, H. 10-06-P, 10-03-O Wardill, H.R. 12-11-P, 10-16-P, 10-18-P Warner, D. 01-10-P Warr, D. 26-022-P Warr, D.G. 11-06-O Wassersug, R.J. 24-05-O Watanabe, K. 17-14-P Watanabe, S. 11-34-P Watanabe, T. 25-17-P Watel, M. 26-011-P Wayn, L. 04-38-P Weaver, E. 10-41-P Weber, K. 22-11-P Wee, B. 04-04-O Wee, H.L. 26-038-P Wehner, P.S. 16-11-P Weinstein, A. 20-18-P Weinstein, C. 27-02-O Weir, P. 17-02-O Weiss, G. 22-25-P Welslau, M. 04-11-P Wen, S. 26-033-P Wenzel, J. 22-25-P Were, P. 16-22-P Wessel, I. 23-36-P Wessling, G. 26-042-P Weyde, K. 24-46-P Weyl Ben Arush, M. 16-21-P Wheelwright, S. 07-04-P Whelan, P. 04-29-P White, I. 10-06-P, 10-41-P White, I.A. 10-18-P White, I.E. 12-11-P White, J. 04-02-O Whitfield, K. 14-10-P, 14-03-O Whittaker, A.L. 10-38-P Wiafe-Addai, B. 24-35-P Wiafe, S. 24-35-P Wiedenbein, L. IS-25

S22 Wiegand, J. Wienke, A. Wignall, A. Wilberg, P. Wiles, S. Williams, J. Williams, L. Williams, M. Wilson, A. Wilson, K. Wilting, K. Winkler, K. Winokur, A. Winstanley, J. Winter, J. Winther, B. Wiredu, P. Wojcik, T. Wolff, S. Won, J.H. Won, Y.J. Wong, A. Wong, C.M. Wong, E.

Wong, E.M.L. Wong, L. Wong, M. Wong, S. Wong, S.Y. Woodland, J. Woods, M. Wozniak, B. Wu, H. 20-10-P Wu, J.

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 11-33-P 07-04-P 10-27-P, 10-20-P, 10-41-P 24-19-P, 15-02-O 10-37-P 17-07-P, 03-04-P, 19-02-P, 03-21-P, 17-47-P 12-10-P, 11-10-P 14-11-P 05-05-P 26-032-P 15-19-P 20-05-P 26-090-P 22-37-P, 20-12-P, 15-05-P 24-02-O 23-42-P 05-09-P 26-100-P 17-71-P 26-096-P 24-07-P 04-26-P, 03-04-P 22-41-P 01-31-P, 22-30-P, 11-25-P, 09-10-P, 06-14-P, 01-26-P, 03-38-P, 17-94-P, 17-85-P, 01-23-P, 17-84-P, 12-18-P 18-23-P 04-15-P 18-03-O 11-35-P 17-19-P 26-051-P 13-10-P 10-41-P

Wu, L. Wu, L.M. Wu, M.F. Wu, X. Wulff-Burchfield, E.M.

04-26-P, 03-11-P, 03-07-P, 17-05-O 24-33-P 12-04-P 03-25-P 01-05-P, 01-31-P 09-03-P

X Xavier, T.M. Xie, L. Xiong, Z. Xiong, Z.Y. Xu, H. Xu, L. Xu, Y.

15-09-P 18-27-P, 18-26-P 01-08-P 01-07-P 08-05-P, 08-01-O 08-05-P, 08-01-O 23-17-P

Y Y, L.E.E. Yacan, L. Yadav, B. Yagasaki, K. Yagata, H. Yaghmaie, F. Yahalom, R. Yahiro, Y.

24-30-P 03-26-P 08-08-P 22-22-P 25-17-P 17-45-P, 17-30-P 15-16-P 17-33-P

Yajima, T. 25-17-P Yakymenko, D. 22-07-P Yalcin, S. 18-57-P, 18-24-P Yamada, S. 26-013-P Yamada, T. 17-25-P Yamada, Y. 11-43-P Yamamoto, H. 11-32-P Yamamoto, N. 17-25-P Yamamoto, R. 17-25-P Yaman, E. 26-027-P Yamashita, A. 02-07-P Yamauchi, H. 17-14-P Yamauchi, S. 23-15-P Yan, L. 01-06-P Yan, Y. 02-02-O, 02-01-O Yanagisawa, K. 18-12-P Yanamandra, U. 13-19-P Yang, D. 06-07-P Yang, M. 26-008-P Yangin, H. 04-35-P Yao, R. 22-21-P Yap, A. 03-10-P Yap, E. 04-15-P Yap, Y. 18-03-O Yapar-Taskoylu, B. 17-76-P Yarandi, F. 26-077-P Yardley, L. 06-11-P, 06-08-P Yaren, A. 18-57-P, 17-76-P Yarom, N. 15-05-P, 15-16-P Yaseen, H. 22-31-P Yashio, H. 09-08-P Yasojima, H. 25-11-P Yavuzsen, T. 18-57-P, 17-76-P Yazici, O. 26-045-P Yee, A. 01-09-P Yen, C.J. 03-25-P Yen, C.Y. 18-38-P Yennu, S. 17-08-P, 17-05-O, 17-47-P Yennurajalingam, S. 03-11-P Yeo, H. 18-03-O Yeung, S. 14-07-P Yigit, B. 04-32-P Yigit, G. 04-01-O Yildirim, B. 02-09-P Yildirim, Y. 15-23-P Yildiz, A. 09-07-P, 09-06-P Yildiz, I. 18-24-P, 18-25-P Yildiz, Y. 18-24-P, 18-25-P Yip, D. 24-24-P Yip, E. 22-21-P Ymashita, A.I.K.O. 14-19-P Yoffe, T. 15-16-P Yonemoto, N. 11-29-P Yong, W. 04-15-P, 18-03-O Yoon, S. 17-12-P Yoshida, Y. 25-17-P Yoshidome, K. 25-11-P Yoshimura, A. 25-17-P Yoshimura, S. 09-02-P Yoshinami, T. 25-11-P Yoshizawa, H. 11-34-P Young, A. 25-09-P, 22-37-P, 20-12-P, 21-07-P

Young, J. Young, J.M. Young, S. Yu, M.S. Yuki, T. Yun, J. Yurick, J. Yusuf, S.W. Z Zaccarelli, E. Zachariae, R. Zahra, K. Zaidel, E. Zaki, N. Zalpour, A. Zamani, A. Zamora, P. Zarowski, C. Zasadny, X. Zaydiner, B. Zegarski, W. Zeitzer, J. Zeller, B. Zendedel, K. Zeng, L. Zhang, J. Zhang, L. Zhang, P. Zhang, S. Zhang, X. Zhang, Y. Zhang, Y.I. Zhang, Z. Zhang, Z.H.E. Zhao, H. Zheng, K. Zhong, W. Zhou, K. Zhou, M. Zhou, X. Zhu, L. Zhu, Y. Ziegler, V. Zielinski, R. Zigogianni, A. Zilli, T. Zimmerman, C. Zimmermann, C.

Zipfel, M. Zoumblios, C.H. Zovko, T. Zschiedrich, S. Zubair, M. Zucchi, P. Zukauskaite, R. Zura, R. Zwisler, A.D. Zylberman, M.

26-021-P 26-001-O, 22-15-P 10-11-P 03-25-P 09-08-P 26-096-P, 25-19-P 09-01-O 25-01-O

08-07-P 12-04-P 26-077-P 26-035-P 03-01-O 25-01-O 22-23-P 04-11-P 24-05-O 10-01-O 12-09-P 23-47-P, 23-19-P 18-10-P 16-02-O 17-45-P, 17-30-P 03-28-P, 01-30-P, 01-26-P 02-08-P 22-30-P, 22-10-P, 11-25-P, 06-14-P, 11-35-P 01-08-P 17-77-P 01-05-P, 01-31-P 17-27-P 17-47-P 11-20-P, 11-07-P 17-27-P 26-008-P, 11-02-O 01-05-P 11-22-P 21-09-P, 22-21-P 11-40-P, 03-28-P, 01-30-P 11-15-P 01-10-P 22-46-P 10-27-P, 10-14-P 26-023-P 15-22-P 22-11-P 12-06-P 17-16-P, 17-48-P, 17-11-P, 17-03-O, 17-50-P, 17-22-P, 26-051-P 26-068-P 10-48-P 02-12-P 20-05-P 24-22-P 18-21-P 15-01-O, 10-22-P 25-06-P IS-29, 22-17-P 26-035-P

S23

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 IS-01 Supportive Care is a Continuum LATE TOXICITIES INDUCED BY ANTI-NEOPLASTIC AGENTS; A HALF CENTURY EVALUATION OFADVANTAGES AND CHALLENGES L. Einhorn1 Medicine, Indiana University, Indianapolis, USA

1

Introduction Fifty years ago there was significant therapeutic nihilism concerning chemotherapy of cancer. Many drug regimens were associated with severe acute toxicity, such as myelosuppression, mucositis, and severe nausea and vomiting. Objectives In 1973, cisplatin entered clinical trials. Cisplatin combination chemotherapy was demonstrated to actually cure a metastatic solid tumor, namely testicular cancer. During the succeeding decades, platinum and nonplatinum based combination chemotherapy was used in many common solid tumors with routine improvement in acute quality of life and prolongation of survival. Methods Today late toxicities of chemotherapy are a major research topic. Platinum is a model for looking at late complications of chemotherapy such as ototoxicity, neurotoxicity, fertility, second malignancies and cardiovascular toxicity. Platinum is standard first-line chemotherapy in a dozen different solid tumors. Results Studies are evaluating late complications of platinum-based chemotherapy in patients with testicular cancer, including clinical parameters and genomic analysis. Conclusions Several decades ago, advances were made in preventing acute toxicity of chemotherapy, especially nausea and vomiting. Hopefully, in the next half century, we will be able to recognize and prevent late complications as well.

IS-02 Supportive Care is a Continuum THE ROLE OF PREHABILITATION AND REHABILITATION IN HIGH-QUALITY CANCER CARE J. Silver1 1 Physical Medicine and Rehabilitation, Harvard Medical School, Boston, USA This lecture focuses on evidence-based cancer rehabilitation with the goal of understanding how these services can be incorporated into high-quality oncology care. Prehabilitation begins shortly after diagnosis and before acute cancer treatments begin. By definition, cancer prehabilitation is “A process on the cancer continuum of care that occurs between the time of cancer diagnosis and the beginning of acute treatment and includes physical and psychological assessments that establish a baseline functional level, identify impairments, and provide interventions that promote physical and psychological health to reduce the incidence and/or severity of future impairments.”[i] Impairment-driven rehabilitation focuses on problems that may be pre-existing or arise due to cancer or its treatment. Screenings, assessments and interventions should be coordinated to support physical and psychological outcomes as well as health-related quality of life. Cancer rehabilitation is medical care delivered by trained specialists such as physiatrists and physical, occupational and speech therapists. This

medical care focuses on the appropriate diagnosis of and evidence-based treatment for physical, cognitive and functional impairments. Interventions are designed to not only reduce symptom burden but to improve function and decrease disability. Assessments and interventions should continue throughout the care continuum with a focus on improving outcomes in cancer at every stage. Rehabilitation professionals should work collaboratively with supportive oncology and other interdisciplinary colleagues to achieve the triple aim—improved patient outcomes, increased patient satisfaction with care and decreased per capita healthcare costs. [i] Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013;92(8):715–727.

IS-03 Euthanasia, assisted dying EUTHANASIA IN BELGIUM D. Lossignol1 Supportive care, Institut Jules Bordet, Brussels, Belgium

1

Introduction Since 2002, the Belgian legal framework authorizes the practice of euthanasia, under certain clear conditions. All cases have to be reported to the Assessment and Control Commission (ACC). To date, more than 9000 cases have been reported since 2002 Objectives To present an objective statement on euthanasia. Methods To make a statement about the Belgian experience requires considering different points: data and evaluation from the ACC reports, their analysis, consequences on medical practice, legal and medical perspectives, critics and attacks about the legal framework, the concept of individual and institutional conscience clause. Euthanasia for minor is now depenalized under conditions. Results Regarding all these topics, we note that the Belgian experience is more than an example and shows that adequate answers may be provided to patients experiencing intolerable suffering. Conclusions Euthanasia is no longer a “taboo” in countries where freedom of speech is respected.

IS-04 Endocrine Issues in Cancer OBESITY, DIABETES AND CANCER OUTCOME P. Goodwin1 1 Medicine, Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital University of Toronto, Toronto, Canada The current obesity epidemic is associated with a parallel increase in Type 2 diabetes (T2DM). Obesity has been consistently associated with increased risk of, and mortality from, most types of cancer including common cancers such as breast, prostate, colorectal and endometrial but not lung. Post-diagnosis, obesity has been extensively studied in breast cancer where it is associated with adverse prognosis; there is emerging evidence that similar associations exist for other cancers. The biologic basis for the obesity-cancer link is likely multifactorial, including reprogrammed systemic physiology

S24 (elevated estrogens, insulin resistance, dysglycemia, altered adipokines, low grade inflammation) as well as altered tumor microenvironment (inflammatory cells, cytokines, adipokines) leading to activation of key signalling pathways (e.g. PI3K, MAPK, TNFα, STAT3), increased proliferation, reduced apoptosis, and enhancement of metastatic potential. T2DM has been associated with a modest increase in cancer risk. Agents used to treat T2DM may also impact cancer risk—lower risk in patients receiving metformin has received the greatest attention. Biases inherent in observational studies may have contributed to these reported associations. T2DM at cancer diagnosis may lead to increased treatment toxicity (e.g. with chemotherapy or surgery) and require treatment modification. T2DM has also been associated with poor cancer outcomes, in part due to comorbid conditions but also due to increased cancer mortality. Intervention research targeting diet, physical activity and weight loss or using anti-diabetic agents such as metformin is underway.

IS-05 Endocrine Issues in Cancer HYPOTHYROIDISM AFTER RADIOTHERAPY M.F. Rønjom1, C. Brink2, L. Hegedüs3, J. Overgaard4, J. Johansen1 Department of Oncology, Odense University Hospital, Odense, Denmark 2 Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark 3 Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark 4 Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark 1

Introduction Radiation-induced hypothyroidism (RIHT) is a well-known late effect after radiotherapy (RT) to the neck in head and neck squamous cell carcinoma (HNSCC), Hodgkin lymphoma, and breast cancer. Objectives To investigate the reported incidence and risk factors for development of RIHT as well as normal tissue complication probability (NTCP) models and dose constraints for radiation treatment planning. Methods Review of the literature on RIHT and data extraction from our studies of two independent cohorts of patients with HNSCC treated with definitive RT without surgery. Results Subclinical hypothyroidism has been reported in 24–50 % and overt hypothyroidism in 6–20 % of patients. We found an estimated 5year incidence of biochemical hypothyroidism of 26 %. A high radiation dose to the thyroid gland and a small volume were significant risk factors for RIHT, which is supported by other studies. In the literature, surgery to the neck and sex have also been found to be significant risk factors whereas chemotherapy does not seem to be of importance in patients with HNSCC. NTCP models taking both thyroid volume and mean dose to the gland have been proposed for prediction of RIHT as well as threshold values for thyroid dose for RT planning. Conclusions Radiation-induced hypothyroidism is a frequent late effect after RT to the neck. Surgery, radiation dose, and thyroid volume seem to affect the risk of RIHT. Considering the frequency of RIHT and the possible consequences of hypothyroidism, thyroid dose constraints are needed in RT planning. Furthermore, thyroid function should be monitored after RT to the neck.

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 IS-06 Use of E-Health in Supportive Care E-HEALTH PATIENTS EXPERIENCE J. Pelouchova1, 2, 3 European Cancer Patient Coalition, Brussels 2 Leukemia Patient Advocates Foundation, Bern 3 Diagnoza leukemia, Czech Republic

1

With the twenty-first century representing a decade of targeted therapies in oncology, the focus on e-health is emphasized in the field of patient’s use of technology. The increasing demand for information on cancer is connected to improving treatment outcomes, legislative changes enabling patients to access medical records and the constant rise of Internet connectivity. These factors contribute to a general need for information concerned with disease-related facts, treatment options, medical innovations, as well as medical record management and improved doctor-patient communication. With the ongoing development of the Internet as the prime medium of information distribution, the importance of electronic technologies in supporting information access is increasing. The use of devices such as iPhones/iPads enables patients to utilize specially designed applications for tracing and assembling medical evidence (e.g. results of lab tests), facilitates the response to targeted surveys on aspects of quality of life and can ensure the continuous monitoring of treatment side effects. Another advantage concerns the option of communicating online with healthcare professionals and hence avoiding unnecessary visits to medical centres, ensuring a cost-effective and faster information flow. A key factor for the potential of e-health is also apparent in the field of patient networking. Disease-specific patient organisations can build networks to enhance knowledge sharing on treatment development and improve distribution of best practices in patient advocacy related to treatment access. The future aim should be to improve patient information tools, develop joint campaigns and build alliances on various issues to help disseminate these resources amongst patients of all generations.

IS-07 Best Supportive Care in Patients with Haematological Malignancies SUPPORTIVE CARE IN HAEMATOLOGY L. Kjeldsen1 1 Department of Haematology, National University Hospital Rigshospitalet, Copenhagen, Denmark Introduction Many haematological diseases are characterized by impairment of both the innate and acquired immune system, either due to the disease itself or as a consequence of treatment. Therefore, most patients with haematological disorders are in need for supportive care. Objectives To give an overview regarding the extensive use of supportive care treatments in haematology. Methods Systematic review of published literature regarding different aspects of supportive care in haematology including use of transfusions, haematopoietic growth factors, prophylactic antimicrobials, immunoglobulins and bisphosphonates. Results Dependingontheintensityofchemotherapythereisfrequentlyaneedfor transfusions with both blood and platelets. Patients with neutropenic fever are occupying a large proportion of the beds in haematology units,

S25

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 although many infections can be prevented by the use of prophylactic antibiotics or granulocyte colony stimulating agents. By systematic use of prophylactic antibiotics, transfusions and thorough patient education, outpatient treatment of patients with acute leukaemia, patients receiving high dose therapy with autologous stem cell support and even patients undergoing allogeneic stem cell transplantation has proven feasible. Patients with low risk myelodysplastic syndrome often suffer from transfusion dependence, which in a large proportion can successfully be treated with erythropoiesis stimulating agents (ESA), sometimes in combination with G-CSF, although data regarding improvement of quality of life by ESA treatment are conflicting. ESAs are also used in other haematological malignancies especially in multiple myeloma and chronic lymphocytic leukaemia, where also substitution with immunoglobulins is often given due to the inherent immunoparesis. The bone disease in multiple myeloma can be improved by bisphosphonates. Conclusions Supportive care treatments in haematology have improved over time allowing more and more outpatient treatment, in spite of prolonged treatment induced bone marrow suppression.

IS-08 Best Supportive Care in Patients with Haematological Malignancies GENERAL MANAGEMENT OF NEUTROPENIC PATIENTS P. Combrez1 1 Department of Hematology and Hematopoietic Stem Cell Transplantation, Jules Bordet Institute, Brussels, Belgium Neutropenia is the most common dose-limiting toxicity of cancer chemotherapy, and complications from chemotherapy-induced neutropenia (CIN) can cause significant morbidity and mortality. In fact, Given and Shewood (2005) identified CIN as a nursing-sensitive patient outcome symptom. Expert nursing assessmant, intervention, education and evaluation facilitate patient management of CIN. To identify and highlighted evidence-based management of CIN and related complications, and to provide effective nursing interventions which should be implemented in daily practice. Extensive review and summary of published neutropenia litterature, clinical practice guidelines and meta-analyses. Prevention of infection should be the primary focus of oncology nurses’ practice rather than management of neutropenia. Based on a review of the litterature following classification of costeffective nursing interventions for the prevention and management of febrile neutropenia (FN), according to the level of evidence, can be proposed: Low Evidence: wearing mask by the health care provider, low bacterial food and dressing of tunneled central catheters. Moderate Evidence: systematic use of HEPA-filtered air for prevention of Aspergillus infection and Laminar Air Flow rooms. High Evidence: frequent oral care, venous access devices not placed during neutropenia, antimicrobial prophylaxis if neutropenia ≤ 500/mm3 is expected during more than 7 days, construction barriers, avoiding fresh flowers and plants and prompt action when neutropenic fever (administration of antibiotics in 2 h after first fever). Oncology nurses play critical roles in the areas of clinical practice, research and education as related to the prevention and management of CIN and are charged with maintaining their knowledge of the evidence and guidelines. In doing so, oncology nurses can be confident that clinical evidence is driving their decision-making processes to ensure quality cancer care and provide patients with the best opportunity for favorable long-term outcomes.

IS-09 Supportive Care in the Elderly NURSING FACILITIES AND CANCER SUPPORTIVE CARE: PROVIDING BEST PRACTICES CLINICAL SERVICES TO OLDER ADULT CANCER PATIENTS B. Appel Esbensen1 1 Research Unit, Glostrup Hospital, Glostrup, Denmark Introduction In spite of a growing number of older people with cancer, the research has been limited on how they manage their situation and how nursing care to this group is performed. Objectives To outline, how it is possible from a nursing and interdisciplinary perspective, to integrate knowledge from nursing research in other chronic diseases and geriatrics, into the care of older adults with cancer. Methods Based on existing research from different nursing disciplines, factors with significant meaning to older adults with cancer, and how they can manage to live with a chronic disease are identified. Furthermore, how this quite new knowledge might be incorporated into nursing practice. Results Research on aspects of symptom management, and cognitive and behavioural aspects of chronic diseases has revealed a different understanding of how older individuals cope with chronic disease. In addition, Comprehensive Geriatric Assessment (CGA) has proved to be a method to identify vulnerable individuals among elderly with cancer and to optimize care. CGA has also proved to be a sound procedure to recognize the heterogeneity of the elderly population and to focus care plans accordingly. Such combined knowledge may provide guidance on how to set-up a more accurate intervention for the individual in clinical practice. Conclusions In caring for older adults with cancer, it is recommended to set up appropriate intervention strategies aiming to identify a person’s resources based on an interdisciplinary evidence based understanding of older adults with a chronic disease and to make use of CGA.

IS-10 Pharmaceutical Supportive Care PHARMACOGENOMICS IN SUPPORTIVE CARE A. Chan1 Pharmacy, National University of Singapore, Singapore, Singapore

1

In clinical practice, we frequently observe that certain patients with cancer are highly sensitive to adverse effects of anticancer treatment, or certain patients are less sensitive to certain supportive care means to mitigate adverse effects. Inter-individual differences are consistently observed with most anticancer agents or supportive care agents, and some of these differences may be explained by pharmacogenomics. Pharmacogenomics is the study on how all of the genes (the genome) can influence responses to drugs, including the individual differences of toxicities occurrence and severity. In this talk, the audience will be introduced to some foundational knowledge on pharmacogenomics and how it may impact on supportive care decisions for our patients. A number of examples will be discussed. We will also discuss the challenges in terms of translating genomic information into daily clinical practice to personalize supportive care.

S26 IS-11 Pharmaceutical Supportive Care UNMASKING SIDE EFFECTS FROM “FIRST-IN-MAN” ANTINEOPLASTIC MEDICINE U. Lassen1 1 Dept. Oncology Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark Patients referred for phase 1 oncology trials have exhausted all conventional treatment options, as this is a strict inclusion criteria. The majority of patients have advanced disease and carry a variety of complex symptoms and perhaps some sequelae after prior therapy. The patients are also required to have a favourable performance status of PS 0 or 1. Therefore, most patients are within a narrow window before deteoriation, driven by hope, and perhaps not motivated for palliative treatment. Dealing with these patients is difficult. The evaluation of side effect and safety is the primary endpoint of phase 1 trials, and the patients must spend more time in the clinic for investigations, compared to prior standard therapy. In addition, the patients undergo many examinations and blood sampling for pharmacokinetic,—dynamic and—genomic analyses. So participating in phase 1 trials is time consuming and may be cumbersome. The identification of the right patients for this is delicate: who should be included and who should be referred for palliation. The Phase 1 Units are the resort for the patient, and it is necessary to be devoted to giving the best supportive care on one side and the active treatment on the other side. It is often a matter of precision to choose the right moment to introduce more specialized palliative initiatives, when is becomes apparent that the study drug is not active, and at the same time be able to discriminate between progressive disease related symptoms and study drug related adverse events.

IS-12 Oral Care in Head and Neck Cancer FOCUS ON TASTE DISTURBANCES A.G. Boltong1 1 Cancer Information and Support Services, Cancer Council Victoria, Melbourne, Australia Introduction It is accepted in sensory science that taste is but one component of flavor. However, widespread and colloquial use of the word ‘taste’ means that patient-reported ‘taste’ changes actually refer to many domains outside the sense of taste itself. This anomaly is not widely understood across supportive care teams, making clinical management of flavor problems difficult. Further challenges are that routine methods of assessing taste and flavor related complications are not employed in the clinical oncology setting and no clinical guidelines exist for the management of such problems. Objectives This lecture aims to: 1) Define taste and related concepts including flavor and food hedonics 2) Provide an overview of current assessment tools 3) Describe patterns of true taste changes in oncology populations and evidence of effective management strategies 4) Describe an emerging taxonomy of ‘taste’ to help better identify the clinical problem and relevant support mechanisms Methods This lecture is informed by empirical research of patients and clinicians; as well as systematic literature reviews. Multidisciplinary collaborators include sensory scientists, oncologists, dietitians, dentists and oncology nurse researchers.

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Results Cancer treatment has adverse effects on taste, smell, touch, food liking and appetite. This has gastronomic, nutritional and emotional consequences. Clinically applied ‘taste’ assessment tools usually measure other elements of flavor, although taste is mentioned. Laboratory derived tools often lack clinical utility. Conclusions A linguistic platform that matches language used by patients to specific sensory and hedonic domains is posed as a future approach to management of flavor related problems.

IS-13 Complementary and Alternative Medicine in Cancer Care COMPLEMENTARY AND ALTERNATIVE MEDICINE IN CANCER CARE: NEW DATA CALL FOR MINDSHIFTING? A. Charalambous1 1 Nursing, Cyprus University of Technology, Limassol, Cyprus Introduction Complementary therapies are adjuncts to mainstream care to improve quality of life through decreasing the adverse effects of anticancer treatments or through alleviating the symptoms of cancer through improving the general well-being of the patient. On the contrary alternative therapies are generally promoted as such-for use as actual antitumor treatments. Objectives To present the latest scientific evidence for the efficacy and safety of first line complementary therapies. Methods This is a comprehensive review of the relevant literature Results There is sufficient evidence to support Acupuncture and acupressure for alleviating chemotherapy-induced nausea and vomiting, aromatherapy to improve well-being, relaxation to control pain and reduce fatigue and visualization to reduce anxiety and depression just to report a few. This scientific evidence has allowed for a phenomenon to grow known as integrative care where patients are using non-conventional treatments or therapies alongside their conventional course of care which are seen as supportive to the therapeutic process whether or not they have direct biological effects on cancer. Conclusions The popularity of integrative care has grown because it incorporates complementary therapies that are rational, cost-effective, non-invasive and also empowering the patient by allowing him to assume an active role in their care. Combining the effective complementary therapies with mainstream oncology care to address patients’ physical, psychological and spiritual needs is recommended in clinical practice.

IS-14 Novel Therapies and Best Supportive Care in Cutaneous Malignancies EFFICACY OF AGENTS TARGETING THE BRAF/MEK PATHWAY P. Gerber1 Dermatology, Heinrich-Heine-Universitat, Düsseldorf, Germany

1

Introduction Malignant melanoma is responsible for approximately 80 % of skincancer related deaths. In recent years novel treatment strategies have revolutionized the managemed of advanced stages of the disease.

S27

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Objectives To present the current clinical data and presonal experience on BRAF/MEK-therapy for advanced malignant melanoma. Methods Review of the recent literatur and presonal clinical experience. Results In 2011 Chapman et al. demonstrated that the BRAF-inhibitor (BRAFi) vemurafenib achieved patient response rates of 48 % as compared to 5 % for the standard chemotherapy (dacarbazine). At 6 months, the OS was 84 % in the vemurafenib group and 65 % in the darcabazine group. Subsequently, similar results were reported for dabrafenib, another BRAFi. Despite their efficacy, most patients treated with BRAFi develop mechanisms of acquired resistance, eventually leading to disease progression. A main mechanism of this resistance is caused by a BRAFindependent activation of the downstream MAP-kinase MEK. Most recently MEK-inhibitors (MEKi) have been introduced for the treatment of advanced malignant melanoma. Larkin et al. reported 9-month intermin OS-rates of 73 % for vemurafenib alone and 81 % for the combination of vemurafenib and the MEK-i cobimetinib. Robert et al. reported 12months interim OS-rates of 65 % for vemurafenib alone and 72 % for patients receiving a combination of dabrafenib and the MEK-i trametinib. BRAFi-therapy is associated with the development of inflammatory rashes (>30 %), photosensitivity (>10 %) and secondary skin tumors (e.g. squamous-cell-carcinomas, SCC, or keratoacanthomas, KA; up to 20 %). Interestingly, the combination of BRAFi and MEKi reduced the frequency of secondary SCC or KA to 1 %. Conclusions The introduction of the BRAFi and MEKi has revolutionized the treatment of advanced malignant melanoma. Both drugs were amongst the first to achieve a significant improved overall-survival (OS) in patients with advanced stages of the disease.

IS-15 ISOO CE Course and Business Meeting ANTIMICROBIAL RESISTANCE Y. Soga1 1 Division of Hospital Dentistry, Okayama University Hospital, Okayama, Japan Oral and systemic infections arising from the oral cavity are significant problems in cancer patients treated with intensive chemotherapy regimens. Oral mucositis is a common symptomatic complication associated with myeloablative chemotherapy, and a significant cause of suffering morbidity and mortality. Infection by multi-drug-resistant bacteria is the worst type. Objectives To show antimicrobial resistance of bacteria on the oral mucosa undergoing intensive myeloablative chemotherapy, by discussing a typical case and studies in hematopoietic cell transplantation (HCT) patients. Methods A case is presented with opportunistic multi-drug-resistant bacteria on the oral mucosa during HCT. In addition, studies on bacterial substitution, bacterial antibiotic sensitivity, and detection frequency of mecA, which mediates methicillin resistance, on the oral mucosa after HCT are discussed. Results An HCT patient with multi-drug-resistant Stenotrophomonas maltophilia on the oral mucosa developed sepsis and died. Our studies showed that bacterial substitution of coagulase-negative staphylococci (CoNS) for streptococci occurs frequently, there were many antibiotic-resistant bacteria on the oral mucosa after HCT, and mecA was detected at high frequency in the oral mucosa of patients undergoing HCT. Conclusions Oral mucosal bacteria in patients after HCT, with typical intensive myeloablative chemotherapy, had high antimicrobial resistance. Oral

bacteria on the mucosa of patients undergoing other myeloablative chemotherapy regimens would also have antimicrobial resistance if many antibiotics are used. In such cases, oral mucositis is an infection route of these bacteria. Appropriate oral care for cancer patients possibly with mucositis and antimicrobial resistance bacteria would be important as supportive care.

IS-16 ISOO CE Course and Business Meeting DIFFERENTIAL DIAGNOSIS OF ORAL LEUKOPLAKIA AND LEUKOPLAKIC LESIONS I. van der Waal1 1 Dept. of Oral and Maxillofacial Surgery/Pathology, VU medical center/ ACTA, Amsterdam, Netherlands In an international meeting in 2005, held under the auspices of the WHO, oral leukoplakia has been defined as: ‘A white plaque of questionable risk having excluded (other) known diseases or disorders that carry no increased risk for cancer’. A list of “known”, predominantly white diseases or disorders that carry no increased risk for cancer is presented in Table 1. These lesions will be briefly discussed. In the majority of cases the diagnosis can be established on clinical grounds alone; in a few disorders there is a distinct role for a biopsy. Nevertheless, there remains an occasional patient in whom no firm diagnosis can be established in spite of the availability of a biopsy specimen. Table 1. Known white diseases and disorders that may occur in the mouth Alveolar ridge “keratosis” Aspirin burn Candidiasis, hyperplastic type Contact lesion (Amalgam restoration associated lesion) Frictional lesion Hairy leukoplakia Leukoedema Lichen planus* Lupus erythematosus Morsicatio (habitual chewing or biting of the cheek, tongue, lips) Syphilis, secondary (‘mucous patches’, lichenoid lesions) Verrucous carcinoma White sponge nevus *There is an ongoing discussion in the literature about the premalignant character

IS-17 Chemotherapy Induced Neurological Complications GENOMIC RISKS FOR DEVELOPING CIPN L. Eckhoff1, M. Ewertz1 Oncology, Odense University Hospital, Odense, Denmark

1

Introduction Chemotherapy-induced Peripheral Neuropathy (CIPN) may occur as a dose-limiting toxicity during chemotherapy with taxanes, and platinum compounds. CIPN may regress after treatment completion, but if it persists

S28 it is likely to have a negative impact on quality of life (QoL). So far, the most promising preventive measure is to equip patients with frozen gloves and socks during treatment, but no drugs have been shown to be effective in the prevention of CIPN. Therefore, research efforts have been directed to focus on factors that may predict the occurrence of CIPN prior to treatment. Objectives Single nucleotide polymorphisms (SNP) are the most common type of genetic variation among people and can be identified by a diverse range of SNP genotyping methods. Methods A review will be presented of possible associations between SNPs and the risk of CIPN induced by taxanes and platinum compounds. Results Focus will be on SNPs in drug transporters, detoxification enzymes, genes involved in DNA repair mechanisms, and others. Conclusions The literature does not give a clear picture of the predictive value of determining SNPs prior to treatment. As the number of long-term cancer survivors increases, a new focus on long-term effects of chemotherapyinduced side effects has emerged. Hopefully in the future, the knowledge gained from application of translational genomics to CIPN will improve the quality of life of cancer survivors.

IS-18 MASCC AFSOS Symposium

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 IS-19 MASCC AFSOS Symposium MUCOSITUS GUIDELINES: AN UPDATE R.J. Bensadoun1 1 Radiation Oncology, Centre de Haute Energie, Nice, France Introduction Mucositis Guidelines: An Update. Objectives Oral and gastrointestinal mucositis due to cancer therapies such as highdose chemotherapy and/or radiation continues to be an important clinical problem. Fortunately, there have been strategic advances over the past decade relative to understanding the molecular basis of the injury, opportunities for development of drugs and devices to prevent or treat the toxicity. Methods The new ESMO Mucositis guidelines represent updates from the version published in the 2011 Annals of Oncology, including recent suggestions regarding management of targeted cancer therapeutics-associated stomatitis. Results This important and comprehensive update of ESMO Mucositis guidelines will be presented and discussed, with a focus on new data, and comparison with AFSOS, MASCC and ASCO guidelines on this topic. Conclusions Email: [email protected]

BACK HOME: EVIDENCE FOR SUPPORTIVE NETWORK; HOW, WHEN AND FOR WHO? M. Lemonde1 1 Faculty of Health Sciences, University of Ontario Institute of Techonology, Oshawa, Canada Introduction Discharge from hospital follow-up is a key time point in the cancer journey. With recommendations from cancer survivors, attention to the return home is important as it can be a period of emotional reactions and challenges for both the patient and the caregiver. Supportive network is defined as a group of people who provide emotional and practical help to someone in serious difficulty, which can be relevant to the individual living with cancer and his/her caregiver. Optimum home care for patients living with cancer depend on adequate care for the caregivers to continue providing care. Carers reported the need to be prepared for their caring role for their relative at home with cancer, to be visible to professionals by being involved during the consultation, to receive clear and specific information about the relative’s condition, treatment progression, illness prognosis and to be emotionally supported. In addition, the hospital-to-home transition has to be facilitated by the following elements: translating knowledge into safe, health-promoting actions at home, inclusion of caregivers at every step of the transition process which is congruent with what they need and anticipating needs back home in order to make arrangements to meet them Objectives To describe the process to capture the return home from a supportive network perspective. Methods A literature review and synthesis to describe the return home of individuals living with cancer. Results The results will be an understanding of the factors to consider and when to implement them for the individuals living with cancer and their caregiver Conclusions This presentation will target the importance and relativeness of the supportive network particularly through the caregiver in the home environment of those living with cancer.

IS-20 MASCC AFSOS Symposium BREATHLESSNESS AT THE PALLIATIVE TIME: FROM GUIDELINES TO PRACTICE C. Mazzocato1 1 medicine, CHUV, Lausanne, Switzerland Introduction Dyspnea is commonly encountered by many cancer patients in the terminal stage of their disease. It is a devastating symptom and it severely hampers their quality of life. It often is associated with anxiety and depression. The management of cancer-related dyspnea remains a challenge because of lack of systematic guidelines for clinical care. Objectives The objectives of this parallel session are to discuss of pharmacological and non-pharmacological options to improve this symptom. Methods Review of recent literature. Results For patients who are not actively dying, strategies should be focused on treating the underlying cause of the breathlessness while concurrently controlling symptomatic distress. Optimal outcomes from palliative care interventions require a multi-level approach, involving pharmacological and non-pharmacological interventions. Pharmacological interventions include opioids, bronchodilators, steroids, diuretics, and psychotropic drugs. The evidence for these drugs is variable, and sometimes weak. Nonpharmacological interventions involve techniques to improve breathing efficiency, use of non-invasive ventilation, and of high-flow oxygen, particularly in patients with severe hypoxemia or significant cachexia with respiratory muscle weakness. Psychosocial support seeking to reduce anxiety and distress can also improve the management of dyspnea. Conclusions Optimal outcomes from supportive and palliative care interventions require a multi-level approach to improve the management of dyspnea at end-of-life cancer patients.

S29

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 IS-21 Fatigue HOW DO WE DEFINE FATIGUE AND WHAT IS NEW? K. Olson1 Faculty of Nursing, University of Alberta, Alberta, Canada

1

Background Fatigue has been identified as the symptom that frequently triggers the initial medical consultation prior to a cancer diagnosis, as a symptom that often occurs during cancer treatment, as the most distressing symptom experienced by those with advanced cancer, and as a symptom that is also reported by cancer survivors. Objective In this presentation I will review definitions of fatigue and discuss new findings regarding its etiology and management across the cancer trajectory, including recently released clinical practice guidelines. Results A full understanding of the etiology of fatigue has been elusive, given its multidimensional nature and shifts that may occur over time. Early attempts to manage fatigue showed that an increase in hemoglobin did not result in an improvement in fatigue to the degree expected. Recent reviews of available evidence showed significant improvements in fatigue following both exercise and psychosocial interventions, and no significant improvement following pharmacologic interventions. Evaluation of patient outcomes based on current clinical practice guidelines is warranted.

IS-22 Fatigue COMPASSION FATIGUE: HOW TO DEAL WITH IT? E. van Muilekom1 1 Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands Introduction Compassion fatigue has been studied amongst health care professionals for a long time. Where burn out is mostly related to a conflict in the work setting, compassion fatigue stems from emotional engagement and interpersonal intensity associated with witnessing tragedy with the work setting. Burnout arises when assertiveness-goal achievement intentions are not met. Compassion fatigue evolves when rescue-caretaking strategies are unsuccessful, leading to caregiver feelings of distress and guilt. Burnout and compassion fatigue can cause feelings of frustration, powerlessness, and diminished morale ensue. Objectives The objectives of this presentation are to explore the differences between compassion fatigue and burn out, the risk factors for healthcare workers, symptoms and manangement. Methods Multiple environmental stressors, such as, workload, long hours, need to respond to complex patient needs: pain, traumatic injury, emotional distress, can result in feeling tired, depressed, angry, ineffective, apathetic, headaches, insomnia, and gastrointestinal distress. Ignoring these symptoms can easily result in cumulative stress. Results Compassion fatigue will not only influence the individual but will also have its impact on workers recruitment and retention, patient satisfaction and patient safety. Encouraging self-care strategies and offering workplace interventions can address a key distinction in daily practice. It is also important that managers, educators and researchers are aware of this phenomena and facilitate prevention strategies like counseling, support

groups, de-briefing sessions, massage sessions, bereavement interventions and attention to spiritual needs. Conclusions Healthcare provides are at risk for compassion fatigue, sometimes the work environment cannot be changed but prevention, early detection and management can help to prevent workers getting in this situation with all its consequences.

IS-23 Fatigue FATIGUE IN ADVANCED CANCER A. Charalambous1 1 Nursing, Cyprus University of Technology, Limassol, Cyprus Fatigue is one of the most common and debilitating symptoms experienced by patients with cancer. Cancer-related fatigue (CRF) is characterized by feelings of tiredness, weakness, and lack of energy and it differs from tiredness in the general population as it is not associated with increased or decreased physical activity, nor is it relieved by rest. It occurs both as a consequence of the cancer itself and as a side effect of cancer treatment. Objectives To advance the knowledge of fatigue in patients with advanced cancer. Methods This is a comprehensive review of the relevant literature. Results Etiologic factors associated with CRF include cachexia, infection, anaemia, neurological changes, psychological distress, metabolic and endocrine disorders, over-exertion, medications, side-effects of anti-neoplastic treatment and paraneoplastic neurological syndromes. Prevalence of fatigue in patients with cancer varies between 17 and 96 %. Cancer-related fatigue is often clustered with other symptoms including pain, changes in sleep patterns, and emotional distress, making it even more devastating to the patient. The management of CRF in patients with advanced cancer is complex and incorporates conventional as well as unconventional interventions. Conclusions Cancer-related fatigue is a consistent and serious problem for many patients with advance cancer. Its high prevalence indicates that CRF remains a phenomenon that is not well understood or managed in this population. Cancer-related fatigue can limit communication and adaptation, prevent patient involvement in social interactions, and disrupt daily life. Its subjective and non-life-threatening nature along with the thought to be an unavoidable symptom in cancer may result to go ignored or under treated.

IS-24 How to write a manuscript for Supportive Care in Cancer EDITOR’S VIEW F. Ashbury1, P. Hesketh2, I. Olver3 Editor-in-Chief, Supportive Care in Cancer, Toronto, Canada 2 Sophia Gordon Cancer Center & Thoracic Oncology, Lahey Health Cancer Institute, Burlington, USA 3 Sansom Institute for Health Research, University of South Australia, Adelaide, Australia

1

Introduction Supportive Care in Cancer (SCC) is a multidisciplinary, peerreviewed journal dedicated to publishing the highest quality

S30

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

original research and reviews concerning the supportive care needs of cancer patients from diagnosis through to end-of-life. SCC is the official journal of the Multinational Association of Supportive Care in Cancer. Papers published in SCC cover many important topics, including communication, rehabilitation and survivorship, clinical interventions, behavioural interventions, targeted therapies and novel agents, radiation therapy, palliative care, the science of symptoms, ethics, guidelines and policy, and quality of life. The session focuses on preparing and submitting manuscripts to SCC for publication consideration—key issues and lessons learned. Objectives The objectives of the session include: - strategies to ensure relevance of your paper for SCC - the submission process - planning and writing the manuscript - understanding the peer-review process - responding to decisions This workshop will be particularly useful for young investigators and people who have limited experience with writing articles for peerreviewed journals. Methods The session will include the editor’s, author’s and reviewer’s perspectives to give participants insights to inform a more competitive submission. Results The content and guidance from today’s session should improve authors’ understanding of SCC’s processes and facilitate preparation of manuscripts for submission to SCC and peer review. Conclusions Almost 40 % of papers received are accepted for publication. Most papers require revision before a final acceptance decision. Understanding the submission and review process for a prominent, international journal such as SCC can assist authors in preparing more competitive submissions.

based12-week pedometer intervention, with usual care on cardiorespiratory fitness (VO2-peak) Methods Primary outcome: VO2 peak was determined by direct measures of respiratory gases at baseline, week 6 and week 12. Secondary outcomes: Physiological measures (respiratory exchange ratio, maximum heart rate, spirometry, full-body dual-energy X-ray absorptiometry scan, blood cholesterols, se-insulin and se-glucose, digital pedometer steps, aerobic walking time and patient- reported outcomes. Results A recommendation based physical activity screening instrument in order to correspond with VO2-peak was applicable to identify preillness sedentary cancer patients. Convincing recruitment (67 %), safety and intervention adherence was seen among breast cancer patients; while the attendance rate for colon cancer patients was notably lower (33 %). VO2-peak declined on average 12 % across study groups though secondary physiological measures indices may favor high intensity exercise. Pedometer use was well adapted in breast or colon cancer patients. Conclusions The complexity of integrating exercise intervention within adjuvant chemotherapy for sedentary breast cancer patients seemed adequate in timing and dose, why comparative effects will be tested in a larger RCT.

IS-25 Supportive Care in Breast Cancer - the Significance of Life Style

Introduction Breast Cancer is the most common cancer among women. With the increasing longevity and developments in breast cancer related with early detection, multimodal cancer therapy, and better supportive care, population of breast cancer survivors is increasing. The term “breast cancer survivor” applies to individuals from the time of diagnosis, recently diagnosed with breast cancer, undergoing active treatment or post- treatment follow-up, as well as those living with terminal disease. As this population grows, information related to whether lifestyle factors such as diet or physical activity can influence prognosis is of increasing interest. Objectives Analyze the literature related to diet, lifestyle and breast cancer recurrence or survival. Understand the importance of multi-professional team and care coordination among the different actors involve in survivorship care. Methods Relevant English literature was identified by searching the PubMed database using the search terms “breast cancer survivor” along with “obesity”, “diet”, “physical activity”, “Survivorship Care Plans”. We focused on a large epidemiological studies and metaanalyses to ensure the most thorough and up to date synthesis of availed data. Results A multitude of studies investigating the impact of lifestyle modification on breast cancer survivors have produced highly variable and contradictory results. Conclusions Healthcare providers must become more involved in recommending (monitoring and implementation) healthy lifestyle behaviors for their patients.

USE OF EXERCISE IN PATIENTS WITH BREAST CANCER T. Møller1, C. Lillelund1, C. Andersen1, K. Bloomquist1, K. Bang Christensen2, B. Ejlertsen3, L. Noergaard Petersen3, L. Wiedenbein4, U. Breitenstein3, L. Adamsen4 1 The Copenhagen University Hospital Centre for Health Care Research, The Copenhagen University Hospital Rigshospitalet, copenhagen, Denmark 2 Department of biostatistics, The University of copenhagen, copenhagen, Denmark 3 Department of Oncology, the Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark 4 The Copenhagen University Hospital Centre for Health Care Research, the Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark Introduction Anti-neoplastic treatment may enhance physical inactivity and it remains unclear what optimal setting, dosage and combination of exercise and health promoting components best facilitate patient adherence and symptom management to support sustainable lifestyle changes in an at-risk population of pre-illness physically inactive cancer patients. Objectives Verified sedentary patients with breast or colon cancer referred to adjuvant chemotherapy were eligible to enter a three-armed randomised feasibility study comparing a 12-week supervised hospital-based moderate to high intensity exercise intervention or alternate an instructive home-

IS-26 Supportive Care in Breast Cancer - the Significance of Life Style HEALTHY DIET AND LIFESTYLE FOR BREAST CANCER PATIENTS C. Lacerda1 1 Day Hospital, IPOLFG EPE, Lisbon, Portugal

S31

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 Lifestyle modification may provide patients with feelings of control and self-determination because they become active participants in managing their own health. We need more studies that relate dietary factors and healthy lifestyles to the increase of survivorship for the breast cancer patients.

IS-27 Mucositis UPDATES ON CLINICAL STUDIES OF PALIFERMIN FOR ORAL AND GASTROINTESTINAL MUCOSITIS N.M.A. Blijlevens1 1 Hematology, Radboud University Medical Center, Nijmegen, Netherlands Palifermin, a recombinant derivative of human keratinocyte growth factor, was the first drug approved by the FDA and EMA for the prevention of severe oral mucositis induced by highly mucotoxic total body irradiation-containing conditioning regimens for autologous haematopoietic stem cell transplantation (HSCT). Mucositis is a dose-limiting toxicity of cytotoxic treatment for cancer especially severe oral and gastro-intestinal mucositis as this can hamper timely and optimal cytotoxic therapy because patients need to be hospitalized for supportive measures such as iv narcotic analgesics, total parenteral nutrition, iv antibiotics. Mucositis also has a marked negative impact on both the quality of life and healthrelated costs. This paper will discuss the most important clinical studies of palifermin that attempted to reduce severe oral and gastro-intestinal mucositis and to improve mucositis-related patient-reported outcomes. The focus will be on patients undergoing HSCT, those treated with combined chemoradiotherapy for head and neck cancer as well as those treated with less mucotoxic therapy for sarcoma or colorectal cancer. Palifermin is generally well tolerated with mild-to-moderate skin and oral adverse events that are totally dependent on the schedule of administration. Since its introduction palifermin has fascinated many clinicians but several questions remain regarding the optimal use of this potent drug not least because of its other pleiotrophic effects e.g. the protective role of epithelial (skin, mucosa, thymus) lining and its presumed immunological activity. Hopefully new studies can be performed to investigate those areas of interest.

IS-28 Mucositis STOMATITIS SECONDARY TO TARGETED ANTI-CANCER AGENTS O. Nicolatou-Galitis1 Dental School, University of Athens, Athens, Greece

1

Introduction. The term «stomatitis» was used to distinguish the oral mucosal toxicity secondary to targeted anti-cancer agents from the specific «oral mucositis» related to conventional anti-cancer therapies. Objective. To present stomatitis secondary to targeted anti-cancer agents. Methods. The relevant english literature was reviewed. Results. Stomatitis, characterized as aphthous-like ulcers, was a frequent dose-limiting toxicity related to the class of mTOR inhibitors. Diffuse hyperkeratotic whitening of the oral mucosa, with or without burning sensation, emerged as another “class-effect” toxicity related to BRAF inhibitors, while oral cancer development was reported. Stomatitis, oral mucositis, mucosal inflammation, oral changes, stomatitis and related oral symptoms were also reported,

associated with different targeted agents. Increased oral mucosal toxicity was observed when targeted agents were combined. Symptoms included painful mucosa, dysphagia, burning mouth or gingivae, taste alterations, and xerostomia. Lack of specific oral examination was associated with limited characterization of the clinical picture, while anectodal case reports described necrotizing mucositis or painful depapillation of the tongue. Different pathobiological mechanisms were hypothesized to correspond to the different clinical oral mucosal toxicities, necessitating appropriate assessment scales and management strategies. Conclusion. Distinct dose-limiting oral mucosal toxicities emerged secondary to targeted anti-cancer agents. An expert oral examination, included in the clinical studies, would contribute to the characterization of the clinical picture and the underlying pathobiology, resulting to appropriate assessment scales and management strategies. The rapid evolution of oncological therapies, including the upcoming immune checkpoint inhibitors and combination therapies further highlight the need of the endorsement of oral examination.

IS-29 Rehabilitation LESSONS TO BE LEARNED FROM REHABILITATION OF NON-CANCER PATIENTS A.D. Zwisler1 National Centre of rehabilitation and palliation, University Hospital Odense, Odense, Denmark

1

Introduction Rehabilitation was introduced back in 1950–60, and has been accepted as part of comprehensive care aimed at patients with cardiac diseases for more than 20 years. There is well established evidence that rehabilitation improves quality of life, and physical and psychological functional level in cardiac patients. Further rehabilitation reduces re-hospitalization, and mortality, and are considered a cost-effective intervention in cardiac care. Rehabilitation services aimed at cardiac patients have been developed trough out the world during the last decade. Despite solid evidence a number of organizational challenges still exist in order to ensure rehabilitation services as part of comprehensive cardiac care. Parallel it has been documented that rehabilitation improves quality of life among cancer survivors, and rehabilitation services are under the development within the field of cancer care. Objectives The aim of this presentation is to give an overview of the development and status of rehabilitation aimed at patients with cardiac diseases and to draw parallels to development of rehabilitation as part of comprehensive cancer care. Methods The presentation will be based on systematic literature review supplemented with data from organizational and economic analysis. Results The results will be presented with focus on the complex intervention of rehabilitation and the effect of the intervention. Further results demonstration the patient-perspective, organizational challenges and economic aspects of rehabilitation will be presented in the context of cardiac and cancer care. Conclusions Parallel situations within the field of rehabilitation can be identified across the diagnostic entities of cardiac disease and cancer. The presentation will discuss what to consider in the process of developing rehabilitation services within cancer care based on learning from cardiac care.

S32

Support Care Cancer (2015) 23 (Suppl 1):S1–S388

Bone

3

01-01-O

4

TREATMENT AND PREVENTION OF OSTEONECROSIS OF THE JAW ASSOCIATED WITH MEDICATION:2009–2014

Introduction Palliative surgeries are known to reduce tumor volume and reduce pain in terminally sick children with osteos and Ewing sarcomas. The role of palliative surgery is controversial more so in countries with poor resources. Objectives To evaluate the outcome of palliative surgery in patients with Osteosarocma and Ewing sarcomas vis a vis resource challenged environment. Methods We retrospectively evaluated a total of 443 biopsy proven sarcomas of the extremities who were treated at our MSK Oncology service over a period of 10 years. Patients who underwent palliative surgeries (amputation, tumor debulking and intralesional resections) were included for evaluation. All included patients had distant metastatic disease at presentation. Results A total of 126 (28 %) patients were treated with palliative intent at the time of surgery. Main reason for late presentation were socioeconomic. Amputation was done in 77 cases, debulking in 27 and intralesional resection was done in 22 cases. High tumor volume was the commonest reason for an amputation. All patients were followed up on a regular basis. Evaluation of pain relief and MSTS Functional Scoring was done at follow-ups. Survivorship analysis was done. 29 (23 %) patients showed a good quality survival of more than 24 months. Thirty-seven patients died within 8 weeks of surgery while 54 patients died within 6 months of the index procedure. Conclusions Palliative surgery has a definite role in the management of high volume limb extremities particularly in resource challenged situations like ours.

E. Papadopoulou1, O. Nicolatou-Galitis1, E. Vardas1, P. Repousis2, A. Ardavanis3, D. Bafaloukos4, J. Sgouros5, C. Christodoulou6, M. Vaslamatzis7, H. Linardou4, E. Ntalakou8, N. Marioli9, D. Stefanou3, K. Syrigos9 1 Dental School, University of Athens, Athens, Greece 2 Clinic of Hematology, Metaxa Cancer Hospital, Piraeus, Greece 3 1st Pathology/Oncology Department, Agios Savas Hospital, Athens, Greece 4 1st Oncology Department, Metropolitan Hospital, Athens, Greece 5 3rd Oncology Clinic, Agioi Anargyroi Hospital, Athens, Greece 6 2nd Oncology Department, Metropolitan Hospital, Athens, Greece 7 Oncology Department, Evangelismos General Hospital, Athens, Greece 8 Oncology Unit3rd Department of Medicine, Sotiria Hospital, Athens, Greece 9 Oncology Unit 3rd Department of Medicine, Sotiria Hospital, Athens, Greece Introduction Osteonecrosis of the jaws is a significant complication associated with antiresorptive and antiangiogenic agents. Objectives To present our experience in the treatment and prevention of medicationassociated osteonecrosis of the jaw between 2009 and 2014. Methods Four-hundred-fourteen patients were evaluated between 2009 and 2014. Underlying diagnosis was multiple myeloma (38.8 %), breast cancer (35.9 %), lung cancer (13.3 %) and other malignancies. Patients received zoledronic acid (67.7 %), or other antiresorptives (median time 27.3 months), while 66 patients (15.9 %) received concurrent antiangiogenics. One patient with osteonecrosis stage II received pazopanib alone. Osteonecrosis was diagnosed in 154 patients, while 260 patients were referred for prevention, before/after the initiation of antiresorptives. Results Osteonecrosis Group: Mandible was affected in 98/154 cases (63.6 %), maxilla in 40/154 (26 %) and both jaws in 15/154 (9.7 %). Dental extraction preceded osteonecrosis in 44.2 % of the cases. Fifty-eight patients (37.7 %) presented with non-exposed and 96 with exposed bone (62.3 %). Patients were managed with longterm or intermittent antibiotics; dental extractions were performed in 24 patients and local applications of ozone oil in 47 patients. Of all 154 osteonecrosis patients, 12 (9.1 %) healed, 60 (45.5 %) are stable, 52 (39.4 %) are asymptomatic with minor mucosal inflammation and 7 (5.3 %) progressed. Prevention group: Dental extractions were performed in 18 patients. All dental extractions healed. No osteonecrosis was observed in the prevention group. Conclusions This report does not support the dental extraction as the main risk factor of osteonecrosis.

01-02-O PALLIATIVE SURGICAL INTENT IN THE TREATMENT OF BONE SARCOMAS: A MIDTERM REVIEW FROM A RESOURCE CHALLENGED ENVIRONMENT S. Khan1, R. Poudel1, A. Mridha2, S. Bakhshi3, S. Rastog1, S. Gamnagati4 Orthopaedics, All India Institute of Medical Sciences, Delhi, India 2 Pathology, All India Institute of Medical Sciences, Delhi, India

1

Medical Oncology, All India Institute of Medical Sciences, Delhi, India Radio-diagnosis, All India Institute of Medical Sciences, Delhi, India

01-03-O RISK OF OSTEOPOROSIS SUBSEQUENT TO CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER C. Christensen1, T. Frøslev2, D. Cronin Fenton2, P. Hermann3, M. Ewertz1 Department of Oncology, Odense University Hospital, Odense, Denmark 2 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 3 Department of Endocrinology, Odense University Hospital, Odense, Denmark 1

Introduction Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as corticosteroids which are the most common cause of secondary osteoporosis with a 7–17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among

S33

Support Care Cancer (2015) 23 (Suppl 1):S1–S388 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 % receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P >0.05). Conclusions During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA.

01-04-P COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APPRAISAL OF THREE PIVOTAL TRIALS S. Strite1, M. Stuart2, V. Beckman3, K. Öhrling4 1 Evidence-based Clinical Improvement, Delfini Group LLC, Portland, USA 2 Evidence-based Clinical Improvement, Delfini Group LLC, Seattle, USA 3 Global Scientific Communications, Amgen Inc., Thousand Oaks, USA 4 Global Development, Amgen Inc., Thousand Oaks, USA Introduction Rigorous critical appraisal of clinical trials to assess bias and chance effects, which can distort trial results, can help evaluate the validity of research findings. In a pre-specified integrated analysis of three phase 3 pivotal trials in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors or multiple myeloma (N = 5723), denosumab was reported to be superior to ZA for the prevention of SREs, with statistically and clinically significant differences. Objectives Delfini Group performed critical appraisals of the three individual pivotal trials and the integrated analysis. Methods Published trials (Lipton et al., EJC, 2012; Stopeck et al., JCO, 2010; Henry et al., JCO, 2011, Fizazi et al., Lancet, 2011) and supplementary information were analyzed. Potential threats to study validity, such as selection, performance, and assessment bias, and the likelihood for chance effects instead of true effects, were evaluated. A detailed analysis of attrition (discontinuation or loss to follow up) was conducted to assess the presence of attrition bias. Results The trials were found to be of high-quality evidence and at low risk of bias and chance effects. Important quality features included a robust randomization process, high likelihood of patients remaining balanced and blinded throughout the study, and a high degree of adherence to assigned treatments. These and other factors make bias from attrition unlikely. Conclusions The critical appraisal confirmed that the results of the integrated analysis and three pivotal trials were robust, with denosumab providing clinically meaningful benefit in patients with bone metastases from advanced cancer.

01-05-P EFFICACY OF SURGICAL TREATMENT STRATEGIES FOR LONG BONE METASTASES X. Zhang1, X. Wu2, K. Zheng1, E. Chow2, E. Qiu1 1 Bone and Soft Tissue Tumor, Liaoning Cancer Hospital & Institute, Shenyang, China 2 Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada Introduction Impending and pathological fractures are often treated using surgical methods. Objectives To analyse the surgical treatment of long bone metastases. Methods Patients treated for a pathologic or impending fracture were treated from 2007 to 2010 with three treatment modalities: a) resection of the diaphyseal lesion and reconstruction with intramedullary nail combined with bone cement, b) resection of the metaphyseal lesion and reconstruction with cemented tumor prosthesis, c) Intra-lesional curettage and reconstruction with intramedullary nail and bone grafting. Functional evaluation was done by Enneking’s system. Results The cohort consisted of 26 men and 19 women with median age of 54 years, and femur (33 cases) and humerus (12 cases). Pathological fractures were seen in 18 cases. Intra-lesional curettage was used in two patients, resection of the metaphyseal lesion and prosthetic replacement in 14, resection of the diaphyseal lesion and reconstruction with intramedullary nail and bone cement in 29. The complete metastasectomy was associated significantly with a less postoperative complication compared with intra-lesional curettage (P25 to ≤25 Gy (p=0.28). As well, no statistically significant difference existed in HO progression between postoperative vs preoperative radiation (p=0.43). Conclusions Radiotherapy, either prescribed postoperatively or preoperatively, is effective in preventing HO progression. The effects of different fractionation schemes and dose are not clear from this analysis. The meta-analysis was limited by the small number of studies that met the inclusion criteria.

01-13-P COMPARATIVE STUDY: HYPERCALCEMIA IN BREAST AND PROSTATE CANCER PATIENTS ATTENDING THE NATIONAL CANCER INSTITUTE (NCI)-CENTRAL SUDAN F. Hamad1, D. Abuidris2 Biochemistry, Gezira University, Wad Medani, Sudan 2 Oncology, National Cancer Institue, Wad Medani, Sudan

1

Results The bone is the third most common site for metastatic disease in tumors of all types and the second most common in breast and prostate cancer. Methods The aim of this study was to find the incidence of Hypercalcemia in new cases with breast and prostate cancers at National Cancer Institute (NCI), Gezira University, Sudan. Objectives The study was performed on 200 cases of female breast cancer and 200 of prostate cancer patients. The biochemical parameters measured were serum calcium and albumin. They were measured by spectrophotometer. Anthropometrics measurements determined was the body mass index (BMI). A questionnaire was designed in order to obtain information regarding demographics details and stage of cancer. Introduction Mean age for female was (48.74±13.04), and for males were (71.04± 7.04). Hypercalcemia was detected in 44(11.0 %) of the total patients. Hypercalcemia was appearing in 28(14.0 %) of females breast cancer and 16(8.0 %) of prostate cancer patients. 47.6 % of the female had (BMI) over 25 kg/m2. (77.3 %) of patients were presented with advance stages. Mean serum calcium were (9.17±1.62 and 8.6o±1.41 mg/dl respectively). The mean serum albumin concentration was (4.04±0.69, 3.82±0.80) mg/dl. Conclusions Conclusion: Calcium and albumin levels among Sudanese females’ breast and prostate cancer patients were similar to the internationally published levels. Hypercalcemia is common condition among breast

and prostate cancer patients and should be checked whenever there is a symptom because it can lead to many serious complications and death.

01-14-P BONE HEALTH ASSESSMENT IN THE MANAGEMENT OF EARLY BREAST CANCER IN WOMEN: A SINGLE CENTER, RETROSPECTIVE ANALYSIS R. Giusti1, V. Durante2, P. Pellegrini2, S. Lauro2, F. Conti3, P. Marchetti2 Medical Oncology, Sant’Andrea Hospital, Rome, Italy 2 Medical Oncology, Sant’Andrea Hospital - Sapienza University of Rome, Rome, Italy 3 Diabetes Unit, Sant’Andrea Hospital - Department of Clinical and Molecular medicine Sapienza University of Rome, Rome, Italy

1

Introduction Extension of survival among breast cancer (BC) patients makes paramount the consideration of long-term consequences of cancer treatments, with important reference for osteoporosis and skeletalrelated events. Maintenance of bone integrity is an important aspect to consider in the management of BC. Timely assessments are essentials for early intervention on bone health management. Objectives Aim of the study was to correlate biochemical (serum PTH, calcium and phosphate) and instrumental (lumbar and femoral BMD, T-score, Z-score) bone parameters with prognostic factors for recurrence (stage of disease, ER, PgR, HER-2 and p53 expression) and treatment (Chemotherapy, CT; Hormonotherapy, HT; Chemo+Hormonotherapy, CT+HT). Methods From January 2004 to May 2013, 61 patients who underwent adjuvant treatment for early BC were followed for biochemical and instrumental bone health assessment. Data were reviewed and analyzed using Principal Component Analysis (PCA), MATLAB® ver. 5.2 software. Chosen threshold of statistical significance was p3) are standard approaches. Under these circumstances, in CP presenting with ONJ stage 2 and 3, about 50 % remain stable and 20 % worsen. Hyperbaric oxygen and LLLT remain controversial. Objectives The aim of our study is to review the available data about the possible efficacy of LLLT for the management of ONJ, in addition to standard therapy. Methods We found six prospective studies in which LLLT has been evaluated for ONJ (stage 2 and 3) in CP; these studies are summarized in the table below. Results In spite of obvious limitations of our review, such as the small size of the studies, the variable selection of the patients, the differences in the medical and surgical treatments and the various types of LLLT used in those studies, it appears that the addition of LLLT improves the outcome of ONJ (48 % of CR and 50 % of PR) as compared to controls (13 % of CR and 39 % of PR); the overall response rate being 97 and 48 % respectively. No adverse effects related to LLLT were observed. Conclusions To conclude, LLLT might have a role in the management of ONJ in BPtreated CP; prospective controlled studies are warranted.

L. El Osta1, B. El Osta2, R. Tannous1, S. Lakiss1, M. El Gemayel1, N. El Osta1 Department of Public Health, Faculty of Medicine Saint-Joseph University, Beirut, Lebanon 2 Department of Hematology-Oncology, Georgia Regents University, GA, USA 1

Introduction Bisphosphonates are commonly prescribed to prevent skeletal complications and relieve bone pain induced by malignancies. However, these benefits are associated with multiple complications. Objectives To evaluate the knowledge and attitude of Lebanese physicians regarding bisphosphonates-related complications. Methods An observational cross-sectional survey was conducted at a major tertiary teaching hospital in Beirut. Data were collected through an anonymous structured self-administered questionnaire distributed to physicians expected to regularly prescribe bisphosphonates (n=215). The questionnaire assessed participants’ knowledge, fear and experience regarding bisphosphonates-reported side effects. Results One hundred fifty-seven physicians completed the questionnaire (response rate: 73 %): 77.2 and 75.2 % of them considered that gastrointestinal intolerance and osteonecrosis of the jaw (ONJ) are linked to bisphosphonates, respectively. Conversely, the least recognised complications are ocular inflammation (7.6 %) and severe musculoskeletal pain (37.6 %). The association of bisphosphonates with oesophageal cancer, atrial fibrillation and hepatotoxicity was wrongly reported by 11.5, 13.4 and 24.8 % of respondents, respectively. Physicians are mainly concerned about ONJ, atypical fractures and nephrotoxicity, when prescribing a bisphosphonate. However, the complications frequently encountered in their practice are gastrointestinal intolerance (44.6 %) and flu-like symptoms (26.7 %). Knowledge and attitude regarding bisphosphonates-related toxicities depend statistically on the physicians’ specialty (−p-value